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 INTRODUCTION 
The Siddha system of medicine contains rich Saiva Siddhantham, Philosophy, 
Alchemy and Materia Medica etc.,  Under Materia Medica the Siddha system deals 
with the combination of Herbs, Minerals, Metals, and Animal and Marine products. 
 According to Siddha medical science,  the Universe originally consist of atoms 
which contribute to the five basic elements, viz., earth, water, fire, air and space 
which correspond to the organs of the human body and they  constitute the base for all 
corporeal things in the world. 
"¾Äí¸¡ðÊÂ¢ó¾î º¼Á¡É ¨Åõâ¾õ 
¿¢Äí¸¡ðÊ ¿£÷¸¡ðÊ ¿¢ýÈ¢ó ¾£¸¡ðÊ 
ÅÄí¸¡ðÊ Å¡ÔÅ¡ø ÅÇ÷ó§¾ Â¢Õó¾ 
ÌÄí¸¡ðÊ Å¡É¢ü ÌÊÂ¡Â¢Õó¾§¾ 
þÕó¾¢ÎÁ¢ù ¨Åó¾¡¦ÄÎò¾ º¼Á¢Ð" 
- ¾¢ÕãÄ÷ ¿¡Ê 
  
Siddha system consists of 96 principles, 3 vital humors ie Vatham, Pitham, Kabham 
and 7 body constituents viz, Saram, Senneer, Oon, Kozhuppu, Enbu, Moolai and 
Sukkilam or Suronitham. Fewer than 7 body constituents Senneer is prioritized in the 
second order next to saram. 
 
''¦ºýÁ Á¡ïºÃ£Ãó¦¾¡ñ ßüÈ¡Èí ÌÄÁ¡õ 
¦ºö¸¢ýÈ «ÅÃÅ÷¸û¨¸Â¡ §Ä¾¡ý 
¾ýÉÁ¡õ ÃºÁ¢Ãò¾ Á¡í¸¢ºã §Á¨¾ 
¾¨ºÁî¨º ¦Â¡ÎÍì ¸¢Äó¾¡§¾ Æ¡¸¢ 
¯ýÉÁ¡õ ¯Õ¦ÅýÛï ºÃ£ÃÁ¡¸¢ 
¯Â÷ºð¨¼ Ãºï §º÷óÐ §Ã¡¸Á¡¸¢ 
ÅýÉÅ¡õ Å¡¾À¢ò¾ §ºðÀ Á¡¸¢ 
ÅÕ¸¢ýÈ º¼ò¾¢ÉÐ Åý¨Á §¸§Ç.'' 
                           - ä¸¢ ¿¡Ê 
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    Siddhars developed methods and medication that are essential to strengthen the 
physical and mental status of the human being.  Food is considered to be basic 
building material of human body, which gets processed into three humors viz, Vatha, 
Pitha and Kabha. The equilibrium of these three humors is considered as health and 
its disturbance or imbalance leads to disease or pathologic state. 
 
        According to Saint Yugi, the etiology of Pandu are frequent attacks of diarrhoea, 
excessive intake of salt and sour food, living in hot surroundings, excessive chewing 
of pawn and nuts, excessive intake of alcohol, day time sleep  are correlated with the 
etiology of  Anaemia in Modern science. 
 
        PithaPandu is characterised by yellowish colouration and pallor of the skin, 
diminished vision, thirst, and fainting, pungent taste like pepper, chest pain, dyspnoea, 
giddiness and bitter taste which may be correlated with iron deficiency anaemia in 
modern science. 
 
           Anaemia constitutes a serious health problem in many tropical countries 
because of the prevalence of malaria and other parasitic infections (Dacie and Lewis, 
1994). In anaemia there is decreased level of circulating haemoglobin, less than 13 
g/dl in male and 12 g/dl in females (Okochi et al., 2003). In the tropics, due to 
endemicity of malaria, between 10 to 20% of the population presents less than 10 g/dl 
of Hb (Diallo et al., 2008). Children are more vulnerable. 
 
    Iron Deficiency Anaemia (IDA) is the single most common disorder affecting 
mankind. It is estimated that more than 2 billion people suffer from IDA worldwide. 
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In India nearly, 90 percent of adolescent girls, women and children suffer from iron 
deficiency. Almost 20 percent of maternal deaths are because of iron deficiency 
anaemia. 
 
       Effective therapeutic Siddha formulations are traditionally employed to alleviate 
anaemia.  The investigator selected“KARISALANKANNI CHOORANAM” which 
is indicated for pandu specifically in the sastric literature Sigicha Rathna Deepam  
(Part I : Ref: Page: 162).All the ingredients in this formula is used as pothu karpam 
and sirappu karpam for many ailments as rejuvenator. The major ingredient of 
Karisalankanni chooranam is Karisalai which has a potent haematinic action used for 
Pitha Paandu  
 
 The ingredients of this formulation are purely herbal drugs found to be 
efficacious and cost effective. The above said drug formulation, has not undergone 
any clinical trial, so far. Hence the Principal Investigator has selected the drug 
“KARISALANKANNI CHOORANAM” to find out the therapeutic efficacy in 
pittha paandu. As per the standard protocol designed by the investigator, safety 
studies and Clinical trial were conducted in Ayothidoss pandithar Hospital, National 
Institute of Siddha, Chennai.  The study was explained in detailed. 
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AIM AND OBJECTIVES 
 
  The aim of this study is to introduce an effective Siddha medicine for pittha 
paandu noi and to document the formulation. 
 
OBJECTIVES 
 
1) Primary objective: 
                   To evaluate the Siddha Therapeutic efficacy of the Poly Herbal 
formulation  
“KARISALANKANNI CHOORNAM” (Internal) in “ PITHA PANDU” (Iron 
Deficienccy  Anaemia)  
 
 2) Secondary objective:  
 -To evaluate the safety profile (acute, long term toxicity studies) of the trial drug 
-To study the effect of other co-factors such as age, sex & dietary influence  
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REVIEW OF LITERATURE 
SIDDHA ASPECTS 
 
PANDU NOI 
 
VERU PEYARKAL (SYNONYMS): 
Veluppu noi, Venmai noi, Venpaandam. 
 
IYAL (DEFINITION):  
Pandu noi is a disease , characterized by changing of natural colour of the body, pallor 
of skin, nails, and conjunctiva. 
 
 
The great Siddhar Agathiyar defined Pandu in the following verses; 
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In the text Uyir Kaakum Siddha Maruthuvam, it is quoted as follows; 
 
NOI VARUM VAZHI (ETIOLOGY) 
        According to Yugimuni the cause of Pandu are as follows; 
 
        From the above mentioned lines, it is clear that frequent attacks of diarrhoea, 
excessive intake of salt and sour food, living in hot surroundings, excessive chewing 
of pawn and nuts, excessive intake of alcohol, day time sleep are some of the factors 
causing Pandu noi. 
According to Theraiyar vagadam; 
       
 
It is mentioned that negligence of food and water causes Pandu noi. 
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According to Thanvanthiri vaithyam; 
 
 
 
Imbalance between the three thathus [Vatham, Pitham, and Kabam], perversion of 
appetite such as eating mud (PICA) and excessive heat accumulation due to altered 
Abana vayu, excessive sorrow, and psychosocial factors are some of the causes of 
Pandu noi. 
 
NOI ENN (CLASSIFICATION): 
 
According to Yugimuni Pandu noi is classified into 5 types 
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Thanvanthiri classified Pandu into 7 types 
 
 
Classification of Pandu noi based on various Siddha books: 
AGASTHIAR GUNAVAAGADAM 
According to Agasthiyar gunavaagadam pandu noi is classified in to 5 types         
1. Vatha pandu     
2. Pitha pandu      
3. Kaba pandu     
4. Vida  pandu      
5. Mukkutra pandu   
   
VAITHYA SARA SANKRAHAM 
According to vaithya sara sankraham pandu noi is classified in to 5 types         
1. Vatha pandu 
2. Pitha pandu 
3. Moola pandu 
4. Moolapitha pandu 
5. Vida pandu 
 
YUGI CHINTHAMANI-800  
According to yugi chinthamani-800 pandu noi is classified in to 5 types  
1. Vatha pandu     
2. Pitha pandu      
3. Kaba pandu      
4. Mukkutra pandu     
5. Vida pandu  
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T.V. SAMBASIVAM PILLAI 
According to T.V. sambasivam pillai pandu noi is classified in to 8 types  
1. Vatha pandu 
2. Pitha pandu 
3. Kaba pandu 
4. Mukkutra pandu 
5. Oothu pandu 
6. Neer pandu 
7. Eri pandu 
8. Vida pandu 
 
THANVANTHIRI VAITHIYAM 
According to Thanvanthiri vaithiyam pandu noi is classified in to 7 types  
1. Vatha pandu     
2. Pitha pandu      
3. Kaba pandu      
4. Mukkutra pandu     
5. Pitha vatha pandu     
6. Sannipatha pandu     
7. Paithiya pandu 
 
ANUBOGA  VAITHIYA  DEVARAGASIYAM 
According to Anuboga  vaithiya  devaragasiyam pandu noi is classified in to 6 
types 
1. Vatha pandu 
2. Pitha pandu 
3. Kaba pandu 
4. Mukkutra pandu 
5.Miruthikapuktha pandu 
6. Vida pandu 
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PARARASA SEKARAM 
According to Pararasa sekaram pandu noi is classified in to 5 types 
1. Vatha pandu     
2. Pitha pandu      
3. Kaba pandu      
4. Sanni pandu     
5. Miruthika pandu  
 
MADAVA NITHANAM 
According to Madava Nithanam pandu noi is classified in to 5 types 
1. Vatha pandu 
2. Pitha pandu  
3. Kaba pandu  
4. Sanni pandu 
5. Mann pandu 
 
JEEVARAKSHAMIRTHAM 
According to Jeevarakshamirtham pandu noi is classified in to 5 types   
1. Vatha pandu     
2. Pitha pandu      
3. Kaba pandu     
4. Tridosha pandu     
5. Miruthikapuktha pandu 
 
ASHTANGA HRIDAYAM  
According to Ashtanga hridayam pandu noi is classified in to 5 types   
1. Vatha pandu 
2. Pitha pandu  
3. Kaba pandu  
4. Sanni pandu 
5. Mannul pandu 
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KURIKUNANGAL IN PANDU NOI (CLINICAL FEATURES) : 
1. Murkurikunangal (Premonitory symptoms): 
In Siddha Maruthuvam Pothu, Kuppusamy Mudaliar states; 
Pandu patients exhibit the following symptoms from their initial stage of development 
itself. The patient experiences insidious onset of fatiguability, dyspnoea on exertion, 
diminished vision, faintness, palpitation and pallor of the skin. 
Theraiyar Neerkkuri illustrates that;  
 
Oliguria occurs  suddenly and sometimes it occurs  even after intake of excessive  of 
water are explained as premonitory symptom of Pandu noi. 
2. POTHU KURIGUNANGAL (GENERAL SIGNS AND SYMPTOMS): 
In Siddha Maruthuvam Pothu, Kuppusamy Mudaliar states; 
Inability to walk, headache, palpitation, blurring of vision, giddiness, syncope, 
dyspnoea, anorexia, vomiting, paleness of the skin, nailbeds become swollen and 
pallor, fissured tongue, glossitis, hoarseness of voice are general signs and symptoms 
of Pandu noi. In females scanty menstruation, sometimes menorrhagia may occur. If it 
occurs in children and elderly, it may manifest because of worm infestation and blood 
disorders. If it occurs in pitha thegi, anorexia, indigestion, burning sensation, pallor of 
skin, glossitis, and dysphagia, vomitus with bile, bitter taste of the tongue and 
diarrhoea occurs. If the symptoms persist for longer duration it results in jaundice. 
Agasthiyar Gunavaagadam states that; 
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Stomatitis, dryness of the skin, pallor of the face, eyes, lips, tongue and nails, 
lassitude, tiredness, low volume pulse, anorexia, swelling of the eyelids, dyspnoea on 
exertion, palpitation, oedema of the ankle joint, added heart sounds are mentioned as 
the signs and symptoms of Pandu noi. 
 
SYMPTOMS OF VARIOUS TYPES OF PANDU: 
1. Vatha Pandu: 
 
The symptoms of VathaPandu are lower abdominal pain, thirst, loss of appetite, 
dryness of the skin and visible veins due to pallor of the skin, redness of the eyes, 
constipation, headache, anasarca and pallor of the skin. 
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2. Pitha Pandu:   
       
 
Yellowish discolouration and pallor of the skin, diminished vision, thirst, fainting, 
pungent taste like pepper, chest pain, dyspnoea, giddiness and bitter taste. 
 
3. Kaba Pandu : 
 
       
 
Pallor of the skin, salty taste, pilo erection of the skin, vomiting, husky voice, 
sneezing, cough with expectoration, fainting, lassitude, ejaculation of semen, anasarca 
and thirst. 
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4. Mukkutra Pandu: 
       
 
           Anorexia, thrist, dyspnoea, anasarca, chest pain, lassitude, sneezing, warmness 
of the skin. 
 
5. Vida Pandu: 
        
 
Pallor of the skin, excessive thirst, anorexia, vomiting, hiccough, cough, dyspnoea, 
flatulence, diarrhoea, fever, heaviness of the chest, anasarca. 
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MUKKUTRA VERUPAADUGAL (PATHOLOGY): 
Udal vanmai is affected due to excessive intake of salt and sour foods, which 
cause indigestion and loss of appetite. This affects Rasam and Raththa thathus which 
lead to increase in Pitham and do not give nutrition to the body affecting Ranjagam 
leading to pallor of the skin. The increased Pitham affects both Vatham and Kabam 
increasing the pallor of the skin. Further Kabam increases producing generalized 
swelling of the body. 
 
PINIYARI MURAIMAI (DIAGNOSIS): 
 
 It is based upon three main principles. They are 
1. Porialarithal (Inspection) 
2. Pulanalarithal (Palpation) 
3. Vinathal (Interrogation) 
 
ENNVAGAI THERVUKAL (EIGHT TOOLS OF DIAGNOSIS): 
 
Ennvagai Thervugal is a unique method of diagnosing the disease, which was 
developed by Siddhars. 
 
PANDU IN RELATION WITH ENNVAGAI THERVUKAL: 
 
1. Naadi (Pulse) 
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There are three vital naadi viz, Vatham, Pitham, Kabham present in our body, as 
mentioned in the following poem, 
 
 
Vatha, Pitha and Kabha naadi are in the ratio of 1:1/2:1/4 proportion in   normal 
condition. This is stated as follows, 
 
 
By combination of the above said three naadi, six thontha naadi are formed. They are 
Vathapitham, Vathakabham, Pithavatham, Pithakabham, Kabhavatham and 
Kabhapitham. This is stated as follows, 
 
- 
 
     Naadi is responsible for the existence of life.  It is a suitable diagnostic tool 
used by Siddhars. It is recognised as one of the principle means of diagnosis and 
prognosis of the disease from time immemorial. 
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NAADI NADAI  IN PANDU NOI: 
1. Pitha Naadi: 
 
2. Kaba Naadi:  
 
 
3. Vatha Kaba Naadi: 
4. Kaba Vatha Naadi: 
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5. Kaba Pitha Naadi: 
 
       
6. Pitha Vaatha Naadi:  
2. Sparisam (Palpation): 
 
The warmth, hot, chillness, dryness, roughness of the skin, oozing, sweating, 
tenderness, fissures, depigmented changes in the skin, swelling, ulcer and 
hepatosplenomegaly may be noted. 
            In PithaPandu, hot sensation, dryness, roughness of the skin, sweating, 
swelling, hepatospleenomegaly are seen. 
 
3. Naa (Tongue): 
 
The colour, dry or wet, coating, texture, salivation, redness, ulceration, fissure, pallor, 
any malignant growth, predominant taste in the tongue, speech, movement and 
deviation of the tongue along with the conditions of the teeth and gums should be 
noted. 
 
In PithaPandu, pallor of the tongue, dryness, ulceration, fissure, bitter or pungent 
taste of tongue, baldness and loss of taste buds are seen. 
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4. Niram (Colour): 
 
Changes in the colour of the skin, teeth, eyes, nail, lips due to Vatham, Pitham, 
Kabam and Mukkutram, hypo and hyper pigmentation are noted. 
 
In PithaPandu pallor of skin, conjuctiva and nail beds are noted. 
 
 
5. Mozhi (Sound): 
 
This includes clarity of speech, any disturbances, high or low-pitched voice, slurring 
and incoherent speech and hoarseness of voice. 
 
 
6. Vizhi (Eyes): 
 
Hyperemia, ulceration, response of pupil, pallor, protrusion, sunken eyes, sharpness of 
vision, excessive lacrimation and accumulation of secretion at the angle of eyes, 
visual disturbance and any specific diseases of the eyes should be noted. 
 
In PithaPandu noi, pallor of conjuctiva and dull vision are noted. 
 
 
7. Malam (Faeces): 
 
Colour, consistency, quality, smell, frequency, constipation/diarrhoea, presence of 
mucous, blood and undigested food particles in the stool should be studied. In Pandu 
noi, the following changes may be noted. 
 
In PithaPandu noi, diarrhoea is noted. 
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8. Moothiram (Urine): 
 
Neer Ilakkanam (Method of collection of urine): 
       
 
Prior to the day of urine examination, the patient is advised to take balanced 
diet and the quantity of food must be proportionate to his appetite. The patient should 
sleep well. After waking up in the morning, the first voided urine is collected in a 
wide mouthed glass container and is subjected to the analysis within one and half 
hours. 
 
Neerkkuri:  
 
Urine has the following five characters, 
 
 1. Niram  - Colour of the Urine 
 2. Edai  - Specific gravity of the Urine 
 3. Manam - Smell of the Urine 
 4. Nurai - Frothy nature of the Urine 
 5. Enjal  - Quantity (Increased or decreased amount) of Urine voided 
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Neerkkuri in Pandu noi: 
 
 Neikkuri:  
 
The urine specimen collected for Neikkuri is kept open in a glass dish being exposed 
well to the sunlight. Add one drop of gingelly oil without shaking. It should not be 
disturbed from its position and spreading of the oil drop should be noted. 
Oil spreads like a snake   - Vatha neer 
Oil spreads like a ring    - Pitha neer 
Oil remaining and floating like a pearl - Kaba neer 
 
Neikkuri in Pandu noi: 
 
If the oil spreads like a kathir (ray) it indicates Pandu noi. 
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ROLE OF MUKKUTRAM IN PANDU: 
 
Vatham:  Its mathirai alavu is 1 mathirai.  
Location of vatham in the body: Vatham is located in the abanan, faeces, 
idakalai, spermatic cord, pelvic bone, skin, nerves, joints, hair and muscles. 
 
Ten forms of Vatham:  
 
1. Pranan (Uyirkaal): It resides in the heart and legs to nose and controls knowledge, 
mind and five objects of sense, useful for breathing. 
  
In PithaPandu noi, dysnoea is present, if pranan is affected. 
 
2. Abanan (Keezh nokkukaal): It is located in the lower abdomen and extremities. It 
is responsible for excretion of urine, stools, ejaculation of sperm and menstrual flow. 
 
           In PithaPandu noi, diarrhoea, oliguria, ammenorohoea or oligomennorohoea 
are present, when abanan is affected. 
 
3. Viyanan (Paravukaal): It resides mainly at the heart and responsible for 
movements of the body and sensation. 
 
In PithaPandu noi, swelling of the body, pallor of eyes and lips, numbness are 
present due to the affection of viyanan. 
 
4. Samanan (Nadukkaal): It is located in the stomach, helps for proper digestion and 
balances the above four vaayus in equillibirium. 
 
In PithaPandu noi, anorexia and any of the above four vaayus affection are present 
when samanan is affected. 
 
5. Uthanan (Melnokkukaal): It is located in the chest and responsible for vomiting, 
cough and sneezing reflexes. 
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In PithaPandu noi, excessive thirst is present due to the affection of uthanan. 
 
6. Naagan: It resides in the eyes and is responsible for opening and closing of the 
eyelids and intelligence. 
 
7. Koorman: It is located in the eyes. It causes winking of the eyelids, yawning and 
closure of mouth. It gives strength and helps to visualize things and causes lacrimal 
secretion. 
 
               In PithaPandu noi, blurred vision is present when koorman is affected. 
 
8. Kirukaran: It is located in the throat and responsible for salivation, nasal secretion 
and appetite. 
 
In PithaPandu, anorexia and dryness of mouth are present when kirukaran is 
affected. 
 
9. Devathathan: Its location is at eruvai and karuvai. It is responsible for laziness, 
sleep and anger. 
 
In PithaPandu, fatigue and insomnia are present when devathathan is affected. 
 
10. Dhananjeyan:  It resides in the nose and escapes on the third day after death by 
bursting out of the cranium. 
Pitham:  Its mathirai alavu is ½   mathirai  
 
General Characteristics of Pitham: 
 Veppam  - Hot 
 Koormai - Sharpness 
 Neippu - Lubricative 
 Nekizhchi - Viscousity 
 Pitham conceives the properties of the substance to which it combines. 
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Location of Pitham in the Body 
 Pingalai 
 Praanavayu 
 Moolakkini  
 Neerpai - Urinary bladder 
 Irudhayam - Heart 
 Thalai - Head 
 Kopuzh - Naval 
 Undhi - Abdomen 
 Iraippai - Stomach 
 Viyarvai - Sweat 
 Naavil oorukindra neer - Salivary secreation 
 Senneer - Blood 
 Saaram - Chyle. 
 Kan - Eye. 
 Thol – Skin 
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Five forms of pitham: 
 
1. Anala pitham:  This gives appetite and helps for digestion. 
 
In PithaPandu, loss of appetite is present when it is affected. 
 
2. Ranjagam: It gives colour to the blood. 
 
In PithaPandu, pallor of conjunctiva and skin are present when it is affected. 
 
3. Saathagam:  It controls the entire body functions responsible for the activities of   
the body 
  
            In Pithapandu, inability to do the works properly and sluggishness are present 
when it is affected. 
 
4. Alosagam: This gives brightness to the eyes. 
          
               In PithaPandu, dull vision is present if alosagam is affected. 
 
5. Prasagam:  It gives complexion to the skin. 
 
In Pithapandu, altered skin lusture is present when it is affected. 
 
Kabam: Its mathirai alavu is ¼ mathirai.  
 
Location of Kabam in the body: 
 
Kabam is located in Samanavayu, Sperm, Head, Tongue, Vulva, Fat tissue, Bone 
marrow, Blood, Nose, Chest, Nerve, Bone, Brain, Eyes and Joints. 
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Five forms of Kabam: 
 
1. Avalambagam: It controls heart, lungs and supports other forms of kabam 
 
In PithaPandu, dyspnoea is present when it is affected. 
2. Kilethagam: It makes the food wet and helps for digestion. 
 
In PithaPandu, indigestion is present when it is affected. 
 
3. Pothagam:  It is responsible for taste. 
 
In PithaPandu, bitter or pungent taste is present when it is affected.  
 
4. Tharpagam: It keeps the eyes cool. 
           
          In PithaPandu, burning sensation of eye is present when it is affected. 
 
5. Santhigam:  It is responsible for the lubrication and aids free movements of joints. 
 
Paruvakaalam (Season): 
 
The whole year is divided into six seasons, they are as follows; 
 
1. Kaar kaalam  - Avani and Puratasi  - Aug 16 to Oct 15 
2. Koothir kaalam  - Ayppasi and Karthigai - Oct 16 to Dec 15 
3. Munpani kaalam  - Markazhi and Thai  - Dec 16 to Feb 15 
4. Pinpani kaalam  - Maasi and Panguni  - Feb 16 to Apr 15 
5. Ilavenil kaalam  - Chithirai and Vaigasi - Apr 16 to June15 
6. Mudhuvenil kaalam - Aani and Aadi  - June 16 toAug15 
 
Seasonal influence of earth, Water bodies, Flora and Fauna will have its impact in 
human being‟s physiology inturn make them susceptible to certain specific diseases 
which are common in that season.  
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Physiological alterations of Mukkutram: 
Mukkutrm Thannilai Valarchi Vetrunilai Valarchi Thannilai Adaithal 
Vatham Muthuvenil kaalam  Kaar kaalam Koothir kaalam 
Pitham Kaar kaalam Koothir kaalam Munpani kaalam 
Kabam Pin pani kaalam Ilavenil kaalam Muthuvenil kaalam 
 
Nilam: 
1. Kurinji  - Hill region and its surroundings 
2. Mullai  - Forest region and its surroundings 
3. Marutham  - Cultivating region and its surroundings 
4. Neithal  - Coastal region and its surroundings 
5. Palai  - Desert region and its surroundings 
 
People living in Kurinji, Mullai, Neithal and Palai may have in increased chance to 
acquire Pithapandu noi. 
 
Udal Kattugal: 
 
Our body consists of seven udal kattugal. It gives strength to the body 
 
1. Saaram  - It gives strength to the body and mind. 
2. Senneer - It is responsible for knowledge, strength, boldness and healthy       
                         complexion. 
3. Oon  - Gives structure and shape to the body and is responsible for  
the movement of the body. 
4. Kozhuppu - Lubricates the organs and proceeds on its own works. 
5. Enbu  - Protects vital organs and is useful for movements. 
6. Moolai - Present inside the bones and it gives strength and maintains  
   the normal conditions of the bone. 
7. Venneer - Responsible for the propagation of species. 
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In PithaPandu, 
Fatigue, dyspnoea and tiredness are present, if Saaram is affected. 
Pallor of skin and conjunctiva are present, if Senneer is affected. 
Swelling of the body is present, if Oon is affected. 
Ammenorrhoea / oligomenorrhoea is present, if Suronitham is affected. 
Sluggishness in sexual life is present, if Sukkilam is affected. 
 
 
PROGNOSIS OF PANDU: 
Curable and Incurable Types: 
 
 According to Siddha Maruthuvam,  
 
 The possibilities of cure for Nanju Veluppu noi are rare. 
 All other types of Veluppunoi are curable. 
 Eventhough, if any of the following symptoms or diseases like 
vomiting, diarrhoea, odema, thirst, diabetes, tuberculosis gets 
associated in the above said four Veluppu noi, then it is not curable 
easily.  
 
According to Sarabendrar Vaidhya Muraigal: 
 
The Pandu noi, which is chronic in nature, is not treatable. In acute stage, also odema 
with yellowish discolouration, if present is not curable. Constipation or greenish 
dysentery, if occurs also is not curable. 
 
Extreme pallorness of teeth, nail and eyes and the vision to every object seems to be 
whitish is not curable. 
 
Emaciation of the Pandu noi persons, with odema present in head, upperlimb and 
lower limb, swelling of the external genetalia, inguinal region, frequent fainting, 
diarrhoea and fever in pandu noi is not curable. 
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According to Agathiya Vaithiya Pillai Tamil; 
 
Kannusamiyam states that;  
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According to Sadhaga Naadi ;  
 
 
NOI NEEKKAM (TREATMENT): 
 
The speciality of Siddha treatment emphasise not only for complete healing but also 
for the prevention and rejuvenation. This is said as follows,  
 
Kappu (Prevention) 
Neekkam ((Treatment) 
Niraivu (Restoration) 
 
Siddha system has stated that even during the time of conception, some defects creep 
into the fertilized embryo. These defects form the basis of the manifestation of certain 
constitutional disease later on during the existence of the individual. 
 
Diseases are produced by the unequillibrium of three thathus, which may be due to 
various causes like diet, life style pattern, mental and physical activities. 
 
When treating the disease the following principles must be noted.  
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So, it is essential to know about the disease and the Cause for the onset of disease, 
body constituent of the patient, severity and chronicity of the illness, the season and 
the time of onset of the disease must be observed. 
 
Line of Treatment of Pandu: 
 
The aim is to normalize the vitiated Mukkutram, Vayus and the affected Saram and 
Senneer thathu.  
Before starting the actual treatment, the presence of toxins in the body produced due 
to derangement of three thathus should be controlled. This is explained as follows.  
 
Usually for pitha diseases, emetics are given to restore the deranged Pitham. But there 
are some exceptions to this rule. For instance, in Pandu noi, since the patient is 
already weak and drows, the administration of emetic medicine is excluded from the 
line of treatment. 
 
As per Siddha Maruthuvam, the line of treatment includes: 
 
1. Mild laxatives can be administrated to neutralize the deranged thaathus. 
2. To improve haemoglobin content of blood, iron preparations are used.  
3. Pathiyam ie, diet restrictions are advised to normalize the affected thathu. 
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TREATMENT:     
              Medicine Name: KARISALANKANNI CHOORANAM (Internal) 
              Dosage: Thirikadi pramanam [1g] [24] 
                          ( Twice/day) before food. 
              
              Adjuvant:  white sugar 
 
              Course: 1/2 Mandalam[24 days] 
DIET :  
- 
- 
Diet regimen for Pandu Noi : 
 
Diet should be of  
 
       1. Stimulating appetite 
       2. Strengthening the body  
       3. Easily digestable should be taken. 
 
For Pandu noi, the following food items are advised. 
 
 Easily digestible foods like porridge, mutton soup, and bone soup must be 
given in acute stages of Pandu noi.  
 Tender brinjal, tender country bean, pepper, garlic, anise seed, ginger, onion 
green Peas, bengal gram, vegetable soups are advised to consume in diet. 
 After the normal appetite is restored properly, prepared meat of Kaadai 
[quail], Udumbu [Monitor] can also be given. They tone up the deblitated 
system and also help in rejuvenation. 
 Tamarind, tea, coffee, betel chewing, tobacco chewing and alcohol are 
advised to avoid as they prevent absorption of the drug. 
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MODERN ASPECT 
ANAEMIA 
Definition 
 Anaemia is strictly defined as a decrease in red blood cell (RBC) mass. 
The function of the RBC is to deliver oxygen from the lungs to the tissues and carbon 
dioxide from the tissues to the lungs. This is accomplished by using hemoglobin (Hb), 
a tetramer protein composed of heme and globin. Anaemia impairs the body‟s ability 
for gas exchange by decreasing the number of RBCs transporting oxygen and carbon 
dioxide. 
WHO‟s criterion for Anaemia in adults is an Hb value of less than 12.5 g/dL. 
Children aged 6 months to 6 years are considered anemic at Hb levels less than 11 
g/dL, and children aged 6-14 years are considered anemic when Hb levels are less 
than 12 g/dL. The disadvantage of such arbitrary criteria is that a few healthy 
individuals fall below the reference range, and some people with an underlying 
disorder fall within the reference range for Hb concentration.  
Erythrocyte life cycle 
 Erythroid precursors develop in bone marrow at rates usually 
determined by the requirement for sufficient circulating Hb to oxygenate tissues 
adequately. Erythroid precursors differentiate sequentially from stem cells to 
progenitor cells to erythroblasts to normoblasts in a process requiring growth factors 
and cytokines. This process of differentiation requires several days. Normally, 
erythroid precursors are released into circulation as reticulocytes.  
 Reticulocytes are so called because of the reticular meshwork of rRNA 
they harbor. They remain in the circulation for approximately 1 day before they 
mature into erythrocytes, after the digestion of RNA by reticuloendothelial cells. The 
mature erythrocyte remains in circulation for about 120 days before being engulfed 
and destroyed by phagocytic cells of the reticuloendothelial system.  
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 Erythrocytes are highly deformable and increase their diameter from 7 
µm to 13 µm when they traverse capillaries with a 3-µm diameter. They possess a 
negative charge on their surface, which may serve to discourage phagocytosis. 
Because erythrocytes have no nucleus, they lack a Krebs cycle and rely on glycolysis 
via the Embden-Meyerhof and pentose pathways for energy. Many enzymes required 
by the aerobic and anaerobic glycolytic pathways decrease within the cell as it ages. 
In addition, the aging cell has a decrease in potassium concentration and an increase 
in sodium concentration. These factors contribute to the demise of the erythrocyte at 
the end of its 120-day lifespan.  
Pathophysiology 
 The physiologic response to Anaemia varies according to acuity and 
the type of insult. Gradual onset may allow for compensatory mechanisms to take 
place. With Anaemia due to acute blood loss, a reduction in oxygen-carrying capacity 
occurs along with a decrease in intravascular volume, with resultant hypoxia and 
hypovolemia. Hypovolemia leads to hypotension, which is detected by stretch 
receptors in the carotid bulb, aortic arch, heart, and lungs. These receptors transmit 
impulses along afferent fibers of the vagus and glossopharyngeal nerves to the 
medulla oblongata, cerebral cortex, and pituitary gland.  
 In the medulla, sympathetic outflow is enhanced, while 
parasympathetic activity is diminished. Increased sympathetic outflow leads to 
norepinephrine release from sympathetic nerve endings and discharge of epinephrine 
and norepinephrine from the adrenal medulla. Sympathetic connection to the 
hypothalamic nuclei increases antidiuretic hormone (ADH) secretion from the 
pituitary gland.. ADH increases free water reabsorption in the distal collecting tubules. 
In response to decreased renal perfusion, juxtaglomerular cells in the afferent 
arterioles release renin into the renal circulation, leading to increased angiotensin I, 
which is converted by angiotensin-converting enzyme (ACE) to angiotensin II.  
 Angiotensin II has a potent pressor effect on arteriolar smooth muscle. 
Angiotensin II also stimulates the zona glomerulosa of the adrenal cortex to produce 
aldosterone. Aldosterone increases sodium reabsorption from the proximal tubules of 
the kidney, thus increasing intravascular volume. The primary effect of the 
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sympathetic nervous system is to maintain perfusion to the tissues by increasing 
systemic vascular resistance (SVR). The augmented venous tone increases the preload 
and, hence, the end-diastolic volume, which increases stroke volume. Therefore, 
stroke volume, heart rate, and SVR all are maximized by the sympathetic nervous 
system. Oxygen delivery is enhanced by the increased blood flow.  
 In states of hypovolemic hypoxia, the increased venous tone due to 
sympathetic discharge is thought to dominate the vasodilator effects of hypoxia. 
Counterregulatory hormones (eg, glucagon, epinephrine, cortisol) are thought to shift 
intracellular water to the intravascular space, perhaps because of the resultant 
hyperglycemia. This contribution to the intravascular volume has not been clearly 
elucidated.  
Etiology of Anaemia 
 Basically, only 3 causes of Anaemia exist: blood loss, increased RBC 
destruction (hemolysis), and decreased production of RBCs. Each of these causes 
includes a number of etiologies that require specific and appropriate therapy. Genetic 
etiologies include the following:  
 Hemoglobinopathies 
 Thalassemias 
 Enzyme abnormalities of the glycolytic pathways 
 Defects of the RBC cytoskeleton 
 Congenital dyserythropoietic Anaemia 
 Rh null disease 
 Hereditary xerocytosis 
 Abetalipoproteinemia 
 Fanconi Anaemia 
Nutritional etiologies include the following: 
 Iron deficiency 
 Vitamin B-12 deficiency 
 Folate deficiency 
 Starvation and generalized malnutrition 
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Physical etiologies include the following: 
 Trauma 
 Burns 
 Frostbite 
 Prosthetic valves and surfaces 
Chronic disease and malignant etiologies include the following: 
 Renal disease 
 Hepatic disease 
 Chronic infections 
 Neoplasia 
 Collagen vascular diseases 
Infectious etiologies include the following: 
 Viral - Hepatitis, infectious mononucleosis, cytomegalovirus 
 Bacterial - Clostridia, gram-negative sepsis 
 Protozoal - Malaria, leishmaniasis, toxoplasmosis 
 Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic 
syndrome may be a cause of Anaemia. Hereditary spherocytosis either may present 
with a severe hemolytic Anaemia or may be asymptomatic with compensated 
hemolysis. Similarly, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency may 
manifest as chronic hemolytic Anaemia or exist without Anaemia until the patient 
receives an oxidant medication. Immunologic etiologies for Anaemia may include 
antibody-mediated abnormalities. In the emergency department (ED), acute 
hemorrhage is by far the most common etiology for Anaemia.  
Examine optic fundi carefully but not at the expense of the conjunctivae and 
the sclerae, which can show pallor, icterus, splinter hemorrhages, petechiae, comma 
signs in the conjunctival vessels, or telangiectasia that can be helpful in planning 
additional studies.  
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Iron Deficiency Anaemia 
 
Definition 
Iron deficiency is defined as a decreased total iron body content. Iron 
deficiency Anaemia occurs when iron deficiency is severe enough to diminish 
erythropoiesis and cause the development of Anaemia. 
 Iron deficiency is the most prevalent single deficiency state on a worldwide 
basis. It is important economically because it diminishes the capability of individuals 
who are affected to perform physical labor, and it diminishes both growth and 
learning in children.  
 
Pathophysiology 
Iron is vital for all living organisms because it is essential for multiple 
metabolic processes, including oxygen transport, DNA synthesis, and electron 
transport. Iron equilibrium in the body is regulated carefully to ensure that sufficient 
iron is absorbed in order to compensate for body losses of iron. Whereas body loss of 
iron quantitatively is as important as absorption in terms of maintaining iron 
equilibrium, it is a more passive process than absorption. 
 
The total body iron in a 70-kg man is about 4 g. This is maintained by a balance 
between absorption and body losses. Although the body only absorbs 1 mg daily to 
maintain equilibrium, the internal requirement for iron is greater (20-25 mg). An 
erythrocyte has a lifespan of 120 days so that 0.8% of red blood cells are destroyed 
and replaced each day. A man with 5 L of blood volume has 2.5 g of iron 
incorporated into the hemoglobin, with a daily turnover of 20 mg for hemoglobin 
synthesis and degradation and another 5 mg for other requirements. Most of this iron 
passes through the plasma for reutilization. Iron in excess of these requirements is 
deposited in body stores as ferritin or hemosiderin.  
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In healthy people, the body concentration of iron (approximately 60 parts per 
million [ppm]) is regulated carefully by absorptive cells in the proximal small 
intestine, which alter iron absorption to match body losses of iron. Persistent errors in 
iron balance lead to either iron deficiency Anaemia or hemosiderosis. Both are 
disorders with potential adverse consequences. 
Mucosal cells in the proximal small intestine mediate iron absorption. Intestinal cells 
are born in the crypts of Lieberkuhn and migrate to the tips of the villi. The cells are 
sloughed into the intestinal lumen at the end of their 2- to 3-day lifespan. Absorptive 
cells remain attuned to the body requirement for iron by incorporating proportionate 
quantities of body iron into the absorptive cells. This iron and recently absorbed iron 
decrease uptake of iron from the gut lumen by satiation of iron-binding proteins with 
iron, by stimulating an iron regulatory element, or both. The incorporation of iron into 
these cells in quantities proportional to body stores of iron also provides a limited 
method of increasing iron excretion in individuals replete in iron.  
Either diminished absorbable dietary iron or excessive loss of body iron can 
cause iron deficiency. Diminished absorption usually is due to an insufficient intake 
of dietary iron in an absorbable form. Hemorrhage is the most common cause of 
excessive loss of body iron, but it can occur with hemoglobinuria from intravascular 
hemolysis. Malabsorption of iron is relatively uncommon in the absence of small 
bowel disease (sprue, celiac disease, regional enteritis) or previous GI surgery.  
Iron uptake in the proximal small bowel occurs by 3 separate pathways. These 
are the heme pathway and 2 distinct pathways for ferric and ferrous iron. 
Three pathways exist in enterocytes for uptake of food iron. In the United States and 
Europe, most absorbed iron is derived from heme. Heme is digested enzymatically 
free of globin and enters the enterocyte as a metalloporphyrin. Within the cell iron is 
released from heme by heme oxygenase to pass into the body as inorganic iron. Most 
dietary inorganic iron is ferric iron. This can enter the absorptive cell via the integrin-
mobilferrin pathway (IMP).Some dietary iron is reduced in the gut lumen and enters 
the absorptive cell via the divalent metal transporter-1 (DMT-1/DCT-1/Nramp-2). 
The proteins of both pathways interact within the enterocyte with paraferritin, a large 
protein complex capable of ferrireduction. Excess iron is stored as ferritin to protect 
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the cell from oxidative damage. Iron leaves the cell to enter plasma facilitated by 
ferroportin and hephaestin, which associate with an apotransferrin receptor. The 
enterocyte is informed of body requirements for iron by transporting iron from plasma 
into the cell using a holotransferrin receptor.  
Dietary iron contains both heme and nonheme iron. Both chemical forms are absorbed 
noncompetitively into duodenal and jejunal mucosal cells. Many of the factors that 
alter the absorption of nonheme iron have little effect upon the absorption of heme 
iron because of the differences in their chemical structures. Iron is released from heme 
within the intestinal absorptive cell by heme oxygenase and then transferred into the 
body as nonheme iron.  
Heme enters the cell as an intact metalloporphyrin, presumably by a vesicular 
mechanism. It is degraded within the enterocyte by heme oxygenase with release of 
iron so that it traverses the basolateral cell membrane in competition with nonheme 
iron to bind transferrin in the plasma.  
Ferric iron utilizes a different pathway to enter cells than ferrous iron. This 
was shown by competitive inhibition studies, the use of blocking antibodies against 
divalent metal transporter-1 (DMT-1) and beta3-integrin, and transfection 
experiments using DMT-1 DNA. This research indicated that ferric iron utilizes 
beta3-integrin and mobilferrin, while ferrous iron uses DMT-1 to enter cells.  
Which pathway transports most nonheme iron in humans is not known. Most 
nonheme dietary iron is ferric iron. Iron absorption in mice and rats may involve more 
ferrous iron because they excrete moderate quantities of ascorbate in intestinal 
secretions. Humans, however, are a scorbutic species and are unable to synthesize 
ascorbate to reduce ferric iron.  
Other proteins appear to be related to iron absorption. These are stimulators of 
iron transport (SFT), which are reported to increase the absorption of both ferric and 
ferrous iron, and hephaestin, which is postulated to be important in the transfer of iron 
from enterocytes into the plasma. The relationships and interactions among the newly 
described proteins are not known at this time and are being explored in a number of 
laboratories.  
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The iron concentration within enterocytes varies directly with the body‟s 
requirement for iron. Absorptive cells of iron-deficient humans and animals contain 
little stainable iron, whereas those of subjects who are replete in iron contain 
significantly higher amounts. Untreated phenotypic hemochromatosis creates little 
stainable iron in the enterocyte, similar to iron deficiency. Iron within the enterocyte 
may operate by up-regulation of a receptor, saturation of an iron-binding protein, or 
both.  
In contrast to findings in iron deficiency, enhanced erythropoiesis, or hypoxia, 
endotoxin rapidly diminishes iron absorption without altering enterocyte iron 
concentration. This suggests that endotoxin and, perhaps, cytokines alter iron 
absorption by a different mechanism. This is the effect of hepcidin and the balance of 
hepcidin versus erythropoietin. 
 
Most iron delivered to nonintestinal cells is bound to transferrin. Transferrin 
iron is delivered into nonintestinal cells via 2 pathways: the classical transferrin 
receptor pathway (high affinity, low capacity) and the pathway independent of the 
transferrin receptor (low affinity, high capacity). Otherwise, the nonsaturability of 
transferrin binding to cells cannot be explained.  
 
In the classical transferrin pathway, the transferrin iron complex enters the cell 
within an endosome. Acidification of the endosome releases the iron from transferrin 
so that it can enter the cell. The apotransferrin is delivered by the endosome to the 
plasma for reutilization. The method by which the transferrin receptor–independent 
pathway delivers iron to the cell is not known.  
 
Nonintestinal cells also possess the mobilferrin integrin and DMT-1 pathways. 
Their function in the absence of an iron-saturated transferrin is uncertain; however, 
their presence in nonintestinal cells suggests that they may participate in intracellular 
functions in addition to their capability to facilitate cellular uptake of iron.  
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Etiology 
 
Dietary factors 
Meat provides a source of heme iron, which is less affected by the dietary 
constituents that markedly diminish bioavailability than nonheme iron is. The 
prevalence of iron deficiency Anaemia is low in geographic areas where meat is an 
important constituent of the diet. In areas where meat is sparse, iron deficiency is 
commonplace.  
Substances that diminish the absorption of ferrous and ferric iron include 
phytates, oxalates, phosphates, carbonates, and tannates These substances have little 
effect upon the absorption of heme iron. Similarly, ascorbic acid increases the 
absorption of ferric and ferrous iron and has little effect upon the absorption of heme 
iron. 
Both non heme iron and heme iron have 6 coordinating bonds; however, 4 of the 
bonds in heme bind pyrroles, making them unavailable for chelation by other 
compounds. Therefore, ascorbic acid chelates nonheme iron to enhance absorption but 
has no effect upon heme iron. Many dietary components, such as phytates, 
phosphates, oxalates, and tannates, bind nonheme iron to decrease nonheme iron 
absorption. They do not affect heme. This explains why heme is so effectively 
absorbed with foods containing these chelators. Iron hemoglobin structure.  
Purified heme is absorbed poorly because heme polymerizes into 
macromolecules. Globin degradation products diminish heme polymerization, making 
it more available for absorption. They also increase the absorption of nonheme iron 
because the peptides from degraded globin bind the iron to prevent both precipitation 
and polymerization; thus, absorption of the iron in spinach is increased when the 
spinach eaten with meat. Heme and nonheme iron uptake by intestinal absorptive cells 
is noncompetitive.  
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Hemorrhage 
Bleeding for any reason produces iron depletion. If sufficient blood loss 
occurs, iron deficiency Anaemia ensues A single sudden loss of blood produces a 
posthemorrhagic Anaemia that is normocytic. The bone marrow is stimulated to 
increase production of hemoglobin, thereby depleting iron in body stores. Once they 
are depleted, hemoglobin synthesis is impaired and microcytic hypochromic 
erythrocytes are produced. 
Maximal changes in the red blood cell (RBC) cellular indices occur in 
approximately 120 days, at a time when all normal erythrocytes produced prior to the 
hemorrhage are replaced by microcytes. Before this time, the peripheral smear shows 
a dimorphic population of erythrocytes, normocytic cells produced before bleeding, 
and microcytic cells produced after bleeding. This is reflected in the red blood cell 
distribution width (RDW); thus, the earliest evidence of the development of an iron-
deficient erythropoiesis is seen in the peripheral smear, in the form of increased 
RDW.  
Malabsorption of iron 
Prolonged achlorhydria may produce iron deficiency because acidic conditions 
are required to release ferric iron from food. Then, it can be chelated with mucins and 
other substances (eg, amino acids, sugars, amino acids, or amides) to keep it soluble 
and available for absorption in the more alkaline duodenum.  
Starch and clay eating produce malabsorption of iron and iron deficiency 
Anaemia. Specific inquiry is required to elicit a history of either starch or clay eating 
because patients do not volunteer the information.  
Extensive surgical removal of the proximal small bowel or chronic diseases 
(eg, untreated sprue or celiac syndrome) can diminish iron absorption. Rarely, patients 
with no history of malabsorption have iron deficiency Anaemia and fail to respond to 
oral iron therapy. Most merely are noncompliant with therapy.  
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Before placing these patients on parenteral therapy, document iron 
malabsorption either by measuring absorption of radioiron or by obtaining a baseline 
fasting serum-iron concentration and repeating the test 30 minutes and 1 hour after 
administration of a freshly prepared oral solution of ferrous sulfate (50-60 mg of iron) 
under observation. The serum iron should increase by 50% over the fasting specimen.  
Genetic abnormalities producing iron deficiency have been shown in rodents 
(sex-linked Anaemia [sla] mice, microcytic Anaemia [mk] mice, Belgrade rat). This 
phenomenon has not been clearly demonstrated in humans; if it exists, it is probably 
an uncommon cause of iron deficiency Anaemia 
Epidemiology 
 
International statistics 
In countries where little meat is in the diet, iron deficiency Anaemia is 6-8 
times more prevalent than in North America and Europe. This occurs despite 
consumption of a diet that contains an equivalent amount of total dietary iron; the 
reason is that heme iron is absorbed better from the diet than nonheme iron. In certain 
geographic areas, intestinal parasites, particularly hookworm, worsen the iron 
deficiency because of blood loss from the GI tract. Anaemia is more profound among 
children and premenopausal women in these environs.  
Age-related demographics 
Healthy newborn infants have a total body iron of 250 mg (80 ppm), which is 
obtained from maternal sources. This decreases to approximately 60 ppm in the first 6 
months of life, while the baby consumes an iron-deficient milk diet. Infants 
consuming cow milk have a greater incidence of iron deficiency because bovine milk 
has a higher concentration of calcium, which competes with iron for absorption. 
Subsequently, growing children must obtain approximately 0.5 mg more iron daily 
than is lost in order to maintain a normal body concentration of 60 ppm.  
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During adult life, equilibrium between body loss and gain is maintained. 
Children are more likely to develop iron deficiency Anaemia. In certain geographic 
areas, hookworm adds to the problem. Children are more likely to walk in soil without 
shoes and develop heavy infestations.  
 
During childbearing years, women have a high incidence of iron deficiency 
Anaemia because of iron losses sustained with pregnancies and menses.  
 
Gastrointestinal neoplasms become increasingly more prevalent with each 
decade of life. They frequently present with GI bleeding that may remain occult for 
long intervals before it is detected. Usually, bleeding from neoplasms in other organs 
is not occult, prompting the patient to seek medical attention before developing severe 
iron depletion. Investigate the etiology of the iron deficiency Anaemia to evaluate for 
a neoplasm.  
 
Sex-related demographics 
An adult male absorbs and loses about 1 mg of iron from a diet containing 10-
20 mg daily. During childbearing years, an adult female loses an average of 2 mg of 
iron daily and must absorb a similar quantity of iron in order to maintain equilibrium. 
Because the average woman eats less than the average man does, she must be more 
than twice as efficient in absorbing dietary iron in order to maintain equilibrium and 
avoid developing iron deficiency Anaemia.  
 
Healthy males lose body iron in sloughed epithelium, in secretions from the 
skin and gut lining, and from small daily losses of blood from the GI tract (0.7 mL 
daily). Cumulatively, this amounts to 1 mg of iron. Males with severe siderosis from 
blood transfusions can lose a maximum of 4 mg daily via these routes without 
additional blood loss.  
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A woman loses about 500 mg of iron with each pregnancy. Menstrual losses 
are highly variable, ranging from 10 to 250 mL (4-100 mg of iron) per period. These 
iron losses in women double their need to absorb iron in comparison to males. A 
special effort should be made to identify and treat iron deficiency during pregnancy 
and early childhood because of the effects of severe iron deficiency upon learning 
capability, growth, and development.  
Race-related demographics 
Race probably has no significant effect upon the occurrence of iron deficiency 
Anaemia; however, because diet and socioeconomic factors play a role in the 
prevalence of iron deficiency, it more frequently is observed in people of various 
racial backgrounds living in poorer areas of the world.  
  
Prognosis 
Iron deficiency Anaemia is an easily treated disorder with an excellent 
outcome; however, it may be caused by an underlying condition with a poor 
prognosis, such as neoplasia. Similarly, the prognosis may be altered by a comorbid 
condition such as coronary artery disease. Promptly and adequately treat a patient 
with iron deficiency Anaemia who is symptomatic with such comorbid conditions.  
Chronic iron deficiency Anaemia is seldom a direct cause of death; however, 
moderate or severe iron deficiency Anaemia can produce sufficient hypoxia to 
aggravate underlying pulmonary and cardiovascular disorders. Hypoxic deaths have 
been observed in patients who refuse blood transfusions for religious reasons. 
Obviously, with brisk hemorrhage, patients may die from hypoxia related to 
posthemorrhagic Anaemia.  
Whereas a number of symptoms, such as ice chewing and leg cramps, occur 
with iron deficiency, the major debility of moderately severe iron deficiency is fatigue 
and muscular dysfunction that impairs muscular work performance.  
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In children, the growth rate may be slowed, and a decreased capability to learn 
is reported. In young children, severe iron deficiency Anaemia is associated with a 
lower intelligence quotient (IQ), a diminished capability to learn, and a suboptimal 
growth rate.  
Patient Education 
Physician education is needed to ensure a greater awareness of iron deficiency 
and the testing needed to establish the diagnosis properly. Physician education also is 
needed to investigate the etiology of the iron deficiency.  
Public health officials in geographic regions where iron deficiency is prevalent 
need to be aware of the significance of iron deficiency, its effect upon work 
performance, and the importance of providing iron during pregnancy and childhood. 
The addition of iron to basic foodstuffs is employed in these areas to diminish the 
problem.  
 
Iron Deficiency Anaemia Clinical Examinations 
History 
Whereas iron deficiency Anaemia is a laboratory diagnosis, a carefully 
obtained history can facilitate its recognition. The history can be useful in establishing 
the etiology of the Anaemia and, perhaps, in estimating its duration.  
Iron deficiency in the absence of Anaemia is asymptomatic. One half of 
patients with moderate iron deficiency Anaemia develop pagophagia. Usually, they 
crave ice to suck or chew. Occasionally, patients are seen who prefer cold celery or 
other cold vegetables in lieu of ice. Leg cramps, which occur on climbing stairs, also 
are common in patients deficient in iron.  
Often, patients can provide a distinct point in time when these symptoms first 
occurred, providing an estimate of the duration of the iron deficiency.  
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Fatigue and diminished capability to perform hard labor are attributed to the 
lack of circulating hemoglobin; however, they occur out of proportion to the degree of 
Anaemia and probably are due to a depletion of proteins that require iron as a part of 
their structure.  
Increasing evidence suggests that deficiency or dysfunction of nonhemoglobin 
proteins has deleterious effects. These include muscle dysfunction, pagophagia, 
dysphagia with esophageal webbing, poor scholastic performance, altered resistance 
to infection, and altered behavior.  
Dietary history 
A dietary history is important. Vegetarians are more likely to develop iron 
deficiency, unless their diet is supplemented with iron. National programs of dietary 
iron supplementation are initiated in many portions of the world where meat is sparse 
in the diet and iron deficiency Anaemia is prevalent. Unfortunately, affluent nations 
also supplement iron in foodstuffs and vitamins without recognizing the potential 
contribution of iron to free radical formation and the prevalence of genetic iron 
overloading disorders.  
Elderly patients, because of poor economic circumstances, may try to survive 
on a “tea and toast” diet because they do not wish to seek aid. They may also be 
hesitant to share this dietary information. This group is far more likely to develop 
protein-calorie mal nutrition before they develop iron deficiency Anaemia.  
A fundamental concept is that after age 1 year, dietary deficiency alone is not 
sufficient to cause clinically significant iron deficiency and a source of blood loss 
should always be sought as part of the management of a patient with iron deficiency 
Anaemia. Infants and toddlers are the primary risk groups for dietary iron deficiency 
Anaemia. Neonates who double their birth weight are a special risk group.  
 
 
 48  
 
Pica is not a cause of iron deficiency Anaemia; pica is a symptom of iron 
deficiency Anaemia. It is the link between iron deficiency Anaemia and lead 
poisoning, which is why iron deficiency Anaemia should always be sought when a 
child is diagnosed with lead poisoning. Hippocrates recognized clay eating; however, 
modern physicians often do not recognize it unless the patient and family are 
specifically queried. Both substances decrease the absorption of dietary iron. Clay 
eating occurs worldwide in all races, though it is more common in Asia Minor. Starch 
eating is a habit in females of African heritage, and it often is started in pregnancy as 
a treatment for morning sickness.  
History of hemorrhage 
Two thirds of body iron is present in circulating red blood cells as 
hemoglobin. Each gram of hemoglobin contains 3.47 mg of iron; thus, each mL of 
blood lost from the body (hemoglobin 15 g/dL) results in a loss of 0.5 mg of iron.  
Bleeding is the most common cause of iron deficiency, either from parasitic 
infection (hookworm) or other causes of blood loss. Patients report a history of 
bleeding from most orifices (hematuria, hematemesis, hemoptysis) before they 
develop chronic iron deficiency Anaemia; however, gastrointestinal bleeding may go 
unrecognized, and excessive menstrual losses may be overlooked. 
Patients often do not understand the significance of a melanotic stool. Unless 
menstrual flow changes, patients do not seek medical attention. If they do, they report 
that their menses are normal in response to inquiry for self-evaluation. Because of the 
marked differences among women with regard to menstrual blood loss (10-250 mL 
per menses), query the patient about a specific history of clots, cramps, and the use of 
multiple tampons and pads.  
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Physical Examination  
  
Anaemia produces nonspecific pallor of the mucous membranes. A number of 
abnormalities of epithelial tissues are described in association with iron deficiency 
Anaemia. These include esophageal webbing, koilonychia, glossitis, angular 
stomatitis, and gastric atrophy.  
 
 
 
Koilonychia Glossitis Angular Stomatitis 
The exact relationship of these epithelial abnormalities to iron deficiency is 
unclear and may involve other factors. For example, in publications from the United 
Kingdom, esophageal webbing and atrophic changes of the tongue and the corner of 
the mouth are reported in as many as 15% of patients with iron deficiency; however, 
they are much less common in the United States and other portions of the world.  
Spleenomegaly may occur with severe, persistent, untreated iron deficiency 
Anaemia.  
Complications of Anaemia 
Iron deficiency Anaemia diminishes work performance by forcing muscles to 
depend on anaerobic metabolism to a greater extent than they do in healthy 
individuals. This change is believed to be attributable to deficiency in iron-containing 
respiratory enzymes rather than to Anaemia.  
Severe Anaemia due to any cause may produce hypoxemia and enhance the 
occurrence of coronary insufficiency and myocardial ischemia. Likewise, it can 
worsen the pulmonary status of patients with chronic pulmonary disease.  
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Defects in structure and function of epithelial tissues may be observed in iron 
deficiency. Fingernails may become brittle or longitudinally ridged, with the 
development of koilonychia (spoon-shaped nails). The tongue may show atrophy of 
the lingual papillae and develop a glossy appearance. Angular stomatitis may occur 
with fissures at the corners of the mouth.  
Dysphagia may occur with solid foods, with webbing of the mucosa at the 
junction of the hypopharynx and the esophagus (Plummer-Vinson syndrome); this has 
been associated with squamous cell carcinoma of the cricoid area. Atrophic gastritis 
occurs in iron deficiency with progressive loss of acid secretion, pepsin, and intrinsic 
factor and development of an antibody to gastric parietal cells. Small intestinal villi 
become blunted.  
Cold intolerance develops in one fifth of patients with chronic iron deficiency 
Anaemia and is manifested by vasomotor disturbances, neurologic pain, or numbness 
and tingling.  
Rarely, severe iron deficiency Anaemia is associated with papilledema, 
increased intracranial pressure, and the clinical picture of pseudotumor cerebri. These 
manifestations are corrected with iron therapy.  
Impaired immune function is reported in subjects who are iron deficient, and 
there are reports that these patients are prone to infection; however, because of the 
presence of other factors, the current evidence is insufficient to establish that this 
impairment is directly due to iron deficiency.  
Children deficient in iron may exhibit behavioral disturbances. Neurologic 
development is impaired in infants and scholastic performance is reduced in children 
of school age. The intelligence quotients (IQs) of schoolchildren deficient in iron are 
reported to be significantly lower than those of their nonanemic peers. Behavioral 
disturbances may manifest as an attention deficit disorder. Growth is impaired in 
infants with iron deficiency. The neurologic damage to an iron-deficient fetus results 
in permanent neurologic injury and typically does not resolve on its own. Iron 
repletion stabilizes the patient so that his or her status does not further decline.  
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Differential Diagnosis 
 Sideroblastic Anaemias 
 Spherocytosis, Hereditary 
 Thalassemia, Alpha 
 Thalassemia, Beta 
Prevention 
Certain populations are at sufficiently high risk for iron deficiency to warrant 
consideration for prophylactic iron therapy. These include pregnant women, women 
with menorrhagia, consumers of a strict vegetarian diet, infants, adolescent females, 
and regular blood donors.  
Pregnant women have been given supplemental iron since World War II, often 
in the form of all-purpose capsules containing vitamins, calcium, and iron. If the 
patient is anemic (hemoglobin < 11 g/dL), administer the iron at a different time of 
day than calcium because calcium inhibits iron absorption.  
The practice of routinely administering iron to pregnant females in affluent 
societies has been challenged; however, it is recommended to provide prophylactic 
iron therapy during the last half of pregnancy, except in settings where careful follow-
up for Anaemia and methods for measurement of serum iron and ferritin are readily 
available.  
Iron supplementation of the diet of infants is advocated. Premature infants 
require more iron supplementation than term infants. Infants weaned early and fed 
bovine milk require more iron because the higher concentration of calcium in cow 
milk inhibits absorption of iron. Usually, infants receive iron from fortified cereal. 
Additional iron is present in commercial milk formulas.  
Iron supplementation in populations living on a largely vegetarian diet is 
advisable because of the lower bioavailability of inorganic iron than heme iron.  
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The addition of iron to basic foodstuffs in affluent nations where meat is an 
important part of the diet is of questionable value and may be harmful. The gene for 
familial hemochromatosis (HFe gene) is prevalent (8% of the US white population). 
Excess body iron is postulated to be important in the etiology of coronary artery 
disease, strokes, certain carcinomas, and neurodegenerative disorders because iron is 
important in free radical formation.  
Long-Term Monitoring 
Monitor patients with iron deficiency Anaemia on an outpatient basis to 
ensure that there is an adequate response to iron therapy and that iron therapy is 
continued until after correction of the Anaemia to replenish body iron stores. Follow-
up also may be important to treat any underlying cause of the iron deficiency.  
Response to iron therapy can be documented by an increase in reticulocytes 5-
10 days after the initiation of iron therapy. The hemoglobin concentration increases 
by about 1 g/dL weekly until normal values are restored. These responses are blunted 
in the presence of sustained blood loss or coexistent factors that impair hemoglobin 
synthesis.  
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PRINCIPLES AND PROPERTIES OF TRIAL DRUG 
1.Karisaalai 
Botanical name  
Eclipta prostrate, Roxb. 
Family  
Compositae. 
English name.  
Trailing eclipta. 
Organoleptic characters 
Taste: Kaipu 
Potency : Vepam 
Division: Karpu 
Parts used.  
Leaves, flowers. 
Action 
Cholagogue, emetic, tonic, aphrodisiac, hepatic tonic. 
Pothu Gunam 
 
 
 
    
 Fzghlk; %ypif tFg;G. 
 
Uses  
Jaundice, pruritis, scabies, enlargement of spleen, liver. 
 
2.Dhania                                 
Botanical name  
Coriandrum sativum, Linn. 
Family  
Umbelliferae 
English name.  
Coriander. 
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Organoleptic characters 
Taste: Karpu 
Potency : Seetha Vepam 
Division: Karpu 
Parts used.  
Fruit, leaves. 
 
Pothugunam 
 
nfhj;Jky;yp ntg;gk; Fsph;fha;r;ry; gpj;jke;jQ; 
rhj;jptpf;fy; jhfnkhL jhJel;lk; - fj;jpnaOk; 
thj tpfhh;klh; td;fh;j;j gptpuzk; 
G+jyj;jpy; yhjfw;Wk; Nghw;W. 
 Fzghlk; %ypif tFg;G. 
 
Chemical Constituents  
Coriandrol, dpinene, lpinene, mucilage, tannin, malic acid 
Action 
Aromatic, stimulant,tonic, carminative,anti-diabetic 
Uses 
Diabetes,flatulence, colic sore-throat, vertigo. 
 
3. Mookkirattai  
Botanical name  
Boerhaavia diffusa, Linn. 
Family  
Nyctagineae. 
English name.  
Spreading hog-weed. 
Organoleptic characters 
Taste: Kaipu 
Potency : Vepam 
Division: Karpu 
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Parts used.  
Herb, root. Punarnavine,  
Chemical Constituents  
potassium nitrate, fat, ash. 
Action 
Stomachic, laxative, diuretic, diaphoretic, expectorant. 
Pothugunam 
 
 
 
-- 
Fzghlk; %ypif tFg;G. 
Uses 
Dropsy, ascities, asthma, heart disease, stone in the kidney, colic. 
 
4. Nellikai 
Botanical name  
Emblica officinalis. 
Family  
Euphorbiaceae. 
English name 
Emblicmyrobalan, Indian gooseberry. 
Organoleptic Charecters 
Taste   -  Pulippu, Thuvarppu, Inippu 
Potency       - Thatpam 
 Pirivu          - Inippu 
Parts used. 
Dried fruit, nut or seed, leaves, rootbark, flowers 
Action 
Refrigerant, diuretic, laxative, astringent. 
Pothugunam 
gpj;jkd iyak; gPerk;tha; ePh; the;jp 
kj;jkyf; fhLk; kaf;fKkpy; - xj;jTU 
tpy;ypf;fh ak;kUq;fh nkd;dhl;fh ye;Njh;e;Nj 
ney;ypfh ak;kUe; JzP. 
Fzghlk; %ypif tFg;G. 
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Uses 
Jaundice, inflammation of lungs, hiccup, dyspepsia, nausea, vomiting, phthisis. 
 
5.Elam 
Botanical name  
 Elettaria cardamomum, Maton. 
Family  
Scitaminaceae. 
English name 
Cardamom.  
Organoleptic characters 
Taste: Karpu 
Potency : Vepam 
Division: Karpu 
 
Parts used. 
Dried ripe seeds, oil from fruits.  
Chemical Constituents  
Fixed oil, essential oil, volatile oil, cincole, free terpineol.  
Action 
Aromatic, stimulant, carminative, stomachic, diuretic. 
Pothugunam 
 
 
 
 
 
Fzghlk; %ypif tFg;G. 
Uses 
Stomach complaints, diarrhea, atonic dyspepsia, vomiting. 
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6. Karunjeragam 
Botanical name 
Nigella sativa, Linn.  
Family 
Rananculaceae 
English name 
Small fennel or Black cumin. 
Parts used 
Dried fruits and seeds. 
 
Organoleptic Characters 
Taste     : Kaippu 
Potency : Veppam 
pirivu     : Kaarppu 
Chemical constituents 
Volatile oil, mucilage, metarbin, melanthin, Arabic acid.  
Action 
Aromatic, diuretic, stomachic, stimulant, carminative, anthelmintic. 
Pothu gunam 
              “¸Õïº£ Ã¸ò¾¡ý ¸ÃôÀ¦É¡Î ÀñÏõ 
                ÅÕïº¢Ã¡öô À£¿ºÓ Á¡üÚõ - «Õó¾¢É¡ø 
                ¸¡öîºø ¾¨ÄÅÄ¢Ôí ¸ñÅÄ¢Ôõ §À¡ÓÄ¸¢ø 
     
-  
 Å¡öîº ÁÕó¦¾É§Å ¨Å.” -  Fzghlk; %ypif tFg;G. 
 
Uses 
 Obstinate hiccup, fever, diarrhea, skin diseases, dropsy, puerperal diseases, sour 
belching. 
7. Thippili 
Botanical name 
Piper longum, Linn. 
Family 
Piperaceae. 
English name 
Dried catkins, long-pepper. 
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Parts used 
Immature berries, stems, roots. 
Organileptic characters 
 
Taste: Pungent 
 Potency: Hot 
Division: Sweet 
 
Chemical constituents 
Resin, volatile oil, fatty oil, inorganic matter, piperine 
Action  
Stimulant, carminative, expectorant, diuretic. 
Pothu gunam 
Uses 
Cough, cold, asthma, hoarseness, hiccup, colic, flatulence. 
 
8.Milagu 
Botanical name 
Piper nigrum, Linn 
Family 
Piperaceae 
English name 
Black pepper, decorticated pepper; common pepper 
Organoleptic characters 
Taste: Kaipu,Karpu 
Potency : Vepam 
Division: Karpu 
Part used 
Dried unripe fruit  
Chemical constituents 
Piperine, piperidine, chavicin. 
 59  
 
Action 
Carminative, antiperiodic, resolvent, anti-pyretic. 
Pothu gunam 
 
Fzghlk; %ypif tFg;G. 
 
Uses 
Dyspepsia, flatulence, colic, worms, ascitis, asthma, gonorrhoea, piles. 
 
9. Thalisa pathiri 
Botanical name 
Taxus buccata, Linn. 
Family 
Coniferae. 
English name 
Himalayan yew. 
Organoleptic characters 
Taste: Karpu 
Potency : Vepam 
Division: Karpu 
Part used 
Leaves. Volatile oil 
Chemical constituents 
Volatile oil tannic and gallic acids, toxin, a resin. 
Action 
Carminative, expectorant, stomachic, tonic, anti lithic, anti spasmodic. 
Pothugunam 
 
 
 
-- 
  Fzghlk; %ypif tFg;G. 
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Uses 
Breast cancer, asthma, haemoptysis, epilepsy, calculus complaints, hysteria, 
spasmodic affections. 
10. Thaandrikai 
Botanical name 
Terminalia bellerica, Roxb. 
Family 
Combretaceae. 
English name 
Belericmyrobalans. 
Part used 
Fruits. 
Pothu  gunam 
Fzghlk; %ypif tFg;G. 
 
Organoleptic characters: 
 
Taste : Bitter 
Potency : Hot 
 Pirivu : Sweet 
Chemical constituents 
Gallo-tannic acid, coloring matter, resin, oil. 
Action 
Astringent, tonic, laxative, expectorant. 
Uses 
Cough, hoarseness, sore-throat, dropsy, dysentery, diarrhea, fractures, asthma. 
11.Kadukkai 
Botanical name 
Terminalia chebula, Retz. 
Family 
Combretaceae. 
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English name 
Myrobalan, chebulic myrobalan. 
Part used 
Dried fruits, galls. 
 
Organoleptic characters: 
 
 Taste : Astringent, sweet, sour, acrid, bitter. 
 Potency : Hot 
 Pirivu : Sweet 
 
Chemical constituents 
Tannin, tannic acid, gallic acid, mucilage, chebulinic acid. 
Action 
Astringent, purgative, alterative, stomachic, laxative, tonic. 
Pothu gunam 
     
 Fzghlk; %ypif tFg;G. 
 
Uses 
Worms, fever, cough, asthma, urinary disease, piles, hiccup, vomiting, swellings. 
 
12.Inji 
Botanical name 
Zingiber officinale, Rosc. 
Family 
Zingiberaceae. 
English name 
Ginger. 
Part used 
Rhizome. 
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Organoleptic characters 
 
Taste: Kaarpu 
Potency: Veppam 
Division: Kaarpu 
 
Chemical constituents 
Phellandrene, gingerol, gingerin. 
Action 
Carminative, aromatic, stimulant, increases 
prostaglandins, adjuvant to tonic remedies. 
Pothu gunam 
 
#iyke;jk; neQ;nrhpg;G NjhlNk gk;koiy 
%yk; ,iug;gpUky; %f;FePh; - thyfg 
Njhlkjp rhue; njhlh;thj Fd;kePh;j; 
Njhlk;M kk;Nghf;FQ; Rf;F. 
Fzghlk; %ypif tFg;G. 
Uses 
Cough, cold, indigestion, dysentery, peptic ulcer, flatulence. 
 
13.Seerakam 
Botanical name 
Cuminum cyminum, Linn 
Family 
Umbelliferae. 
English name 
Cumin seed, caraway seed. 
Organoleptic characters 
Taste: Karpu,Inipu 
Potency : Thatpam 
Division: Inipu 
 
Part used 
Fruit or seed, 
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Chemical constituents 
essential oil. Thymine, carvone, cuminol or cumic aldehyde, cymene or cymol, 
terpene. 
Action 
 Carminative, aromatic, stomachic, stimulant, astringent. 
Pothugunam 
 
 
 
- 
  Fzghlk; %ypif tFg;G. 
Uses 
Hoarseness of voice, dyspepsia, chronic diarrhea, bilious nausea in pregnant women. 
 
14. Athimathuram 
Botanical name 
Glycyrrhiza glabra, Linn 
Family 
Liquorice  
Organoleptic characters 
Taste: Inipu 
Potency : Thatpam 
Division: Inipu 
 
Part used  
Root and Rhizomes 
Chemical constituents 
 Triterpenoids , saponin  , glycyrrhizin , glycyrrhizinic acid , glabrin A&B, 
glycyrrhetol , glabrolide,  isoglabrolide,  isoflavones, coumarins, triterpene  sterols 
etc.. 
Actions  
Tonic, demulcent, expectorant, diuretic, mild laxative, anti-arthritic, anti-  
inflammatory, anti-biotic, anti-viral, anti-ulcer,  memory stimulant (being MAO  
inhibitor), anti-tussive, aphrodisiac, anti-mytotic, estrogenic, anti-oxidant, anti-caries  
agent, anti-neoplastic, anti cholinergic, anti-diuretic, hypolipidemic activity, etc. 
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Pothugunam 
 
 
 
- 
  
      Fzghlk; %ypif tFg;G. 
 
Uses 
Anaemia, menorrhagia-metrorrhagia,  hoarseness of voice, cardiac tonic, 
haematemisis. intrinsic  haemorrhage.  
15.Maramanjal 
Botanical name 
Coscinium fenestratum (Gaertn.) Colebr. 
Family 
Menispermaceae 
English name 
Tree turmeric 
Part used 
Stem. 
Pothu gunam 
 
mod;wfz %yk; mUrp AlNd 
cod;w fzr;RuKk; XLQ; - Rod;Ws;Ns 
tPWRu Ke;jzpAk; tPRku kQ;rSf;Fj; 
NjW nkhopadNk! nrg;G. 
Fzghlk; %ypif tFg;G. 
 
Organoleptic Charecters 
Taste   -  Kaippu 
Potency       - Veppam 
 Pirivu          - Kaarppu 
Chemical constituents 
Phenols, Alkaloids, Terpenoids,  flavanoids 
Uses 
Diabetes mellitus , Fever , Dysentery , Piles ,Ulcers 
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KARISALAI 
  
 
DHANIA 
  
 
MOOKIRATTAI 
  
 
NELLIKAI 
  
 
ELAM 
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KARUNJEERAKAM 
  
 
THIPPILI 
  
 
 
 
 
MILAGU 
 
  
  
 
THALISAPATHIRI 
  
 
THANTRIKAI 
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KADUKKAI 
  
 
SUKKU 
  
 
SEERAGAM 
  
 
ATHIMATHURAM 
  
 
MARAMANJAL 
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METHODS OF THE STUDY 
 
 
PREPARATION OF “KARISALANKANNI CHOORANAM” 
 
Required raw drugs: 
 
1. Karisali -  Eclipta alba,linn 
2. Kadukai – Terminalia chebula, Retz. 
3. Nellivatral– Phyllanthus emblica,Linn 
4. Thaandrikai – Terminalia bellarica.(Gaertn) Rox 
5. Mookkirattai – Boerhaavia diffusa ,linn.  
6. Sukku – Zingiber officinalis,Rosc. 
7. Milagu – Piper nigrum,Linn. 
8. Thippili – Piper longum,Linn. 
9. Karunjeragam –  Nigella sativa ,Linn 
10. Seeragam –Cuminum cyminum,Linn 
11. Athimathuram – Glycrrhiza glabra,Linn  
12. Thalisa pathiri –  Abies spectabilis (d.don ) mirr 
13. Mara manjal – Coscinium fenestratum,(Gaertn)Colebr. 
14. Dhania- Coriandrum sativum ,linn   
15. Elam: Elettaria cardamomum ,maton 
 
Proportion of Drugs:   Karisalai-   4 Thola (48 g)  
                                   Other drugs-1 Thola (12 g) (each) [24] 
 
Source of raw drugs 
  The above said raw drugs are purchased from a well reputed country shop 
.The raw drugs will be authenticated by the  Head of the department of Medicinal 
Botany ,at NIS. The raw drugs are purified and the  medicine is prepared  in 
Gunapadam laborotary of NIS.The prepared medicine is again authenticated by 
the  Head of the department of Gunapadam. 
 
 
 
Purification of the raw drugs: 
 
1.Karisali -  Eclipta alba,linn 
Clean  the leaves with pure cloth and remove the rotten leaves([7]  
 
2.Kadukai – Terminalia chebulla.Retz. 
Soak the kadukai in rice water(kazhuneer), remove the yellowish tint of the water    
and seed and dry it.[8] 
 
3.Nellikai – Phyllanthus emblica,Linn 
Boil it with milk, remove the seed and dry it.[9] 
 
4.Thaandrikai – Terminalia bellarica.(Gaertn) Roxb  
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Soak it in Pandanus odoratissimus( Thaludhalai),Linn.f juice for three hours (1-
Samam) remove the seed and dry it. [10] 
 
5.Sukku – Zingiber officinalis,Rosc 
Double the propotion of  lime stone[calcium carbonate] solution is poured and 
boiled for three hours, then wash it, dry and remove the peel. [11] 
 
6.Milagu – Piper nigrum,Linn. 
Soak it in sour butter milk for three hours. [12] 
 
7.Thippili – Piper longum,Linn. 
Soak it in plumbago zeylanica,Linn(Kodiveli) leaf juice for twenty four minutes  
(1 Nazhigai) and dry it sun.[13] 
 
8.Mara manjal – Coscinium fenestratum,(gaertn)Colebr. 
Remove the peel cut it into pieces and dry it in sunlight. [14] 
 
9.Karunjeragam –  Nigella sativa ,Linn 
Dry it in sunlight &fry it like as golden  yellow colour  [15] 
 
10.Seeragam –Cuminum cyminum,Linn    
Dry it in sunlight &fry it like as golden  yellow colour[16] 
 
11.Athimathuram – Glycrrhiza glabra,Linn  
Wash with clean water and Remove the peel cut it into pieces[17] 
 
12.Mookkirattai – Boerhaavia diffusa ,linn 
Clean the leaves with pure cloth and remove the rotten leaves[18] 
 
13.Thalisa pathiri –  Abies spectabilis (d.don ) mirr 
Clean the leaves with pure cloth and remove the rotten leaves[19] 
 
14.Dhania- coriandrum sativum ,linn   
Boil Kothumali seed with Hotwater & dry it in sunlight[20] 
 
15.Elam: elettaria cardamomum ,maton  
Remove the peel & take the seeds[21] 
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METHOD OF PREPARATION 
       The above mentioned drugs are purified properly as said above and 
they are dried in shade & made into fine powder 
 
 
KARISALANKANNI CHOORANAM 
 
DRUG STORAGE: The drug thus prepared is stored in a clean and dry glass bottles. 
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PROTOCOL 
 
1.0 TITLE :  
A study on the PITHA PANDU (Iron Deficiency Anaemia) and the drug of 
choice   is KARISALANKANNI CHOORANAM”   
 
2.0 REG NO:32101202      /DD/ MM/2011    DATE OF SUBMISSION:14-12-2011 
 
3.0 NAME OF THE INSTITUTION 
     National Institute of Siddha 
     Tambarm Sanatorium, Chennai-47 
     Telephone No : 044-22411611 
     Fax                  : 044-22381314 
     E.Mail            : nischennaisiddha@yahoo.co.in 
     Website            : www.nischennai.org 
 
4.0 NAME AND DESIGNATION: 
      PG STUDENT:           DR. M.GOBI KRISHNAN 
                                          MD II YR[2011-2012] 
                                          DEPARTMENT OF MARUTHUVAM 
 
5.0 BACKGROUND:   
 
Anaemia is one of the worldwide health problem. It has significant prevalence in      
developing countries,like India because of low dietary intake of iron,chronic  blood 
loss due to hookworm infestation& Malaria.The World Health Organization estimates 
that 30% of the world`s population is anaemic of which 50% is attributed to iron 
deficiency anaemia [1].[2] 
 
Every age group is vulnerable to  iron deficiency anaemia,and women are more 
likely to suffer than men because of the loss of blood every month,due to 
mensuration. 
 
       To overcome iron deficiency anaemia in India, The measures to be taken both in 
Preventive& curative aspects.  
 
         A well defined system developed by siddhars,known as Siddha system of 
medicine, in  which the diseases are classified into 4448  types on the basis of  
Mukkutram. In Yoogi Vaithiya Chinthamani text Yoogi Munivar  classified  PANDU 
into 5types and PITHA PANDU[3]  is one among them. 
 
        It include the symptoms like pallor of the skin and mucous membrane, 
fatigue,lassitude,chest discomfort,breathlessness,pica,giddiness,dizziness,angular 
stomatitis,glossitis,pungent or bitter taste [3][4][5]  well explained in siddha literature 
may be correlated with Iron Deficiency Anaemia,in Modern science. 
     
I have Selected Karisalankani Chooranam, Because the main ingredients of this drug 
are available through out the year& It is affordable for the patient. The major 
ingredients have the potency to cure Iron deficiency Anaemia as per our text. 
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  Eventhough currently available oral iron preparations can correct iron deficiency,it 
has gastrointestinal side effects like nausea,constipation or diarrhea and it takes long 
duration to iron get replenshied.  
  
      In   Sigicha Rathna Deepam  “KARISALANKANNI CHOORANAM ” is 
indicated for  pandu specifically (Ref:Page: 162) 
 
The ingredients of this formulation are found to be efficacious & cost effective.  
 
  In  Gunapadam-Mooligai Vaguppu Karisalankanni  has the indication for anaemia [6] 
 
      The above said drug formulation, has not undergone any clinical trial, so far. So, it 
is proposed to carry a Clinical Trial to find out its efficacy in Pitha Pandu.  
  
 
6.0 OBJECTIVES 
 
2) Primary objective: 
                   To evaluate the Siddha Therapeutic efficacy of the Poly Herbal 
formulation  
 
 
 
“KARISALANKANNI CHOORNAM” (Internal) in “ PITHA PANDU”  
  (Iron Deficienccy  Anaemia)  
 2)Secondary objective:  
 -To evaluate the safety profile(acute,long term toxicity studies) of the trial drug 
-To study the effect of other co-factors such as age, sex & dietary influence  
 
 
7.0 STUDY DESIGN AND CONDUCT OF THE STUDY 
 
7.1 Study type: An Open Clinical Trial  
       
7.2Study place: 
           Ayothidasar  Pandithar Hospital, 
           Dept of Maruthuvam 
National Institute of Siddha, 
Tambaram Sanatorium, Chennai-47. 
 
 
7.3  Study period:12 Months 
 
7.4 Sample size:40 patients. 
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7.5Treatment: 
          
     Medicine Name: KARISALANKANNI CHOORANAM (Internal) 
           
    Ref: Sigicha Ratna Deepam- pg 162 
              
              Dosage: Thirikadi pramanam [1g] [24] 
                          ( Twice/day) before food. 
              
              Adjuvant:  white sugar 
 
              Course: 1/2 Mandalam[24 days] 
             
DISPENSING: The Chooranam is  dispensed in Sachets. 
 
 
QUANTITY OF MEDICINE:   
 
A packet of 24 Sachets for 12 days , each  sachet consist of1 gm  
 
The pt have to visit twice for 24 days 
    
 
8.0 SUBJECT SELECTION 
           
      As and when patients  reporting at OPD of Ayothidasar Pandithar Hospital,NIS 
with symptoms of inclusion criteria will be subjected  to screening  test & 
documented using screening  proforma . 
 
 
 
 
9.0 SELECTION CRITERIA 
 
 INCLUSION CRITERIA 
 Age 18-55 of both sexes. 
 Clinical symtoms of Pallor, Breathlessness, Palpitation, Anorexia, 
Giddiness,Numbness,Glossitis,lassitude,Fatigue,koilonychias etc., 
 Hb level  less than normal range ie.,7-13mg/dl for Men,7-10mg/dl for 
Women 
 Patient blood smear shows microcytic hypochromic RBC 
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EXCLUSION CRITERIA 
 infection 
 Bleeding disorder(Bleeding piles,Menorrhagia) 
 Pregnancy and lactation 
 Presence of any associated severe systemic illness (e.g.CA,RA) 
 Endocrine disorder(Thyroid abnormality,Diabetes mellitus) 
 H/o Steroid exposure for prolonged period. 
 Cardiac disease  
 Renal disease 
 Peptic Ulcer 
 Inherited defects(sickle cell Anaemia,Thalassemia) 
 Malabsorption syndrome 
 
WITHDRAWAL CRITERIA 
 Intolerance to the drug, and development of adverse reactions during the 
drug trial  
 Severe abdominal pain 
 Nausea 
 Any other acute illness 
 Poor patient compliance and defaulters 
 
 
11.0 ASSESSMENTS AND INVESTIGATIONS: 
 
        A)Clinical assessment 
             Siddha assessment 
        B)Routine investigations 
        C)Special investigations 
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 A)CLINICAL ASSESSMENT: 
      
 Pallor  
 Oedema of the Body 
 Breathlessness 
 Palpitation  
 Tachycardia 
 Anorexia  
 Giddiness 
 Numbness 
 Tingling sensation 
 Lack of concentration  
 Amenorrhoea.  
 Angular stomatitis  
 Glossitis 
 Cheliosis 
 Koilonychia 
 Hair fall  
 Lassitude 
 Fatigue 
 Pica 
 Faint 
 Chest Discomfort 
 Bitter / Pungent taste[22] [23] 
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SIDDHA ASSESSMENT 
1.Thinai : 
 Kurinchi (hill areas) 
 Mullai ( forest ) 
 Marutham ( fertile land ) 
 Neidhal ( coastal area ) 
 Palai ( desert ) 
2. Paruva Kalam ( season )  
  Karkaalam 
  Koothir kaalm 
  Munpanikaalm 
  Pinpani kaalam 
  Ilavenil kaalam 
  Muthuvenil kaalam 
3. Poripulankal: 
 Mei (Skin etc) 
 Vaai (Tongue etc) 
 Kan (Eye etc) 
 Mooku (Nose etc) 
 Sevi (Ear etc) 
 
4.Kanmedriyam and Gnanenthiriyam: 
 Vaai (Buccal cavity) 
 Kaal (Lower limbs) 
 Kai (Upper limbs) 
 Eruvaai (Anorectal region) 
 Karuvaai (Uro-genital re 
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 5. Ezhuudalkattugal: 
 Saram 
 Senneer 
 Uoon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam /suronitham 
 
 
6.Ennvagaithervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
-Neerkuri 
 -Neikuri 
 
 
SIDDHA PARAMETERS 
     Malam 
         Moothiram  
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B)ROUTINE INVESTIGATIONS           
 Modern Parameters: 
           
  Liver function test- 
                             SGOT: 6-18IU/L 
                             SGPT: 3-26IU/L 
                             Serum alkaline phosphotase: 3-12mg/dl 
 Renal function test-Blood Urea: 16-50mg/dl 
                              Creatinine: 0.6-1.2mg/dl 
                              Uric acid: Men:3-9mg/dl,Women:2.5-
7.5mg/dl 
 
Blood sugar level- Fasting (80-120 mg/dl) 
                                Postbrandial < 130 mg/dl 
                                Random: <140mg/dl 
                            
 Bleeding time: 2-6/min 
 Clotting time: 3-8/min 
 
 Urine:Albumin- Nil 
        Sugar-Nil 
        Deposits-Nil 
        Bile salts-Nil 
        Bile pigments-Nil 
                                              Urobilinogen-Nil 
 
 Motion:Ova-Nil 
           Cyst-Nil 
           Occult blood-Nil 
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C)SPECIAL INVESTIGATIONS: 
    1) Complete Blood count: (Routine Test): 
            * Hb-Men:14-18gms/dl,Women:11-15gms/dl  
                                      *Total RBC-Men:4.5-6.5million/cu.mm for both sex. 
                                      *Total WBC:4000-11,000cubic mm. 
                                      *Differential count: 
    Polymorphs:40-75 % 
    Lymphocytes:20-35% 
    Monocytes:2-10% 
    Esinophils:1-6% 
    Basophils:0-1% 
 
*ESR –Men: 0-10 (mm/hr),Women 0-20 (mm/hr) 
 
(Special Test) 
 Reticulocyte count:1-2% 
 PCV-Men:45-55%,Women:35-45%. 
 MCV:76-96 fl or cubic mm. 
 MCH:27-33 pg. 
 MCHC:31-35% 
                       *   CI-1% 
 
 Platelet count-1,50000-5,00000 lakhs/cubic mm 
 
 Morphology of RBC-Normocytic 
normochromic 
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PATIENT SCREENING 
 
INCLUSION / EXCLUSION 
INCLUSION CRITERIA EXCLUSION 
CRITERIA 
 EXCLUDED FROM TRIAL 
METHODOLOGY 
          STUDY NUMBER 
          HISTORY TAKING 
       LAB INVESTIGATION 
              TRIAL DRUG  
GIVE GENERAL    
TREATMENT 
       CLINICAL ASSESSMENT 
 
OUTCOME 
     IF ANY ADVERSE 
         REACTION 
        TREATED IN OPD 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
  INFORMED CONSENT FORM 
REFERRED TO PHARMACO    
VIGILANCE DEPT OF NIS 
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12.1   STUDY ENROLLMENT 
 In this Clinical Trial   , patients reporting at the OPD with the clinical 
symptoms of  pallor,anorexia,giddiness,odema,palpitation,numbness,fatigue 
etc., will be examined clinically for enrolling in the study based on the 
inclusion and exclusion criteria.  
 The patients who are to be enrolled will  be informed (Form IV) about the 
study, trial drug, possible outcomes and the objectives of the study in the 
language and terms understandable to them. 
 After ascertaining the patient`s willingness, informed consent would be 
obtained in writing from them in the consent form(Form IV-A).                                                                                                              
 All these patients will be given unique registration card in which patient`s 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. will be given, so as to report  easily, if any complications arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Proforma in the history and clinical 
assessment forms separately. Screening Form- I will be filled up; Form I-A,  
      Form –II and Form –III will be used for recording the patient`s history, 
clinical 
      Examination of symptoms and signs and laboratory investigations 
respectively. 
 Patients would be advised to take the trial drug and appropriate dietary advice 
(Form IV-D) would be given according to the patient`s perfect understanding. 
 
13.0CONDUCT OF THE STUDY: 
 
           As per siddha literature,before starting the treatment for PITHA PANDU, 
purgation is  
given with the soup of sesban leaves mixed with palm jaggery ½-1 aazhaku(84-168 
ml) Od at   
early morning, in empty stomach  for one day.[24] 
 
           The trial drug “: KARISALANKANNI CHOORANAM”  - 1 gm is given 
continuously for 24 days.For OP patients ,they should visit the hospital once in 12 
days.At each clinical visit clinical assessment is done and prognosis is noted.For IP 
patients the drug is provided daily and prognosis is noted 
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            Laborotary investigations are done at 0
th
 day& 24
th
 day of the trial.For IP 
patients, who is not in a situation to stay in the hospital for a long time is advised to 
attend the OPD for further continuation of the treatment. 
            During the course of the treatment, patient is advised not to take  
tamarind,tea,coffee,tobacco,betel leaf  and advised to take the diet as given in Form 
IV- D. 
             After the end of the treatment also,the patient is advised to visit the OPD  for 
another 2months for follow-up. If any of the trial patient who fails to collect the trial 
drug on the prescribed day but wants to continue in the trial, from the next day or 
two,he/ she will be allowed, but defaulters of one week and more will not be allowed 
to continue and be withdrawn from the study with fresh case being inducted.   
 
14.0 DATA MANAGEMENT 
 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification.. Whenever study patient visits 
OPD during the study period, the respective patient`s file will be taken and 
necessary recordings will be made at the assessment form or other suitable 
form. 
  The screening forms will be filed separately. 
 The Data recordings will be monitored for completion  by HOD-(Dept of 
Maruthuvam) ,and adverse reactions by the pharmacovigilance department of 
NIS .  
All collected data will be entered into computer using the MS access software .  
All forms will be further scrutinized in presence of Investigator by Sr.Research 
Officer (Statistics) for logical errors and incompleteness of data to avoid any bias. 
No modification in the results is permitted for unbiased reports. Data entry will be 
100% gross checked manually 
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STATISTICAL ANALYSIS: 
 
          All collected data will be entered into the computer and manually cross-
checked the correctness of the data entry. The clinical symptoms and the Hb level will 
be analysed by comparing the two point of data(before and after treatment) paired test 
and chi-square test will be employed to study the efficacy of treatment. Further, the 
effect of age and sex will also be analysed. 
15.0OUT COME OF TREATMENT 
    Primary Outcome: 
            Primary Outcome is  mainly assessed by comparing the pre and post 
treatmental        Hemoglobin level,of the trial patient. 
 
      Secondary Outcome: 
           Secondary outcome is assessed by comparing the following parameters ,before 
and after the treatment. 
                 
1) Reduction of Clinical symptoms 
 
2) Changes in Complete blood count 
 
 
16.0ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT:If the trial patient 
develops any adverse reaction,he/she would be immediately withdrawn from the trial  & 
referred to the Pharmacovigilence ,Dept of NIS. 
 
17.0 ETHICAL ISSUES 
1.Informed consent will be obtained from the patient explaining in the 
understandable language to       the patient. 
      2.After the consent of the patient (through consent form) they will be enrolled in 
the study 
3.Treatment would be provided free of cost.  
 4.No other external or internal medicines will be used. There will be no 
infringement on the rights of patient.    
 5.To prevent any infection, while collecting blood sample from the patient, only  
disposable   syringes, disposable gloves, with proper sterilization of lab equipments 
will   be used.                         
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6.The data collected from the patient will be kept confidentially. The patient will 
be Informed       about    the diagnosis, treatment and follow-up.  
7.The patients who are excluded ( as per exclusion criteria ) are given proper 
treatment at national institute of siddha 
    8.In conditions of treatment failure , adverse reactions, patients will be given  
alternative treatment at  the National Institute of Siddha with full care throughout  
the end.        
 
 18.0 ASSESSMENT FORMS 
 
Form –I              Screening and Selection Proforma 
Form –IA           History Proforma on enrollment 
 
Form    II           Clinical Assessment on enrollment  
Form -IIA          Clinical Assessment during and after the trial 
 
Form –III           Laboratory investigations on enrollment during and after the trial. 
 
Form-IV             Information sheet 
Form –IV A       Consent form 
Form -1V-B       Withdrawal form 
Form  -IV-C       Drug Compliance form 
Form –IV- D      Dietary Advice form. 
Form –IV-E      Adverse Reaction form  
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OBSERVATION AND RESULTS 
 
For this clinical study 40 cases were selected and treated in the Out-patient 
department and In-patient department of Ayothidoss Pandithar Hospital, National 
Institute of Siddha, Chennai-47. Results were observed with respect to the following 
criteria. 
1. Age distribution 
2. Sex distribution 
3. Religion distribution 
4. Socio-ecnomic distribution 
5. Occupational distribution 
6. Educational distribution 
7. Dietary distribution 
8. Reference to Thegi  
9. Reference to Thinai  
10. Reference to Season  
11. Reference to Iymporigal  
12. Reference to Iympulangal  
13. Reference to Kosangal  
14. Reference to Mukutram 
15. Reference to Ezhu udalkattugal 
16. Reference to Ennvagai thervugal 
17. Reference to Neikkuri 
18. Reference to Signs and Symptoms  
19. Reference to OP / IP Investigation Results 
20. Results after treatment 
            i) Primary outcome    -      Hb before and after treatment. 
            ii) Secondary outcome   - Results from Complete Blood Count 
                         - Results from Iron supply studies 
                                                               - Results from clinical signs and symptoms 
 
21. Statistical  Analysis 
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The observation recorded are given below in tabular form  
 
1. AGE DISTRIBUTION 
 
S. No Age No of cases Percentage% 
1 13-20  0 0% 
2 20-40  25 62.5% 
3     40-55 15 37.5% 
  
 
 
 
 
 
Observation and Inference: Among the 40 cases treated 25(62.5%) cases belonged 
to 20-40 years and 15(37.5%) cases belonged to 40-55 years. The percentage is more 
in the age group of 20-40 years.                 
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2. SEX DISTRIBUTION 
 
S. No Sex No of Cases Percentage% 
1 Female  38 95% 
2 Male 2 5% 
 
 
 
 
 
 
Observation and Inference: 38 (95%) of female cases and 2(5%) cases of male 
cases presented with anaemia were included in this study. 
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3. RELIGION DISTRIBUTION 
 
S. No Religion No of cases Percentage% 
1 Hindu 38 95% 
2 Christian 0 0% 
3 Muslim 2 5% 
 
 
 
 
 
 
Observation and Inference: Out of 40 cases, 38 (95%) cases belonged to Hindu and 
2(5%) case belonged to Muslim religion. 
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4. SOCIO-ECNOMIC DISTRIBUTION 
 
S.No Socio-ecnomic status Number of cases Percentage % 
1 Upper middle class 8 20% 
2 Middle class 12 30% 
3 Poor  20 50% 
 
 
 
 
 
 
Observation and Inference: Among the 40 cases, 8(20%) cases belonged to Upper 
middle class economic status, 12(30%) cases belonged to middle class people and 
20(50%) belonged to poor economic status.The percentage is more in poor economic 
group. 
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5. OCCUPATIONAL DISTRIBUTION 
 
 
S. No Occupational status  No of cases Percentage% 
1 Students 0 0 % 
2 working 16 40% 
3 House wives 24 60% 
 
 
 
 
 
 
Observation and Inference:  Of the 40 cases, 16(40%) were working women and 
24(60%) were house wives.The percentage is more in house wives. 
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7. EDUCATIONAL DISTRIBUTION 
S. No Educational Status No of cases Percentage % 
1 Literate – Degree holder 16 40% 
2 Literate – Upto 12th std 20 50% 
3 Illiterate 4 10% 
 
 
 
 
 
 
 
Observation and Inference: Out of 40 cases, 16(40%) cases were degree holders, 20 
(50%) were studied upto 12
th
 standard and 4(10%) were illiterates. 
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8. DIETARY DISTRIBUTION 
S. No                Diet No of cases Percentage% 
1 Vegetarian 12 30% 
2 Non-vegetarian 28 70% 
 
 
 
 
 
 
 
Observation and Inference: Among 40 cases, 70 % of cases belonged to non-
vegetarian dietary habit and 30% belonged to vegetarian dietery habit. 
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8.REFERENCE TO THEGI [BODY CONSTITUTION] 
 
 
S. No              Thegi No of cases Percentage% 
1 Vatham 4 10% 
2 Pitham 28 70% 
3 Kabam 0 0% 
4 Thontham 8 20% 
 
 
 
 
         
 Observation and Inference:  Of the 40 cases, 4(10%) cases were in Vadha body 
constitution 28(70%) cases were in pitha body constitution, 8(20%) cases were in 
thontham body constitution and no cases were in kabam body constitution.The 
percentage was more in pitham type of body constitution.  
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9. REFERENCE TO THINAI 
 
S. No Thinai No of cases Percentage% 
1 Kurinji (Hill area) 0 0% 
2 Mullai (Forest area) 0 0% 
3 Marutham (Fertile area) 12 30% 
4 Neithal (Coastal area) 28 70% 
5 Paalai (Desert area) 0 0% 
 
 
 
 
 
 
Observation and Inference: Among the 40 cases, 12(30 %) belonged to Marutham 
nilam, 28(70 %) belonged to Neithal nilam. 
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10. REFERENCE TO SEASON 
 
S. No Paruva kaalam No of cases Percentage% 
1 Kaar(Aug 16-Oct15) 4 10% 
2 Koothir(Oct 16-Dec 15) 0 0% 
3 Munpani(Dec 16-Feb 15) 0 0% 
4 Pinpani(Feb 16-Apr 15) 0 0% 
5 Elavenil(Apr 16-June 16) 0 0% 
6 Mudhuvenil(June16-Aug 15) 36 90% 
 
 
 
                
Observation and Inference: Among the 40 cases, 4 (10%) cases were treated during 
kaar and 36(90%) in Muthuvenil kalam.  
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11. REFERENCE TO IYMPORIGAL 
S.No Iymporigal 
No of cases affected 
before treatment 
[Percentage%] 
No of cases improved 
after treatment 
[Percentage%] 
1 Mei [skin] 32[80%] 32[80%] 
2 Vaai [Buccalcavity] 12[30%] 12[30 %] 
3 Kan [Eyes] 36[90%] 32[80%] 
4 Mooku[Nose] 0[0%] 0[0%] 
5 Sevi [Ear] 0[0%] 0[0%] 
 
 
 
 
Observation and Inference: 
 Of the 40 cases, Mei [skin] was affected noted as pallor, numbness, dryness, in 
32 (80%) cases and all the patients were improved after the treatment.  
 Of the 40 cases, vaai [buccal cavity] was affected noted as glossitis, angular 
stomatitis, bitter or pungent taste, dryness, pallor, fissured and coated tongue in 
12 (30%) cases and all the patients were improved after the treatment. 
 Of the 40 cases, Kan [eye] was affected noted as pallor, blurred vision in 
36(90%) cases and 32(80%) were improved after the treatment. 
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12. REFERENCE TO IYMPULANGAL 
 
S.No Iympulangal No of cases affected 
before treatment 
[Percentage%] 
No of cases improved 
after treatment 
[Percentage%] 
1 Kai [upper limb] 32[80%] 32[80%] 
2 Kaal [lower limb]  28[70%] 28[70%] 
3 Vaai[Buccalcavity] 12 [30%] 12[30%] 
4 Eruvai[Anus] 8 [20%]  4[10%] 
5 Karuvai[Genital organ] 4 [10%] 4 [4%] 
 
 
 
 
 
Observation and Inference: 
 Of the 40 cases, Kai [upper limb] was affected noted as numbness, pain in 32 
(80%) cases, Kaal [lower limb] was affected noted as numbness, pain, paedal 
edema in 28 (70%),Vaai [buccal cavity] was affected noted as glossitis, angular 
stomatitis, bitter or pungent taste, dryness, pallor, fissured and coated tongue in 
12 (30%) cases, Karuvai was affected (ammenorrhoea) , in 4(10%) cases and all 
the patients were improved after the treatment. 
 
 Of the 40 cases, Eruvai organ was affected (Constipation) in 8(20%) and 4(10%) 
were improved after the treatment.  
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13. REFERENCE TO KOSANGAL 
 
S.No Kosam No of cases affected 
before treatment 
[Percentage%] 
No of cases improved 
after treatment 
[Percentage%] 
1 Annamaya kosam 32 [80%] 32 [80%] 
2 Pranamaya kosam 32 [80%] 28 [70%] 
3 Manomaya kosam 32 [80%] 24 [60%] 
4 Vinganamayakosam 16 [40%] 16 [40%] 
5 Anandamaya kosam 4 [10%] 4 [10%] 
 
 
 
Observation and Inference: 
 Of the 40 cases, Annamayakosam was affected, noted as loss of appetite in 
32(80%) cases, Manomayakosam was affected, noted as palpitation in 32 (80%) 
cases, Vinganamayakosam was affected, noted as pain, numbness and tingling 
sensation in 16 (40%) cases and Anandamayakosam was affected, noted as  
oligomenorrhoea in 4(10%) cases all the patients were improved after the 
treatment. 
 
 Of the 40 cases, Pranamayakosam was affected, noted as breathlessness in 
32(80%) cases and 28(70%) of the patients were improved after the treatment. 
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14. REFERENCE TO MUKKUTRAM 
 
A.VATHAM: 
 
S.No Vatham No of cases 
affected before treatment 
[Percentage%] 
No of cases 
      Improved after  
treatment[Percentage%] 
1 Pranan 36 [90%] 32 [80%] 
2 Abanan 12 [30%] 8 [20%] 
3 Viyanan 32 [80%] 32 [80%] 
4 Uthanan 28 [70% ] 28 [70%] 
5 Samanan 38[90%] 38 [90%] 
6 Naagan 0[0%] 0[0%] 
7 Koormam 8 [20%] 8 [20%] 
8 Kirukaran 36 [90%] 36 [90%] 
9 Devathathan 40 [100%] 40 [100%] 
10 Dhananjeyan Not Applicable Not Applicable 
 
 
 
Observation and Inference: 
 Of the 40 cases, Pranan was affected, noted as breathlessness in 36(90%) cases, 
Abanan was affected, noted as flattulence, constipation, ammenorrhoea and 
oligomenorrhoea in 12(30%) cases and Uthanan was affected, noted as 
breathlessness in 28(70%) cases before the treatment and 32(80%), 8(20%), 
28(70%) cases were improved from the affection of Pranan, Abanan and Uthanan 
respectively, after the treatment. 
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 Of the 40 cases,Viyanan was affected noted as pain, numbness, and tingling 
sensation in 32(80%) cases, Samanan was affected noted as loss of appetite, pain, 
numbness and breathlessness in 38(90%) cases, Koorman was affected noted as 
blurred vision in 8(20%) cases, Kirukaran was affected noted as loss of appetite, 
dryness of mouth in 36(90%) cases , Devadhathan was affected noted as fatigue 
in 40(100%) of the cases and all of them were improved after the treatment. 
 
B.PITHAM: 
 
S. No Pitham No of cases affected 
before treatment 
[Percentage%] 
No of cases improved after 
treatment [Percentage%] 
1 Analam 38 [90%] 38 [90%] 
2 Ranjagam 40 [100%] 37 [92.5%] 
3 Prasagam 40 [100%] 37 [92.5%] 
4 Alosagam 2 [5%] 2 [5%] 
5 Sathagam 37 [92.5%] 37 [92.5%] 
 
 
 
Observation and Inference: 
 Of the 40 cases, Analam was affected  noted as loss of appetite in38(90%) cases, 
Alosagam was affected noted as dull vision in 2(5%) cases, Sathagam was 
affected noted as fatigue  in 37(92.5%) cases and all the cases were improved  after 
the treatment. 
 Of the 40 cases, Ranjagam and Prasagam were affected in all 40(100%) cases  
noted as pallor, of which 37(92.5%) cases were improved after the treatment. 
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C.KABHAM: 
 
S.No Kabam No of cases affected 
before treatment 
[Percentage%] 
No of cases improved 
after treatment 
[Percentage%] 
1 Avalambagam 32[80%] 30[75.5%] 
2 Kilethagam 8 [20%] 8 [20%] 
3 Pothagam 12[30%] 12[30%] 
4 Tharpagam   0 [0%] 0 [0%] 
5 Santhigam 0 [0%] 0 [0%] 
 
 
 
 
Observation and Inference: 
 Of the 40 cases, Avalambagam was affected noted as breathlessness in 32(80%) 
cases before the treatment and 30(75.5%) cases were improved after the treatment. 
 
 Of the 40 cases, Kilethagam was affected noted as indigestion in 8(20%) cases, 
Pothagam was affected in 12(30%) cases noted as feeling of pungent or bitter taste 
of the tongue of which all of them were improved after the treatment. 
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14. REFERENCE TO EZHU UDALKATTUGAL 
S.No Udal kattugal No of cases affected 
before treatment 
[Percentage%] 
No of cases improved 
after treatment 
[Percentage%] 
1 Saaram 40 [100%] 40 [100%] 
2 Senneer 40 [100%]             37 [92.5%] 
3 Oon 12 [30%] 12 [30%] 
4 Kozhuppu 0 [0%] 0 [0%] 
5 Enbu 0 [0%] 0 [0%] 
6 Moolai 0 [0%] 0 [0%] 
7 Suronitham 8[20%] 4 [10%] 
 
      
 
 
Observation and Inference: 
 Regarding seven Udal kattugal, Saaram [noted as fatigue] and Senneer [noted as 
pallor, reduction of Hemoglobin level] were affected in all 40 patients (100%) 
before the treatment and 40(100%) patients of saram affection and 37(92.5%) 
patients of senneer affection were improved after the treatment. 
 Oon was affected noted as paedal edema in 12(30%) cases, before the treatment 
and all of them were improved after the treatment. 
 Suronitham was affected in 8 (20%) patients noted as oligomennorhoea before the 
treatment and 4 (10%) cases were improved after the treatment.       
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15. REFERENCE TO ENVAGAI THERVUGAL 
S.No Ennvagai 
thervugal 
No of cases observed before 
treatment [Percentage%] 
No of cases observed  after 
treatment[ Percentage%] 
1 Pithavatham 
Vathapitham 
38 [95%] 
2 [5%] 
 
24 [60%] 
16 [40%] 
  Affected cases before  
treatment [percentage%] 
Improved cases,after 
treatment [percentage%] 
2 Sparisam 32 [80%] 32 [80%] 
3 Naa 36 [90%] 36 [90%] 
4 Niram 36 [90%] 36 [90%] 
5 Mozhi 0[0%] 0[0%] 
6 Vizhi 36 [90%] 36 [90%] 
7 Malam 8 [20%] 8 [20%] 
8 Moothiram 0[0%] 0[0%] 
 
     
 
 
Observation and Inference: 
 
 Among the Ennvagai Thervugal, Naa [pallor, coated, glossitis, angular stomatitis, 
baldness, fissure, dryness, pungent or bitter taste, decreased salivation] Niram 
[pallor] and Vizhi [pallor] were affected in 36 cases (90%) and all the 36 [90%] 
cases were improved after the treatment. 
80%
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ENVAGAI THERVUGAL
Affected Before treatment Improved After treatment 
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 32 [80%] cases were affected from Sparisam [noted as dryness, hot or cold 
sensation, excessive sweat] and 8[20%] cases were affected from Malam [noted as 
constipation] before the treatment and all of them were improved after the 
treatment. 
 
 38[95%] were observed in pithavatham and 2[5%] vathapitham naadi before the 
treatment and 24[60%] were observed in pithavatham and 16[40%] vathapitham 
naadi after the treatment. 
 
 
16. REFERENCE TO NEIKKURI 
S. N Neikkuri 
No of cases  observed 
before treatment 
[percentage%] 
No of cases 
observedAfter treatment 
[percentage%] 
1 Ring form-Pithaneer  28 [70%]  20 [50%] 
2. Serpentineform-Vathaneer  12 [30%]  20 [50%] 
 
                       
 
 
Observation and Inference:  Of the 40 patients, 28 [70 %] cases were observed in 
Pitha neer and remaining 12 (30 %) cases were observed in Vatha neer before the 
treatment and 20 [50 %] cases were observed in Pitha neer and 20 (50 %) cases were 
observed in Vatha neer after the treatment 
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17. REFERENCE TO SIGNS AND SYMPTOMS 
S.No Signs and symptoms 
No of cases 
Affected before 
treatment 
[percentage%] 
No of cases 
improved after 
treatment 
[percentage%] 
1 Pallor  40 [100%] 37 [92.5%] 
2 Anorexia 32 [80%] 30 [75%] 
3 Fatigue 24 [60%] 24 [60%] 
4 Tachycardia 28 [70%] 28 [70%] 
5 Palpitation 28 [70%] 28 [70%] 
6 Giddiness 28 [70%] 28 [70%] 
7 Breathlessness  32 [80%] 30 [75%] 
8 Pungent taste of tongue 4 [10%] 4 [10%] 
9 Bitter taste of tongue     8 [20%] 8 [20%] 
10 Angular stomatitis   8 [20%]   8 [20%] 
11 Glossitis 4 [10%] 2 [5%] 
12 Lack of concentration 24 [60%] 18 [45%] 
13 Hairfall 28 [70%] 24[60%] 
14 Numbness 16[40%] 16 [40%] 
15 Tingling sensation 12 [30%]   8 [20%] 
16 Ammenorrhoea 0 [0%] 0 [0%] 
17 Oligomenorrhoea   8 [20%] 4 [10%] 
18 Odema 0 [0%] 0 [0%] 
19 Koilonychia 0 [0%] 0 [0%] 
20 Pica 0 [0%] 0 [0%] 
 
 Out of 40 cases, Pallor was noted in all the 40 [100%] cases before the 
treatment. Of which, 37 [92.5%] cases in Pallor showed improvement after the 
treatment. 
 
 Out of 40 cases, Anorexia was noted in 32 [80%] cases of which 30[75%] 
showed improvement after the treatment. 
 Tachycardia, Palpitation, Giddiness was noted in 28 [70%] cases before 
treatement and it was relieved all the 28[70%] after treatement. 
 
  Anorexia and Breathlessness were noted in 32 [80%] cases before treatement 
and it was relieved all the 30[75%] after treatement. 
 
 Out of 40 cases, Lack of concentration was noted in 24[60%] cases before the 
treatment and 18 [45%] showed improvement after the treatment. 
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 Out of 40 cases, Hairfall was noted in 28 [70%] cases before the treatment and 
24 [60%] showed improvement after the treatment. 
 
 Out of 40 cases,  Oligomenorrhoea was noted in 8 [20%] cases before the 
treatment. Of which, 4[10%] cases showed improvement after the treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19. OP / IP INVESTIGATION RESULTS:  
              
                Patients had undergone for Investigations [Blood, Urine and Motion] on 0
th
 
day and 48
th
 day for assessing the prognosis of the treatment and the safety of the 
patients. The reports are given below in the tabular column. 
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R  
 
 
 
 
 
   OP/IP  INVESTIGATION RESULTS 
S No O.P /IP No Name 
Age/ 
Sex 
Before Treatment After Treatment 
Hb  
gms/dl 
RBC 
millio
n/ 
cu.m
m 
PCV  
% 
MCV  
fl 
MCH  
pg 
MCHC 
 % 
PBS 
Hb  
gms/dl 
RBC 
million/ 
cu.mm 
PCV  
% 
MCV  
fl 
MCH  
pg 
MCHC % PBS 
1 B77139 Rani 45/F 10.5 3.9 31.3 79.5 25.6 32.1 H.M 10.9 4.2 33.7 78.6 25.4 32.6 H.M 
2 C84193 Sarojini 37/F 9.3 4.6 34.7 73.8 24.1 32.7 H.M 11.4 4.7 35.5 74.4 23.9 32.1 H.M 
3 B75370 Surya Gandhi 21/F 9.8 3.6 29.9 78.5 25.2 32.1 H.M 12.8 4.1 37.0 86.7 29.9 34.5 H.M 
4 C74519 Renuga 44/F 9.7 4.2 32.9 77.2 25.1 32.5 H.M 10.1 3.9 30.0 75.9 25.9 33.7 H.M 
5 C80290 Sumathi 22/F 9.3 4.4 36.9 82.4 28.1 34.1 H.M 13.0 4.6 38.3 83.4 27.8 33.9 H.M 
6 C71808 Rani 47/F 10.3 4.2 28.4 75.0 24.5 32.7 H.M 10.8 4.3 32.4 75.3 25.1 33.1 H.M 
7 B85745 Usha 44/F 10.0 4.4 33.7 76.1 24.6 32.3 H.M 9.5 4.3 33.2 77.2 24.4 32.2 H.M 
8 C84645 Chandrakantha 39/F 7.0 4.2 26.1 61.8 16.6 26.8 H.M 7.4 4.4 27.6 62.6 16.8 26.8 H.M 
9 C69738 Jamuna 45/F 9.8 4.6 38.0 81.4 27.8 34.2 H.M 12.8 4.6 37.0 80.0 27.7 34.6 N.N 
10 C82941 Rani 30/F 8.3 3.7 29.3 87.7 29.4 33.5 H.M 13.8 4.6 40.9 87.8 29.6 33.7 N.N 
11 C82329 Lakshmi 48/F 9.2 4.2 36.8 86.2 29.0 33.7 H.M 13.3 4.4 38.9 87.5 29.5 34.6 N.N 
12 C65259 Malarvili 35/F 9.4 4.2 36.1 84.3 29.0 34.3 H.M 12.5 4.2 36.4 84.9 29.4 34.6 H.M 
13 B85887 Malasivakumar 42/M 9.6 5.0 32.1 63.4 19.0 29.9 H.M 9.3 4.8 30.9 63.2 19.0 30.1 H.M 
14 B75701 Saraswathi 38/F 9.8 5.1 34.3 66.1 20.8 33.0 H.M 11.3 5.4 35.7 66.0 20.9 31.7 H.M 
15 C84838 Shanthi 38/F 9.8 4.7 40.0 83.5 27.8 33.3 H.M 12.7 4.4 37.1 82.8 28.3 34.2 N.N 
16 C82323 Yasim Khan 40/M 11.1 4.3 38.9 88.8 32.2 36.2 H.M 13.9 4.3 38.0 90.0 32.3 36.6 H.M 
17 C79216 Radika 23/F 9.8 4.0 30.1 74.9 24.4 32.6 H.M 10.0 4.2 31.0 72.9 23.5 32.3 H.M 
18 C75910 eshwari 21/F 9.8 4.7 40.6 85.5 29.5 34.5 H.M 14.0 4.8 40.4 86.2 29.2 34.7 N.N 
19 C85414 Priya 31/F 9.8 4.1 37.5 85.2 29.8 34.9 H.M 13.1 4.4 36.8 83.3 29.6 35.6 H.M 
20 C85572 Indra 28/F 8.9 4.3 38.2 87.6 29.4 33.5 H.M 12.8 4.2 37.0 89.6 30.2 34.6 H.M 
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S 
No 
O.P/I.p No Name 
Age/ 
Sex 
Before Treatment After Treatment 
Hb  
gms/
dl 
RBC 
millio
n/ 
cu.mm 
PCV  
% 
MCV  
fl 
MCH  
pg 
MCHC 
 % 
PBS 
Hb  
gms/dl 
RBC 
million/ 
cu.mm 
PCV  
% 
MCV  
fl 
MCH  
pg 
MCHC 
 % 
PBS 
21 C85518 
Saratha 36/
F 
9.8 3.1 36.6 81.2 27.5 31.3 H.M 12.4 4.4 35.8 80.6 27.9 34.6 N.N 
22 C85417 
Janagi 44/
F 
8.9 3.8 32.9 84.8 28.9 34.0 H.M 11.0 3.7 31.8 85.0 29.0 34.6 
H.M 
23 C86521/4016 Sarojamma 54/F 8.7 3.5 23.4 63.1 18.1 28.6 H.M 6.8 3.6 23.8 63.7 18.6 29.3 H.M 
24 C27061/3986 Valliyammal 45/F 8.9 3.8 29.3 82.5 26.5 32.1 H.M 9.3 4.1 30.7 73.6 32.3 30.3 H.M 
25 C85468 
Tamilselvi 40/
F 
9.0 5.2 40.0 76.7 25.4 33.2 H.M 12.8 5.0 38.6 78.6 35.4 33.2 N.N 
26 C86420/4015 Subarathinam 50/F 9.3 3.8 33.7 88.2 29.8 33.8 H.M 11.7 4.0 40.4 95.4 30.1 45.2 H.M 
27 C79659/4013 Lalitha 23/F 9.8 4.0 31.8 71.9 25.7 35.0 H.M 11.3 4.3 34.4 78.4 25.7 32.8 H.M 
28 C86320/4014 Murugalakshmi 27/F 8.7 4.3 24.6 56.4 15.4 27.2 H.M 7.1 4.5 26.1 57.1 15.7 29.2 H.M 
29 C26014 
Sanmugavalli 51/
F 
9.6 4.4 36.3 81.2 26.8 33.1 H.M 12.3 4.5 36.6 80.4 27.0 33.6 H.M 
30 C85864 Rahamath Nisha 30/F 7.4 3.2 22.4 68.9 22.8 33.0  H.M 7.0 3.7 20.9 76.0 25.8 34.0 H.M 
31 C85412 Renuga 39/F 9.4 4.0 34.1 84.2 27.7 32.8 H.M 10.9 3.9 32.5 88.5 27.4 33.5 H.M 
32 C80021/4024 Malar 36/F 9.4 3.9 35.3 89.4 30.4 34.0 H.M 11.8 3.8 34.6 89.2 30.4 34.1 H.M 
33 C86719/4027 Lalitha 33/F 9.0 3.9 34.7 87.6 31.1 35.4 H.M 12.6 4.0 35.7 88.3 31.2 35.3 N.N 
34 C80773/4028 Malliga 40/F 9.4 4.6 39.1 84.1 29.1 34.8 H.M 14.0 4.7 40.3 84.7 29.4 34.7 N.N 
35 C80725/4943 
Srinivasan 44/
M 
12.6 4.9 35.1 76.0 24.0 34.2 H.M 12.9 4.9 38.5 76.5 26.0 33.9 H.M 
36 C83591 
VijiyaGeetha 36/
F 
9.2 4.3 30.0 68.8 21.1 30.7 H.M 8.5 4.1 27.9 67.7 27.9 30.5 H.M 
37 C87572 Monidevi 35/F 7.8 2.6 86.5 30.0 34.7 25.5 H.M 7.1 4.7 17.9 80.6 34.3 34.1 H.M 
38 C90816 Manimozhi 48/F 9.1 5.0 31.2 62.3 20.3 29.2 H.M 12.8 4.1 37.0 86.7 29.9 34.5 H.M 
39 AL8984 Shanthi 35/F 9.4 4.3 30.5 70.4 21.7 30.8 H.M 10.3 4.6 31.5 70.8 22.2 31.4 H.M 
40 C87999/4132 Renugadevi 42/F 7.3 4.0 23.8 58.6 16.0 27.3 H.M 6.2 4.0 24.9 64.7 17.0 27.0 H.M 
Hb-Hemoglobin,PCV-Packed cell volume,MCV-Mean corpuscular volume,MCH-Mean corpuscular hemoglobin,MCHC-Mean corpuscular hemoglobin concentration,PBS-Pheripheral 
bloodsmear,H.M-Hypochromicmicrocytic,S.H.M-Slightly hypochromic microcytic,N.N-Normochromic normocytic. 
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S.N
. 
NAME 
BLOOD 
Before Treatment After Treatment Before Treatment After Treatment 
TC Cells 
cu.mm 
DC % ESR TC Cells  
cu.mm 
DC % ESR 
BT/min CT/min BT/min CT/min 
P L E ½ hr 1 hr P L E ½ hr 1 hr 
1 Rani 6300 50 46 4 8 16 6600 40 58 2 6 12 2.30 4 2.3 3.45 
2 Sarojini 7500 58 39 3 10 20 10200 50 46 4 8 16 2 4.30 2.30 5 
3 Surya Gandhi 5600 66 27 1 15 2 6500 47 44 1 14 12 2 6 2.30 5 
4 Renuga 5400 56 112 2 10 22 5300 58 38 4 8 16 3 6.15 1.4 3 
5 Sumathi 6100 66 30 4 20 40 7200 39 59 2 10 20 2.30 3.30 2 4.30 
6 Rani 7200 60 38 3 4 8 6400 46 48 6 6 16 2.35 8 2 4 
7 Usha 9000 60 35 5 10 20 6900 64 35 1 24 48 3 5.45 2.3 4.30 
8 Chandrakantha 7500 73 23 4 8 16 6400 63 35 2 8 16 2 5.05 2 4.30 
9 Jamuna 8500 43 44 1 6 20 5200 71 30 6 6 10 1.30 3.30 2.45 2.50 
10 Rani 6800 45 40 4 8 16 6400 65 34 3 4 12 .30 3.40 2 4.30 
11 Lakshmi 4500 50 45 5 8 16 7800 54 37 9 14 12 2 3 2 2 
12 Malarvili 4900 51 18 2 12 44 5100 69 23 3 4 8 3 4 3 4 
13 Malasivakumar 4800 55 40 5 10 20 8300 60 39 1 10 20 2 4.15 2 4 
14 Saraswathi 7700 66 28 6 8 16 6600 62 34 3 8 16 3 6 2 5 
15 Shanthi 7000 63 35 2 10 20 8000 60 36 4 10 20 3 4 5 4.10 
16 Yasim Khan 5200 60 36 4 8 16 5500 74 25 1 2 4 2 7 2 4.30 
17 Radika 6700 55 40 5 20 40 8000 62 30 8 20 40 3 6.45 2.3 4.30 
18 Mageshwari 6500 65 29 6 8 16 7000 68 28 4 4 8 3 6.30 2 4 
19 Priya 5500 65 33 2 6 12 6300 78 18 4 6 12 2 4.30 3.30 4.30 
20 Indra 6700 72 26 2 10 20 6500 79 19 2 10 20 2 4 2 3 
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S.N
. 
NAME 
BLOOD 
Before Treatment After Treatment Before Treatment After Treatment 
TC Cells 
cu.mm 
DC % ESR TC Cells  
cu.mm 
DC % ESR 
BT/min CT/min BT/min CT/min 
P L E ½ hr 1 hr P L E ½ hr 1 hr 
21 Saratha 9000 41 58 1 22 44 8200 58 39 3 10 20 2 3.30 2 4.30 
22 Janagi 4900 54 43 3 2 4 3800 53 44 1 6 12 1.30 4 1.3 3.45 
23 Sarojamma 6500 43 44 2 14 12 4200 52 28 7 10 12 2.40 4.50 2.50 6 
24 Valliyammal 5900 45 43 5 8 24 4800 49 47 4 16 32 2 2.45 4.15 5.30 
25 Tamilselvi 7600 65 33 2 18 36 6700 67 30 3 12 24 2 4.45 3 4 
26 Subarathinam 5000 51 28 3 4 28 7800 33 64 3 5 20 1.45 3 2.20 5.30 
27 Lalitha 6600 62 36 2 2 4 5900 58 39 1 10 16 2 4.30 2 5.15 
28 Murugalakshmi 7800 66 32 2 14 28 5600 56 40 13 12 24 2 5 2.45 5.45 
29 Sanmugavalli 4400 72 27 1 10 20 6700 82 17 1 10 20 1.30 5.30 3.3 5 
30 Rahamath Nisha 6100 72 26 2 4 30 6300 68 28 13 4 28 3 5 2.30 6 
31 Renuga 7500 66 37 5 14 28 5900 56 42 2 6 30 2.30 3.30 1.45 3.30 
32 Malar 5200 60 38 13 10 20 7900 56 35 4 10 12 1.45 6.30 1.45 4 
33 Lalitha 5900 72 83 2 6 12 6900 56 40 12 6 12 1 4 2.15 5.15 
34 Malliga 6800 66 25 4 6 8 6000 65 32 4 20 20 2.30 6.30 2.30 5.40 
35 Srinivasan 7700 58 46 1 12 16 5200 56 41 3 8 40 1.30 2.20 4 3.15 
36 VijiyaGeetha 7300 75 23 2 10 20 7600 71 27 2 12 24 3 4 2 4 
37 Monidevi 6500 58 37 1 12 24 5800 79 18 3 12 12 2.15 4.30 2 4.45 
38 Manimozhi 7100 62 30 3 2 8 6100 55 29 7 30 24 1 4 2 4.30 
39 Shanthi 4600 66 43 9 10 12 6200 63 52 1 14 60 1.40 6 2.30 4 
40 Renugadevi 4700 66 32 2 6 12 4200 60 35 5 6 20 2 6.50 3 4.30 
TC- Total Count ; DC - Differntial Count;  P - Polymorphs ; L - Lymphocytes ; E – Eosinophils; ESR-Erythrocyte sedimentation rate, BT-Bleeding time,CT-Clotting 
time,NG-Not given 
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OP/IP  INVESTIGATIONS 
LIVER FUNCTION TEST 
S.No Name 
Before Treatment [IU/L] After Treatment [IU/L] Before Treatment [IU/L] After Treatment [IU/L] 
T.B D.B I.B T.B D.B I.B SGOT SGPT AP SGOT SGPT AP 
1 Rani 0.6 0.3 0.3 0.7 0.4 0.3 42 24 189 23 23 206 
2 Sarojini 0.5 0.3 0.3 0.6 0.3 0.2 17 17 165 20 18 139 
3 Surya Gandhi 0.5 0.3 0.2 0.6 0.4 0.2 24 28 191 11 19 142 
4 Renuga 0.5 0.3 0.2 0.6 0.3 0.3 39 24 164 33 37 109 
5 Sumathi 0.6 0.3 0.3 0.5 0.3 0.2 27 26 113 34 38 115 
6 Rani 0.7 0.4 0.3 0.5 0.3 0.2 21 16 183 19 21 161 
7 Usha 0.5 0.3 0.2 0.5 0.3 0.2 19 23 130 24 21 232 
8 Chandrakantha 0.5 0.3 0.2 0.7 0.5 0.2 16 20 190 25 29 163 
9 Jamuna 0.6 0.3 0.3 0.7 0.5 0.4 42 45 304 58 67 359 
10 Rani 0.6 0.4 0.2 0.4 0.2 0.2 23 19 221 32 30 119 
11 Lakshmi 0.5 0.3 0.2 0.7 0.5 0.2 37 17 129 24 26 192 
12 Malarvili 0.6 0.4 0.2 0.6 0.4 0.2 13 16 159 16 19 164 
13 Malasivakumar 0.5 0.3 0.2 0.6 0.3 0.3 29 19 235 36 31 221 
14 Saraswathi 0.6 0.4 0.2 0.6 0.3 0.3 17 12 139 16 20 147 
15 Shanthi 0.7 0.4 0.3 0.5 0.4 0.1 29 24 194 30 36 202 
16 Yasim Khan 0.5 0.3 0.2 0.6 0.3 0.3 29 19 235 36 31 221 
17 Radika 0.5 0.3 0.2 0.5 0.3 0.2 18 18 206 26 23 188 
18 Mageshwari 0.5 0.3 0.2 0.6 0.4 0.2 29 19 254 21 25 256 
19 Priya 0.6 0.3 0.3 0.5 0.3 0.2 28 19 124 16 12 156 
20 Indra 0.7 0.4 0.3 0.6 0.4 0.2 30 33 130 40 38 206 
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OP/IP  INVESTIGATIONS 
LIVER FUNCTION TEST 
S.No Name 
Before Treatment [IU/L] After Treatment [IU/L] Before Treatment [IU/L] After Treatment [IU/L] 
T.B D.B I.B T.B D.B I.B SGOT SGPT AP SGOT SGPT AP 
21 Saratha 0.5 0.3 0.2 0.5 0.3 0.2 20 20 196 29 28 129 
22 Janagi 0.9 0.5 0.4 0.9 0.5 0.4 19 11 142 27 22 194 
23 Sarojamma 0.4 0.2 0.2 0.8 0.5 0.3 30 26 276 22 16 168 
24 Valliyammal 0.5 0.3 0.2 0.5 0.3 0.2 24 18 181 25 20 194 
25 Tamilselvi 0.5 0.3 0.2 0.5 0.3 0.2 24 26 182 13 17 139 
26 Subarathinam 0.5 0.3 0.2 0.7 0.4 0.3 23 25 180 20 20 229 
27 Lalitha 0.5 0.4 0.1 0.7 0.5 0.2 17 19 161 32 23 101 
28 Murugalakshmi 0.5 0.2 0.3 0.8 0.5 0.3 18 22 137 34 39 166 
29 Sanmugavalli 0.7 0.4 0.3 0.6 0.4 0.2 30 33 130 40 38 206 
30 Rahamath Nisha 0.8 0.5 0.3 0.5 0.3 0.2 21 23 206 17 19 134 
31 Renuga 0.7 0.4 0.3 0.6 0.3 0.3 21 23 186 14 22 194 
32 Malar 0.8 0.5 0.3 0.5 0.3 0.2 16 17 138 14 20 199 
33 Lalitha 0.8 0.5 0.3 0.7 0.5 0.2 17 15 159 26 20 163 
34 Malliga 0.5 0.3 0.2 0.6 0.3 0.2 18 15 218 25 21 214 
35 Srinivasan 0.5 0.3 0.3 0.4 0.2 0.2 15 21 139 21 12 142 
36 VijiyaGeetha 0.8 0.5 0.3 0.4 0.2 0.2 25 29 175 16 21 223 
37 Monidevi 0.5 0.3 0.2 0.6 0.4 0.2 31 34 295 16 13 189 
38 Manimozhi 0.9 0.5 0.4 0.5 0.3 0.2 20 19 272 16 12 272 
39 Shanthi 0.5 0.3 0.2 0.7 0.4 0.3 19 20 127 36 26 143 
40 Renugadevi 0.7 0.5 0.2 0.6 0.3 0.3 28 27 184 17 21 166 
T.B-Total bilirubin,D.B-Direct bilirubin,I.B-Indirect bilirubin, SGOT-Serum glutamic oxaloacetic transaminase,SGPT-Serum glutamic pyruvate transaminase,AP-Alkaline 
phosphatase.  
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OP/IP INVESTIGATION RESULTS 
S.No Name 
BLOOD  SUGAR/ LIPID PROFILE [mg/dl] RENAL FUNCTION TEST [mg/dl] 
Before Treatment After Treatment Before Treatment After Treatment 
 RBS Lipid profile  [mg/dl] RBS   Lipid profile [mg/dl] 
urea creatinine Uric acid urea creatinine uric acid [mg/dl] TC HDL LDL VLDL TGL [mg/dl] TC HDL LDL VLDL TGL 
1 Rani 107 183 44 116 23 247 94 204 38 133 33 373 21 0.6 3.4 19 0.6 3 
2 Sarojini 75 170 36 145 29 100 68 162 39 104 19 96 19 0.6 4.2 17 0.6 3.9 
3 Surya Gandhi 77 118 35 145 21 105 73 177 36 121 20 99 15 0.6 4.3 33 0.7 4 
4 Renuga 85 265 54 56 13 67 92 122 48 58 17 178 26 0.7 4.5 21 0.6 3.4 
5 Sumathi 87 122 44 66 12 60 118 133 42 75 16 165 16 0.6 6.7 15 0.6 4.3 
6 Rani 75 213 42 115 17 84 154 168 29 113 25 127 15 0.6 4.8 26 0.6 2.6 
7 Usha 95 152 36 94 22 111 114 162 39 97 25 121 25 0.7 5.4 24 0.6 3.7 
8 Chandrakantha 78 276 47 202 27 138 71 232 39 149 44 219 19 0.7 4.3 18 0.6 5.4 
9 Jamuna 102 201 36 129 21 105 97 168 33 127 18 41 19 0.6 4.1 23 0.7 3.7 
10 Rani 74 199 41 125 33 169 76 173 32 114 27 133 18 0.6 4.5 15 0.6 2.6 
11 Lakshmi 104 180 55 102 23 116 92 193 36 92 20 100 20 0.6 4.2 23 0.7 4.6 
12 Malarvili 85 140 41 78 26 104 104 137 37 59 35 174 16 0.6 4.7 19 0.6 3.4 
13 Malasivakumar 93 198 39 121 33 164 95 239 36 170 33 168 16 0.6 3.2 26 0.7 4.3 
14 Saraswathi 94 157 38 90 29 146 79 194 36 126 32 157 16 0.6 4.7 18 0.6 3.1 
15 Shanthi 98 187 42 92 53 50 145 181 37 136 40 198 26 0.7 3.9 20 0.6 6.7 
16 Yasim Khan 105 200 55 129 16 81 108 283 43 207 38 190 19 0.6 3.4 17 0.6 3.9 
17 Radika 85 218 66 104 48 240 83 219 40 104 75 82 15 0.6 4.2 15 0.6 4.2 
18 Mageshwari 119 123 44 162 59 116 124 324 28 221 79 396 17 .7 3.7 23 0.6 4.8 
19 Priya 92 176 32 99 15 265 71 156 30 110 16 80 15 0.80 3.9 16 0.7 4.6 
20 Indra 104 190 54 88 37 189 93 227 38 148 30 84 20 0.6 2.7 17 0.6 3.7 
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OP/IP INVESTIGATION RESULTS 
S.No Name 
BLOOD  SUGAR/ LIPID PROFILE [mg/dl] RENAL FUNCTION TEST [mg/dl] 
Before Treatment After Treatment Before Treatment After Treatment 
 RBS Lipid profile  [mg/dl] RBS   Lipid profile [mg/dl] 
urea creatinine Uric acid urea creatinine uric acid [mg/dl] TC HDL LDL VLDL TGL [mg/dl] TC HDL LDL VLDL TGL 
21 Saratha 118 224 39 164 25 128 91 265 34 192 39 193 29 0.8 3.9 15 0.6 5.7 
22 Janagi 94 140 42 129 10 79 129 213 36 115 36 115 34 0.8 2.9 17 0.6 5.5 
23 Sarojamma 79 173 39 100 33 168 72 139 46 67 26 128 22 0.7 3.7 19 0.6 3.3 
24 Valliyammal 70 245 39 145 21 105 88 175 41 115 19 95 22 0.6 2.8 15 0.6 3.5 
25 Tamilselvi 85 231 37 39 235 40 90 274 38 205 31 155 34 0.9 4.7 25 0.7 3.9 
26 Subarathinam 77 190 36 121 33 164 62 129 30 87 12 58 20 0.6 3.6 16 0.6 3.6 
27 Lalitha 73 165 49 96 20 100 93 236 31 179 20 98 16 0.6 4.7 16 0.6 4.3 
28 Murugalakshmi 90 217 46 142 29 145 79 183 48 109 25 128 25 0.7 3 26 0.7 2.5 
29 Sanmugavalli 157 163 45 96 22 112 82 182 30 101 25 126 23 0.6 2.9 25 0.6 4.7 
30 Rahamath Nisha 118 251 37 154 60 304 92 255 38 168 49 244 15 0.6 4.5 23 0.6 2.5 
31 Renuga 80 191 32 132 27 136 83 160 45 88 27 135 20 0.7 5.1 15 0.6 3.9 
32 Malar 80 183 39 116 28 140 89 162 41 96 19 97 22 0.6 4.7 22 0.6 3.2 
33 Lalitha 87 172 35 99 38 193 91 150 48 75 27 136 22 0.6 3.4 28 0.7 2.6 
34 Malliga 96 155 42 97 16 80 90 186 33 139 14 68 15 0.6 3.8 40 0.9 2.7 
35 Srinivasan 88 250 51 161 38 189 92 241 42 162 37 181 27 0.7 3.4 15 0.6 5 
36 VijiyaGeetha 77 141 28 99 14 73 101 132 39 216 17 87 26 0.6 4.3 20 0.6 2.7 
37 Monidevi 88 148 35 93 20 102 77 126 26 83 17 88 16 0.6 3.3 16 0.6 2.3 
38 Manimozhi 70 94 30 48 23 112 76 181 45 113 23 113 17 0.6 2.7 37 0.6 3 
39 Shanthi 93 225 39 156 30 151 93 240 49 171 21 101 21 0.6 4.4 19 0.6 4.1 
40 Renugadevi 85 208 42 130 36 183 91 119 46 50 23 113 21 0.6 5.2 25 0.6 3.7 
RBS-Random blood sugar, TC-Total cholesterol,HDL-High density cholesterol,LDL-Low density cholesterol,VLDL-Very low density chlosterol,TGL-Triglycerides. 
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MOTION TEST URINE TEST 
  Before treatment After treatment Before treatment After treatment 
S.no 
 
Name 
 
ova cyst OB ova cyst OB A RBS BS BP UB DEP A RBS BS BP UB DEP 
1 Rani nil nil nil nil nil nil nil nil nil neg N 
4-6P 
8-10E 
nil nil nil neg N 
4-8P 
E-plenty 
2 Sarojini nil nil nil nil nil nil nil nil nil neg N 1-2P,E nil nil nil neg N 2-4P,E 
3 Surya Gandhi nil nil nil nil nil nil nil nil nil neg N 
1-3P 
3-4E 
nil nil nil neg N 1-2P,E 
4 Renuga nil nil nil nil nil nil nil nil nil neg N nil nil nil nil neg N 2-4P,E 
5 Sumathi nil nil nil nil nil nil nil nil nil neg N 1-2P,E nil nil nil neg N 2-4P,E 
6 Rani nil nil nil nil nil nil nil nil nil neg N 
2-4P 
8-10E 
nil nil nil neg N 
2-4P 
1-2E 
7 Usha nil nil nil nil nil nil nil nil nil neg N 3-5P,E nil nil nil neg N nil 
8 Chandrakantha nil nil nil nil nil nil nil nil nil neg N 
2-4P 
4-6E 
nil nil nil neg N 
2-4P 
3-6E 
9 Jamuna nil nil nil nil nil nil nil nil nil neg N P,E-plenty nil nil nil neg N P,E-plenty 
10 Rani nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-4P,E 
11 Lakshmi nil nil nil nil nil nil nil nil nil neg N 6-8P,E nil nil nil neg N 3-5P,E 
12 Malarvili P nil nil P nil nil nil nil nil neg N 1-2P,E nil nil nil neg N 2-4P,E 
13 Malasivakumar nil nil nil nil nil nil nil nil nil neg N 1-2P,E nil nil nil neg N 2-4P,E 
14 Saraswathi nil nil nil nil nil nil nil nil nil neg N 
1-2P 
1-3E 
nil nil nil neg N nil 
15 Shanthi nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 
8-10P 
E-plenty 
16 Yasim Khan nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-4P,E 
17 Radika nil nil nil nil nil nil nil nil nil neg N 1-2P,E nil nil nil neg N P,E-plenty 
18 Mageshwari nil nil nil nil nil nil nil nil nil neg N 
1-3P 
2-4E 
nil nil nil neg N 
2-4P 
1-3E 
19 Priya nil nil nil nil nil nil nil nil nil neg N nil nil nil nil neg N 
2-4P 
3-6E 
20 Indra nil nil nil nil nil nil nil nil nil neg N 2-4P nil nil nil neg N 
2-4P 
3-6E 
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MOTION TEST URINE TEST 
  Before treatment After treatment Before treatment After treatment 
S.no Name ova cyst OB ova cyst OB A RBS BS BP UB DEP A RBS BS BP UB DEP 
21 Saratha nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N P,E-plenty 
22 Janagi nil nil nil nil nil nil nil nil nil neg N nil nil nil nil neg N 
4-8P 
8-10 E 
23 Sarojamma nil nil nil nil nil nil nil nil nil neg N 6-8P,E nil nil nil neg N nil 
24 Valliyammal nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-3P,E 
25 Tamilselvi nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-4P,E 
26 Subarathinam nil nil nil nil nil nil nil nil nil neg N 
8-10E 
Pplenty 
nil nil nil neg N 1-2P,E 
27 Lalitha nil nil nil nil nil nil nil nil nil neg N 3-6P,E nil nil nil neg N 
2-3P 
1-2E 
28 Murugalakshmi nil nil nil nil nil nil nil nil nil neg N P,E-plenty nil nil nil neg N P,E-plenty 
29 Sanmugavalli nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-4P,E 
30 RahamathNisha P nil nil nil nil nil nil nil nil neg N P,E-plenty nil nil nil neg N 
1-2P 
0-1E 
31 Renuga P nil nil nil nil nil nil nil nil neg N 
4-5P 
2-3E 
nil nil nil neg N 2-4P,E 
32 Malar nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 1-2P,E 
33 Lalitha nil nil nil nil nil nil nil nil nil neg N 
2-4P 
3-6E 
nil nil nil neg N 
1-2P 
2-4E 
34 Malliga nil nil nil nil nil nil nil nil nil neg N 
2-4P 
3-6E 
nil nil nil neg N 1-2P,E 
35 Srinivasan nil nil nil nil nil nil nil nil nil neg N 2-4P,E nil nil nil neg N 2-3P,E 
36 VijiyaGeetha nil nil nil nil nil nil nil nil nil neg N 4-5P,E nil nil nil neg N 2-4P,E 
37 Monidevi nil nil nil nil nil nil nil nil nil neg N 
1-3P 
1-2E 
nil nil nil neg N 2-4P,E 
38 Manimozhi nil nil nil nil nil nil nil nil nil neg N 
4-8P 
8-10E 
nil nil nil neg N 2-4P,E 
39 Shanthi nil nil nil nil nil nil nil nil nil neg N 
2-4P 
5-6E 
nil nil nil neg N 
2-4P 
1-2E 
40 Renugadevi nil nil nil nil nil nil nil nil nil neg N nil nil nil nil neg N 2-3 P,E 
OB-Occult blood,A-Albumin,RBS-Random blood sugar,BS-Bile salt,BP-Bile pigment,UB-Urobilinogen,DEP-Deposits,N-Normal,Neg-Negative,P,E-Pus cells ,Epithelial cells,P-Present,NG-
not given. 
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20. RESULTS AFTER TREATMENT: 
      
  Results were observed on the basis of two main criteria.  
Primary Outcome:  
Primary Outcome is mainly assessed by comparing the pre and post treatmental 
Hemoglobin level, of the trial patient. 
 
Secondary Outcome: 
Secondary outcome is assessed by comparing the following parameters, before and 
after the treatment.        
1) Reduction of Clinical symptoms 
2) Changes in Complete Blood Count 
 
HEMOGLOBIN CHART BEFORE AND AFTER TREATMENT 
 
S.N OP/IP NO HB BEFORE TMT  HB AFTER TMT 
1 B77139 10.5g 10.9g 
2 C84193 9.3g 11.4g 
3 B75370 9.8g 12.8g 
4 C74519 9.7g 10.1g 
5 C80290 9.3g 13.0g 
6 C71808 10.3g 10.8g 
7 B85745 10.0g 9.5g 
8 C84645 7.0g 7.4g 
9 C69738 9.8g 12.8g 
10 C82941 8.3g 13.8g 
11 C82329 9.2g 13.3g 
12 C65259 9.4g 12.5g 
13 B85887 9.6g 9.3g 
14 B75701 9.8g 11.3g 
15 C84838 9.8g 12.7g 
16 C82323 11.1g 13.9g 
17 C79216 9.8g 10.0g 
18 C75910 9.8g 14.0g 
19 C85414 9.8g 13.1g 
20 C85572 8.9g 12.8g 
21 C85518 9.8g 12.4g 
22 C85417 8.9g 11.0g 
23 C86521/4016 8.7g 6.8g 
24 C27061/3986 8.9g 9.3g 
25 C85468 9.0g 12.8g 
26 C86420/4015 9.3g 11.7g 
27 C79659/4013 9.8g 11.3g 
28 C86320/4014 8.7g 7.1g 
29 C26014 9.6g 12.3g 
30 C85864 7.4g 7.0g 
31 C85412 9.4g 10.9g 
32 C80021/4024 9.4g 11.8g 
33 C86719/4027 9.0g 12.6g 
34 C80773/4028 9.4g 14.0g 
35 C80725/4943 12.6g 12.9g 
36 C83591 9.2g 8.5g 
37 C87572 7.8g 7.1g 
38 C90816 9.1g 12.8g 
39 AL8984 9.4g 10.3g 
40 C87999/4132 7.3g 6.2g 
 120  
 
i) PRIMARY OUTCOME: 
 
 Results derived from the Hemoglobin 
S. N Hemoglobin Improvement 
No of cases 
[Percentage %] 
1  1- 5 gms increase from its base level Good 22 [55%] 
2 0.1-0.9 gms increase from its base level Moderate 10 [25%] 
3 0.1-2 gms decrease from its base level Poor 8 [20%] 
 
 
 
 
 
      
 
Among the 40 cases, 32 [80%] cases showed Good improvement in the 
hemoglobin  level , of which 22(55%) cases showed Moderate improvement of 1 to 5 
grams in the hemoglobin level and 10(25%) cases showed increase of  0.1-0.9 grams 
in the hemoglobin level.8 [20%] cases showed no improvement in  the Hemoglobin 
level. 
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ii) SECONDARY OUTCOME: 
 
1. Results from clinical improvement:  
 
Good, moderate and mild improvements were assessed on the basis as follows, 
 
 
Good improvement 
 Reduction of pallor, hairfall. 
 Restoration of regular menstrual cycle. 
 Relief of  signs and symptoms such as fatigue, palpitation, tachycardia, 
pungent or bitter taste of the tongue, giddiness, breathlessness, 
numbness,tingling sensation. 
 Absence of angular stomatitis, glossitis. 
         
 
 
Moderate improvement                           
 No reduction in pallor, hairfall. 
 Reduction of  signs and symptoms such as fatigue, palpitation, 
tachycardia, pungent or bitter taste of the tongue, giddiness, 
breathlessness, numbness,tingling sensation . 
 Mild improvement in angular stomatitis, glossitis  
    
 
 
Mild improvement                           
 No reduction of pallor, hairfall. 
 Presence of oligomenorrhoea  
 Reduction of  signs and symptoms such as fatigue, palpitation, 
tachycardia, pungent or bitter taste of the tongue, giddiness, 
breathlessness, numbness,tingling sensation and  koilonychia. 
 Presence of angular stomatitis, glossitis  
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S. N Signs and symptoms No of cases [Percentage%] 
1 Good 83.75% 
2 Moderate 10.85% 
3 Mild 5.40% 
          
 
 
 
 
Among the 40 cases, 83.75% cases showed good improvement, 10.85%cases showed 
moderate improvement and 5.40% cases showed mild improvement. 
         
 
2. Results from Complete Blood Count: 
 
Results from RBC: 
 
 
S. N RBC No of cases [Percentage%] 
1 Increased from its  base level 26 [65%] 
2 Did not change from its base level 9 [22.5%] 
3 Reduced from its base level 5 [12.5%] 
 
 
Regarding RBC of the 40 cases, 26 cases (65%) increased from its base level, 9 cases 
(22.5%) did not show any change from its base level and 5 cases (12.5%) showed 
reduction from its base level. 
 
67.5%
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32.5%
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base level
Did not change from 
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base level
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Results from PCV: 
 
S. No PCV No of cases [Percentage %] 
1 Increased from its  base level 22[55%] 
2 Did not change from its base level 0  
3 Reduced from its base level 18[45%] 
 
Regarding PCV of the 40 cases, 22[55%]showed increase from its base level, 
and 18[45%]showed reduction from its base level. 
 
Results from MCV: 
S. N MCV No of cases [percentage%] 
1 Increased from its  base level 27 [67.5%] 
2 Did not change from its base level 0[0%] 
3 Reduced from its base level 13 [32.5%] 
 
Regarding MCV of the 40 cases, 27 [67.5%]showed increase from its base 
level and  13 [32.5%]showed reduction from its base level.  
 
 
      
 
Results from MCH: 
S. N MCH No of cases [Percentage%] 
1 Increased from its  base level 28 [70%] 
2 Did not change from its base level 2 [5%] 
3 Reduced from its base level 10 [25%] 
 
Regarding MCH of the 40 cases, 28 [70%]showed increase from its base level, 
2 [5%]did not show any change in its base level and 10 [25%]showed reduction from 
its base level. 
67.5%
0%
32.5%
MEAN CORPUSCULAR VOLUME
Increased from its  base level
Did not change from its base 
level
Reduced from its base level
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Results from MCHC: 
S. N MCHC No of cases  [percentage%] 
1 Increased from its  base level 26 [65%] 
2 Did not change in its base level 2[5%] 
3 Reduced from its base level 12 [30%] 
 
Regarding MCHC of the 40 cases, 26 [65%]showed increase from its base level and 
12 [30%]showed reduction from its base level. 2[5%] did not change in its base level. 
 
Results   from Morphology of RBC: 
 
S. No Morphology of RBC No of cases [Percentage%] 
After Tmt. 
1 Normocytic Normochromic 9 [22.5%] 
2 Microcytic Hypochromic 31 [77.5%] 
 
Regarding Morphology of RBC, Out of 40 cases, 9 [22.5%] cases became 
Normocytic Normochromic after the treatment and 31 [77.5%]cases remained in 
Microcytic Hypochromic after the treatment.  
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22. STASTICAL ANALYSIS: 
Student Paired „t‟ test was used to test the significance of treatment using before 
and after treatment data on HB, RBC, PCV, MC,MCH, MCHC. 
The level of significance probablity 0.05 was used to test the treatment difference and 
the values were statistically significant. 
 
 
Statistical data for Hemoglobin: 
 
Variable N Mean Std.dev Std. Error 
Mean 
p.value 
Before treatment HB 
After treatment HB 
40 
40 
9.34 
11.10  
.97 
2.24 
.1544 
.3552 
<0.001 
 
The mean ± standard deviation of HB at before and after treatment were 9.34 ± .97 
and 11.10 ± 2.24 which is statistically significant (p <0.001). 
 
 
Stastical data for RBC: 
 
Variable N Mean Std.dev Std.ErrorMean t.value 
Before treatment RBC 40 4.175 .5429 .0858 <0.35 
After treatment RBC 40 4.335 .3833 .0606 
 
RBC before treatment is 4.175 ± .5429 and after treatment is 4.335 ± .3833 which is   
stastically significant (P< 0.35) 
 
 
Stastical data for PCV: 
 
Variable N Mean Std.dev Std.ErrorMean t.value 
Before treatment PCV 40 34.427 9.6885 1.5319 <0.685 
After treatment PCV 40 33.693 5.4620 .8636 
 
PCV before treatment is 34.427 ± 9.6885 and after treatment is 33.693 ± 5.4620 
which is stastically significant (P< 0.685) 
 
 
 
Stastical data for MCV: 
 
Variable N Mean Std.dev Std.ErrorMean t.value 
Before treatment MCV 40 76.130 11.8449 1.8728 <0.64 
After treatment MCV 40 78.870 9.0539 1.4315 
 
MCV before treatment is 76.130 ± 11.8449 and after treatment is 78.870 ± 9.0539 
which is stastically significant (P< 0.64) 
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Stastical data for MCH: 
Variable N Mean Std.dev Std.Error Mean t.value 
Before treatment MCH 40 25.623 4.5625 .7214 <0.000 
After treatment MCH 40 32.373 2.4997 .3952 
 
MCH before treatment is 25.623 ± 4.5625 and after treatment is 32.373 ± 2.4997 
which is stastically significant (P< 0.000) 
 
 
 
Stastical data for MCHC: 
Variable N Mean Std.dev Std.Error Mean t.value 
Beforetreatment MCHC 40 31.735 2.1601 .3415 -1.050 
After treatment MCHC 40 32.0183 1.91430 .30268 
 
MCHC before treatment is 31.735 ± 2.1601 and after treatment is 32.0183 ± 1.91430 
which is stastically significant (P< 0.05) 
 
 
 
 
 
 
Paired Sample Test 
 
Variable T Df Sig. (2-
tailed) 
Significancy 
HB ( BT) – HB (AT) -5.890 39 .000 Highly 
Significant 
RBC (BT)- RBC(AT_ -2.181 39 .035 Significant 
PCV(BT) – PCV(AT) .409 39 .685 Not 
Significant 
MCV(BT) MCV(AT) -1.90 39 .064 Not 
Significant 
MCH(BT)- MCH(AT) -11.824 39 .000 Highly 
Significant 
 
According to the data obtained from Paired Sample Test the level of Haemoglobin 
increased after treatment is highly significant. 
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DISCUSSION 
 
 In Siddha Science, PithaPandu is caused due to derangement of Pitham.The signs 
and symptoms of PithaPandu such as pallor, anorexia, dyspnoea, palpitation,   
blurred vision, pungent taste of tongue, pica etc., are related with Iron Deficiency 
Anaemia in Modern Science. 
 
 PithaPandu [Iron Deficiency Anaemia] is one of the global diseases affecting 2 
billion people all over the world and in India 1 in 77 people are affected.  
 
 Hence the Principal Investigator focused to treat PithaPandu [IDA].The aim of the 
study was to find the theurapeutic efficacy of “KARISALANKANNI 
CHOORANAM” which is indicated for pandu specifically in the ancient literature 
Sigicha Rathna Deepam  (Ref:Page: 162).  
 
 Before the initiation of the study, Institutional Ethical Committee approval [Reg 
No: 1248/ac/oa/CPCSEA/4-02/2011] and Institutional Animal Ethical Committee 
approval [NIS/IEC/2011/03/02] was obtained by submitting well defined protocol, 
at NIS. 
 
 All the raw drugs were  authenticated by Botanist in National Institute of 
Siddha.Certificate no:NIS/MB/43/2012 
 
 The Siddha formulation KARISALANKANNI CHOORANAM was prepared by 
following the standard operating procedure in Gunapadam labarotary, NIS, under 
the supervision of the HOD and Lecturers of Department of Gunapadam. 
 
  The prepared drug KARISALANKANNI CHOORANAM  is then subjected for 
Preclinical, Biochemical and Clinical studies and the observation and results are 
given as follows, 
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PRECLINICAL STUDIES:  
The animals for preclinical studies were purchased from Kings Institute, Guindy, 
Chennai and the study was conducted in Pharmacology Laboratory, NIS. 
 
   i) Acute toxicity study(WHO Guidelines): 
 
 Single dosage of the drug 36mg/animal [10 X] was administered orally to 
Swiss albino mice and observed for the period of 14 days. 
 No mortality and behavior changes were noted for the first 4 hours and for 
the next 24 hours and throughout the study period of 14 days. 
 No weight reduction was noted before and after the acute study duration. 
 Reflexes were found to be normal before and after the study 
 Observations such as grooming, lacrimation, alertness, skin changes etc., 
were found to be normal before and after the study. 
 In Necropsy, the organs of the animal such as Liver, Heart, Lungs, 
Pancreas, Spleen, Stomach, Intestine, Kidney, Urinary bladder and Uterus 
all appeared normal 
 
   ii) Sub-Acute toxicity study results:  
 
 1X dose [36mg/animal], 5X dose [180mg/animal] and 10X dose 
[360mg/animal]  were administered orally  once per day to Wistar albino rats 
for the period of 3 months. 
 No weight loss, abnormal animal behaviours, abnormal metabolic functions 
[urination, lacrimation, defaecation etc.,] and mortality were noted. 
 Necropsy of the animal organs showed normal appearance and weight. 
 All Haematological and Biochemical parameters were within normal limits. 
 The stastical report of the Haematological and Biochemical datas did not show 
any significant difference, between the control and test groups. 
 In Histopathological studies, No abnormal findings were observed in the 
organs such as Heart, Liver, Lungs, Kidneys and Stomach in 1X, 5X and 10X 
compared with control group. 
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QUALITATIVE ANALYSIS OF KARISALANKANNI CHOORANAM: 
 
The Qualitative study was done in Biochemistry Laboratory, NIS and the results are 
as follows, 
 
 Presence of Iron in Ferrous form which is a readily absorbable form.  
 Presence of Magnesium, Sodium, calcium, alkaloids, tanic acid and starch 
which are essential to fulfill the therapeutic need.  
 
CLINICAL STUDIES: 
 
 The clinical study was conducted in OPD and IPD of NIS. 
 
 The patients with the complaints of pallor, anorexia, glossitis, breathlessness, 
palpitation, numbness etc., were screened using screening proforma, for PithaPandu. 
 
 Out of 60 patients screened, 40 patients who satisfied the inclusion and exclusion 
criteria were recruited for the trial. 
 
 Before the start of the trial, Informed Consent was obtained from the patients. 
 
 Out of 40 patients 30 were treated in OPD and 10 were treated in IPD. 
 
 The treatment aim was to regulate the deranged Pitha dosha and to improve the 
Hemoglobin level. 
 
 Specific diet restrictions such as tobacco, betel chewing, tea, coffee and alcohol were 
advised to avoid, during the trial period. 
 
 Labarotary investigations were done on 0th and 24th day for the assessment of safety 
of the patients and efficacy of the drug. 
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 After completion of the trial, patients were followed up for the next 2 months in the 
OPD. 
 After the completion of treatment with the trial drug in 40 cases, highly encouraging 
results were observed in the following Haematological, Stastical and Clinical 
parameters as follows, 
 
RESULTS FROM HAEMATOLOGICAL PARAMETERS: 
 
1. Hemoglobin : Out of 40 cases, 
 32 [80%] cases showed improvement, of which 8 cases reached nomal level.  
                    i)  Increase of 1 to 5 grams of Hb – 22 (55%) 
                    ii) Increase of 0.1- 2.0 grams of Hb – 10 (25%) 
 Remaining 8 [20%] cases showed no improvement. 
 
2. Total RBC: Out of 40 cases, in 26 cases (65%)total RBC increased from its 
base level, 9 cases (22.5%) did not show any change from its base level and 5 
cases (12.5%) showed reduction from its base level. 
 
3. MCV: Out of 40 cases, 27(67.5%) cases showed increase from its base level 
and 13(32.5%) cases showed reduction from its base level. 
 
4. PCV: Out of 40 cases, 22(55%) cases showed increase from its base level, and 
18(45%) cases showed reduction from its base level. 
 
5. MCH: Of the 40 cases, 28(70%) cases showed increase from its base level, 
2(5%) did not show any change and 10 (25%) cases showed reduction from its 
base level. 
 
6. MCHC: Of the 40 cases, 26(65%) cases showed Increase from its base level 
and 2(5%) cases showed reduction from its base level. 
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7. Morphology of RBC: Out of 40 cases, in 9(22.5%) cases showed Normocytic 
Normochromic status after the treatment and 31(77.5%) cases remained in 
Microcytic Hypochromic status after the treatment. 
 
8. Liver function tests, Renal function tests and other blood parameters were found 
to be in normal limits, during the treatmental period and after the treatment. 
 
STATISTICAL REPORT: 
 
The Statistical report states that the Mean ± Standard deviation for, 
i) Hemoglobin before treatment is 9.34 ± .97 and after treatment is    11.10 ± .3552 
which is statistically significant (P < 0.001). 
ii) RBC before treatment is 4.175 ± .5429 and after treatment is 4.335 ± .3833 which 
is   stastically significant (P< 0.35) 
iii) PCV before treatment is 34.427 ± 9.6885 and after treatment is 33.693 ± 5.4620 
which is stastically significant (P< 0.685) 
iv) MCV before treatment is 76.130 ± 11.8449 and after treatment is 78.870 ± 
9.0539 which is stastically significant (P< 0.64) 
v) MCH before treatment is 25.623 ± 4.5625 and after treatment is 32.373 ± 2.4997 
which is stastically significant (P< 0.000) 
vi) MCHC before treatment is 31.735 ± 2.1601and after treatment is 32.0183 ± 
1.91430 which is stastically significant (P< 0.05) 
 
RESULTS FROM CLINICAL PARAMETERS: 
 
 Adverse reaction of the drug was not observed during the course of the study. 
 
 In the clinical trial, Out of 40 cases 32(80%) cases showed good improvement, 
8 cases showed poor improvement and some of the important siddha 
parameters are stated below. 
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Age incidence: The age limit for the cases taken for study ranged from 13 to 55 
years. Among the 40 cases treated, 0 cases (0%) belonged to 13-20years, 25 cases 
(62.5%) belonged to 20-40 years and 15 cases (37.5%) belonged to 40-55 years. The 
percentage is more in the age group of 20-40 years. 
 
Sex incidence: Out of 40 patients screened for the trial, 2 cases were males and all of 
them were found to be under the exclusion criteria were not included and 38 cases 
were females of which 40 of the cases, who satisfied the inclusion and exclusion 
criteria were included in the trial. The inference obtained from the study showed, the 
vulnerability of the female population towards the disease Pithapandu [IDA].  
 
Occupational incidence:  Among the 40 cases, 0 (0%) of them were students, 16 
(40%) of them were working and 24 (60%) of them were house wives. The 
percentage is more in house wives. 
 
Socio-ecnomic Incidence: Among the 40 cases, 8(20%) cases belonged to Upper 
middle class economic status, 12(30%) cases belonged to middle class people and 
20(50%) belonged to poor economic status.The percentage is more in poor economic 
group.The inference obtained from the study showed, poor socio-economic status is a 
main predisposing factor, since the poor people usually consume low nutritional food. 
 
Dietary Factor: Among the 40 cases, 12 (30%) cases were observed to have pure 
vegetarian diet and 28(70%) were taken non-vegtarian diet.The incidence is high in 
non-vegtarians. 
 
Etiology: Generally Pandu noi is due to dietic factors, which cause vitiation of Pitham 
and Kabam Thaathus. History of patients reveal that irregular food habits, excessive 
intake of ash, soil and clay (pica) , over intake of salt, sour and pungent tasted food 
items and malnutritious diet cause this disease. Before treatment 18 of the cases had 
PICA and all of them relieved after the treatment. 
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Thegi [Body constitution]: Of the 40 cases, 4(10%) cases were in Vatham body 
constitution, 28(70%) cases were in Pitham body constitution, 8(20%) cases were in 
thontham body constitution.The percentage was more in pitham type of body 
constitution. 
Iymporigal [Sensory organs]: Of the 40 cases, 
 
 Mei [Skin] was affected noted as pallor, numbness, dryness, in 32 (80%) cases 
and 32 (80%) cases improved after the treatment. 
 
  Vaai [Buccal cavity] was affected noted as glossitis, angular stomatitis, bitter 
or pungent taste, dryness, pallor, fissured and coated tongue in 12 (30%) cases 
and all the patients were improved after the treatment. 
 
 Kan [Eye] was affected noted as pallor, blurred vision in 36 (90%) cases and 
32(80%) cases improved after the treatment. 
 
Iympulangal [Motor organs]: Out of 40 cases, 
 
 Kai [Upper limb] was affected noted as numbness, pain in 32 (80%) cases and 
all the patients were improved after the treatment. 
 Kaal [Lower limb] was affected noted as numbness, pain, paedal edema in 28 
(70%) and all the patients were improved after the treatment. 
 Vaai [Buccal cavity] was affected noted as glossitis, angular stomatitis, bitter 
or pungent taste, dryness, pallor, fissured and coated tongue in 12 (30%) cases 
and all the patients were improved after the treatment. 
 Eruvai [Anus] was affected noted as constipation in 4 (10%) cases and all the 
patients were improved after the treatment. 
 Karuvai [Genital organ] was affected (amennorhea in 4 (10%) all the patients 
were improved after the treatment. 
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Kosam: Of the 40 cases, 
 Annamayakosam was affected, noted as loss of appetite in 32 (80%) cases 
and all the patients were improved after the treatment. 
 
 Manomayakosam was affected, noted as palpitation in 24 (60%) cases and all 
the patients were improved after the treatment. 
 
 Vinganamayakosam was affected, noted as pain, numbness and tingling 
sensation in 16 (40%) cases and all the patients were improved after the 
treatment. 
 
 Pranamayakosam was affected, noted as breathlessness in 32(80%) cases and 
28(70%) of the patients were improved after the treatment. 
 
 Anandamayakosam was affected, noted as ammenorrhoea, oligomenorrhoea 
and constipation in 4 (10%) cases and 4(10%) were improved after the 
treatment. 
 
Mukkutram: 
Vatham: Out of 40 cases, 
 Pranan was affected, noted as breathlessness in 36(90%) cases and 32(80%) 
were improved after the treatment. 
 
 Abanan was affected, noted as constipation, flatulence, ammenorrhoea and 
oligomenorrhoea   in 12(30%) cases and 8(20%) were improved after the 
treatment. 
 
 Uthanan was affected, noted as breathlessness in 28(70%) of the cases   
before the treatment and 28(70%) of the cases were improved after the 
treatment. 
 
 Viyanan was affected noted as pain, numbness and tingling sensation in 
32(80%) cases and all of them were improved after the treatment. 
 135  
 
 Samanan was affected noted as loss of appetite, pain, numbness and 
breathlessness in 38(90%) cases and all of them were improved after the 
treatment. 
 
 Koorman was affected, noted as blurred vision in 8(20%) cases and all of 
them were improved after the treatment. 
 
 Kirukaran was affected noted as loss of appetite, dryness of mouth in 
36(90%) cases and all of them were improved after the treatment. 
 
 Devadhathan was affected, noted as fatigue in 40(100%) of the cases and all 
of them were improved after the treatment. 
 
Pitham: Out of 40 cases, 
 
 Ranjagam was affected in all the 40 [100%] cases, noted as pallor before the 
treatment and 37(92.5%) cases showed improvement after treatment. 
  
 Prasagam was affected in all the 40 [100%] cases, noted as pallor and 37 
(92.5%) cases showed improvement after treatment. 
 
  Analam was affected in 38 (90%) of the cases noted as loss of appetite before 
the treatment and all of them showed improvement after the treatment.  
 
 Alosagam was affected in 2(5%) of the cases noted as dull vision before the 
treatment and all of them were improved after the treatment. 
 
  Sathagam was affected noted as fatigue  in 37(92.5%) cases and all the cases 
were improved from the affection after the treatment. 
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Kabam: Out of 40 cases, 
 
 Avalambagam was affected noted as breathlessness in 32(80%) cases before 
the treatment and 30(75.5%) cases were improved after the treatment. 
 
  Kilethagam was affected noted as indigestion in 8(20%) cases and all of 
them were improved after the treatment. 
 
  Pothagam was affected in 12(30%) cases noted as feeling of pungent or bitter 
taste of the tongue and all of them were improved after the treatment. 
 
Udal Kattugal: Of the 40 cases, 
 
 Saaram [noted as fatigue] was affected in all 40 patients (100%) before the 
treatment and 40(100%) patients were improved after the treatment. 
 
  Senneer [noted as pallor, reduction of Hemoglobin level] was affected in all 
40 patients (100%) before the treatment and 37(92.5%) patients were 
improved after the treatment. 
 
 Oon was affected noted as paedal edema in 12(30%) cases, before the 
treatment and all of them were improved from the affection after the 
treatment. 
 
 Suronitham was affected in 8(20%) patients noted as oligomenorrhoea before 
the treatment of which 4(10%) were improved after the treatment.   
 
Envagai Thervugal: Out of 40 cases, 
 
 Naa [noted as pallor, coated, glossitis, angular stomatitis, baldness, fissure, 
dryness, pungent or bitter taste, decreased salivation] was affected in 36 [90%] 
cases before treatment and 36(90%) cases were improved after the treatment. 
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 Niram [ noted as pallor] was affected in 36 [90%] cases before treatment and 
36(90%) cases were improved  from the affection after the treatment. 
 
 Vizhi [noted as pallor] was affected in all the 36(90%) cases of which 
36(90%) cases were improved from the affection after the treatment. 
 
 Sparisam was affected [noted as dryness, hot or cold sensation, excessive 
sweat] in 32(80%)  cases and all of them were improved after the treatment 
 
 Malam was affected [noted as constipation] in 8(20%) before the treatment 
and all of them were improved after the treatment. 
 
Naadi: According to this study, among 40 cases, Pithavaatham naadi was observed in 
38(95%) cases, Vathapitham naadi was observed in 2 cases before the treatment. 
After the treatment 24(60%) cases in Pithavatham naadi and 16(40%) cases in 
Vathapitham naadi were observed. 
 
Neikkuri: Of the 40 patients, 28 [70 %] cases were observed in Pitha neer and 
remaining 12 (30 %) cases were observed in Vatha neer before the treatment and 20 
[50 %] cases were observed in Pitha neer and 20 (50 %) cases were observed in Vatha 
neer and Pitha neer after the treatment 
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                                              SUMMARY 
 
 The clinical study was to evaluate the Therapeutic efficacy of the siddha 
formulation “KARISALANKANNI CHOORANAM” which is indicated for 
pandu specifically in the ancient literature Sigicha Rathna Deepam (Ref: Page: 
162).  
 
 Before the initiation of the study, Institutional Ethical Committee approval [Reg 
No: 1248/ac/oa/CPCSEA/4-02/2011] and Institutional Animal Ethical Committee 
approval [NIS/IEC/2011/03/02] was obtained by submitting well defined protocol, 
at NIS. 
 
 Institutional Ethical Committee and Institutional Animal Ethical Committee 
approval were obtained before the commencement of the trial by submitting the 
well defined protocol and proforma. 
 
 The raw drugs were collected from the reputed raw drug market in Chennai. 
 
 All the raw drugs were authenticated by Botanist in National Institute of Siddha. 
 
 The medicine was prepared by the Principal Investigator by following the 
standard operating procedure in Gunapadam laboratory, NIS.  
 
 Then the medicine was subjected to the preclinical studies, as per Who 
guideliness, in Pharmacology Lab, NIS and safety of the drug was ensured. 
 
 The prepared medicine was subjected to clinical trial at OPD and IPD of NIS. 
 
 Among the 60 patients screened in the OPD of Department of Maruthuvam, 40 
patients who satisfied the inclusion and exclusion criteria were selected and all 
were females. Since the males did not satisfy the inclusion criteria and exclusion 
criteria were excluded from the study.  
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 Clinical diagnosis of PithaPandu was made by Siddha and Modern methodology. 
 
 The trial drug “: KARISALANKANNI CHOORANAM”  - 1 gm is given 
continuously for 24 days.For OP patients ,they should visit the hospital once in 
12 days.At each clinical visit clinical assessment is done and prognosis is 
noted.For IP patients the drug is provided daily and prognosis is noted. 
 
  Laborotary investigations are done at 0th day& 24th day of the trial.For IP 
patients, who is not in a situation to stay in the hospital for a long time is advised 
to attend the OPD for further continuation of the treatment. 
 
 Out of 40 patients, 30 were treated in OPD and 10 were treated in IPD. 
 
 Assessments and required Lab Investigations were carried out as per protocol and 
the concerned data was recorded in the proforma.  
 Followups of the patient for next 2 months in the OPD after the trial period were 
also carried out, without the trial drug. 
 
 The Statistical analysis showed the datas obtained from the Hematological 
parameters were statistically significant. 
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CONCLUSION 
 
 To conclude Siddha way of approach is certainly the best treatment of Pitha 
pandu(Iron deficiency anaemia) in all aspects the trial drug Karisalankanni chooranam 
could avoid complications. 
 The raw drugs are readily available and easily preparable with least cost and more 
safety. 
 Toxicity study reveals safer study. 
 Clinical study revealed that the trail drug possess good improvement in 83.75% cases 
moderate improvement in 10.85%cases and 5.40% cases showed mild  improvement. 
 The observed difference between the mean ± standard deviation of HB at before and 
after treatment were 9.34 ± .97 and 11.10 ± 2.24 which is statistically significant (p 
<0.001). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 141  
 
ANNEXURE –I 
TOXICOLOGICAL EVALUVATION OF KARISALANKANNI 
CHOORNAM 
 
1. ACUTE TOXICITY STUDY OF KARISALANKANNI CHOORNAM:  
 
Principle: 
 Acute toxicity is carried out in Swiss albino mice with a single exposure of 10 
times of the recommended therapeutic dose of test compound .The study duration will 
be 14 days[WHO guidelines, 1993]. 
 
Animal species  : Swiss albino mice 
Age / Weight        :  6 weeks/ 20-25Gms. 
Gender   :   Both male and female 
Number of Animals  : Mice: 20 
Acclimatization Period : 7 Days 
Clinical dose  : 2000 mg/day 
 
S.
N 
Group No of mice 
1 Vehicle control  10  (5 male, 5 female) 
2 Toxic dose 10X therapeutic dose (72 mg/animal) 10  (5 male, 5 female) 
 
Source of Test Animals:Test animals were obtained from the animal laboratory of 
the King institute, Chennai and stocked at National institute of siddha, Chennai.All 
the animals were kept under standard environmental condition (27± 2 degree 
celcius).The animals had free access to water and standard pellet diet (SaiDurga foods 
pvt.ltd, Bangalore).The principles of laboratory animal care were followed and the   
Institutional Animal Ethical Committee approved the use of animals and the study 
design. (1248/ac/09/CPCSEA/Dec/ 2012),[Reg No: NIS/IEC/2011/3/02]. 
 
 
Route of administration:Oral route was selected, because it is the normal route of 
clinical administrationt substance and vehicle: The KarisalankanniChoornam is 
black in colour with mild astringent taste and mild odour.The test substance is 
insoluble in water, in order to obtain and ensure the uniformity in drug distribution, 
the drug is dissolved by aqueous Tween 80 solution (10%).  
 
Administration of doses: KarisalankanniChoornamwas suspended in aqueous Tween 
80 solution (10%), with uniform mixing and it was administered to the groups in a 
single oral dose. The control groups were received equal volume of the vehicle. The 
animals were weighed before giving the drug. The dose level was calculated 
according to body weight and surface area. Since the clinical dose was 2000mg\day, it 
was converted to animal dose (36 mg/animal) and then administered. The principle of 
laboratory animal care was followed. 
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Observations: Observations were made and recorded systematically and 
continuously observed as per the guideline after substance administration. Animals 
were observed individually (visual observations included skin changes, alertness, 
grooming, aggressiveness, sensitivity to sound, touch and pain, restlessness, tremors, 
convulsion, righting reflex, gripping reflex, pinna reflex, corneal reflex, writhing 
reflex, papillary reflex, urination, salivation, lacrimation for first 4 hrs, then 
periodically during the first 24 hrs. Animals were observed for body weight and 
mortality for 14 days. If animals died during the period of study, the animals were 
sacrificed. At the end of the 14
th
 day all animals were sacrificed and necroscopy was 
done. 
 
Body Weight: Individual weight of animals was determined before the test substance 
was administered and daily for 14 days. Weight changes were calculated and 
recorded. At the end of the test surving animals were weighed and sacrificed. 
 
Results:  KarisalankanniChoornamat the dose 36mg/animal [10X] did not exhibit any 
mortalityin mice.No behavior changes were noted for the first 4 hours and for the next 
24 hours and throughout the study period of 14 days. No weight reduction was noted 
before and after the acute study duration. Reflexes were found to be normal before 
and after the study. All other observations were found to be normal before and after 
the study. In Necropsy, the organs such as Liver, Heart, Lungs, Pancreas, Spleen, 
Stomach, Intestine, Kidney, Urinary bladder and Uterus all appeared normal. 
 
2.SUB ACUTE TOXICITY STUDY OF KARISALANKANNI CHOORNAM: 
Animals             :Wistar albino rats 
Age                    : 6-8 weeks 
Weight   : 150-200 Gms 
Gender   :  Both male and female 
Number of animals   :  40 
Acclimatization period : 7 Days 
Clinical dose   : 2000mg/day 
Clinical duration  : 48 days 
 
Animal source:Test animals were obtained from the animal laboratory of the King 
institute, Chennai,and stocked at animal house in National Institute of Siddha, 
chennai.All the animals were kept under standard environmental condition (27± 2 
degree celcius). The animals had free access to water and standard pellet diet 
(SaiDurga foods pvt.ltd, Bangalore). The principles of laboratory animal care were 
followed and Institutional Animal Ethical Committee approved the use of animals and 
the study design(1248/ac/09/CPCSEA/Dec/ 2012),[Reg No: NIS/IEC/2011/3/02]. 
 
S.No Group No of Rats 
1 Vehicle control 10 (5male,5 female) 
2 1XTherapeutic dose (36 mg/animal) 10 (5male,5 female) 
3 5XTherapeutic dose (180 mg/animal) 10 (5male,5 female) 
4 10XTherapeutic dose(360 mg/animal) 10(5male, 5 female) 
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Identification of animal:By cage number, animal number and individual marking on 
fur. 
Housing & Environment:The animals were housed in polypropylene cages provided 
with bedding of husk under dark and light cycle each of 12 hours. 
 
Administration period:The period of administration of the test substance to animals 
are depending on the expected period of clinical use. Since the clinical dose of the test 
drug is 48 days and as per WHO guidelines the administration period is reported to be 
3 months. 
 
Dose selection:The results of acute toxicity studies in Swiss albino mice indicated 
that KarisalankanniChoornamwas non toxic and no behavioral changes, mortality was 
observed. On the basis of these results, the doses were selected for the study as per 
WHO guidelines.  
 
Preparation and administration of dose:KarisalankanniChoornam was suspended 
in aqueous Tween 80 solution (10%). It was administered to animalsat dose levels of 
1X therapeutic dose (36 mg/animal), 5X therapeutic dose (180 mg/animal) and 10X 
therapeutic dose (360 mg/animal). The control animals were administered vehicle 
only. Administration was by oral (gavage) once a day for 90 days. 
 
METHODOLODY: 
 
Randomization, Numbering and Grouping of animal: The animals were randomly 
divided into four groups for dosing up to 90 days. Each group consist of 10 animals (5 
per sex in each group) were allowed acclimatization period of 7 days to laboratory 
conditions prior to the initiation of treatment.Each animal was fur marked with picric 
acid. The females were nulliparous and non pregnant. 
OBSERVATION: Experimental animals were kept under observation throughout the 
course of study for the following:         
 
Body weight:Weight of each rat was recorded on day 1 and at weekly intervals 
throughout the course of study and at termination to calculate relative organ weights. 
From the data mean body weights and percent body gain were calculated. 
 
Food and water consumption:The quantity of food consumed by groups consisting 
of 10 animals for different doses was recorded at weekly intervals. Food consumed 
per animal was calculated for control and the treated dose groups. 
 
Clinical sings: All animals were observed daily for clinical sings. Time of onset 
intensity and duration of this symptom if any were recorded. Animal behaviours and 
metabolic functions [defaecation, urination, lacrimation etc.,] were noted. 
 
Mortality:All animals were observed twice daily for mortality during entire course of 
study. 
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RESULTS: 
10MG TREATED (Low dose) 
Kidney: shows normal renal tissue with glomeruli and tubules.  
Spleen: shows normal spleen with lymphoid aggregation. 
Liver: shows almost normal hepatocytes and occasional binucleate cells. 
Stomach: shows normal mucosal glands. 
Ovary: shows ovarian stroma with follicles and corpus leuteum. 
Lung: shows normal alveoli. 
Testis: shows normal tubules with spermatogenesis. 
Heart: shows normal cardiac muscle bundles. 
Brain: shows normal brain with nerve fibers and astrocytes. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
Pancrea: shows normal acini with islets of β-cells 
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20MG TREATED (Mid dose) 
Brain: shows brain with edema, microglial proliferation, shows brain 
with micro cystic change and astrocytic proliferation, shows brain with 
mononuclear infiltrate around vessel.  
Kidney: shows renal tissue with focal tubular damage, interstitial 
inflammatory collection. Glomeruli shows epithelial proliferation.  
Liver: shows hepatocytes with focal mild fatty change.  
Spleen: shows congestion with lymphoid hyperplasia.  
Stomach: shows near normal mucosal gland with mild exudates. 
Lung: shows congested alveolar wall with mild thickening and mild 
emphysematous changes.  
Pancreas: shows pancreas with acini and normal islets.  
Testis: shows normal tubules with spermatogenesis. 
Heart: shows congestion and mild inflammatory infiltration in between 
cardiac muscle bundles. 
Ovary: shows ovarian stroma with follicles and corpus leuteum. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
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40MG TREATED (High dose) 
Stomach: shows stomach with superficial erosion and congestion.  
Heart: shows hypertrophic cardiac muscle bundles.  
Spleen: shows lymphoid hyperplasia. 
Brain: shows brain with edema. Astrocytes show degenerative 
changes.shows brain with pyknotic irregular nucleus, shows brain with 
vesicular nuclei and micro cystic changes.  
Liver: shows marked dilatation of sinusoids, degeneration of 
hepatocytes, necrosis.   
Kidney: shows renal tissue with tubular epithelial damage.  
Pancreas: shows atrophic islet cells. 
Testis: Giant cells were formed in the lumen of the seminiferous tubules 
and the spermatogenic cells degenerated. Lung: shows congestion, 
narrowed alveolar space and thickened alveolar     wall. 
Ovary: shows ovarian follicles and corpus leuteum. 
Intestine:Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
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Heart – 10 mg Heart – 20 mg 
    
Heart - 40 mg 
Liver – 10 mg Liver – 20 mg Liver – 40 mg 
Lung – 10 mg Lung – 20 mg Lung – 40 mg 
Kidney – 10 mg Kidney – 20 mg Kidney – 40 mg 
HISTOPATHOLOGY PHOTOS 
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Bone – 10 mg Bone – 20 mg Bone – 40 mg 
 
Intestine – 10 mg  Intestine – 20 mg 
 
Intestine – 40 mg 
 
Ovary – 10 mg  Ovary – 20 mg 
 
Ovaray – 40 mg 
 
Pancrea – 10 mg  Pancrea – 20 mg 
 
Pancrea – 40 mg 
 
Spleen – 10 mg  Spleen – 20 mg 
 
Spleen – 40 mg 
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Stomach – 10 mg Stomach – 20 mg Stomach – 40 mg 
Brain – 10 mg Brain – 20  mg Brain – 40 mg 
 
Testis – 10 mg  Testis – 20 mg 
 
Testis – 40 mg 
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ANNEXURE – II 
Biochemical  Analysis of   KarisalankanniChoornam 
Test Drug details: The following formulation used in the study was processed by the 
methods prescribed in standard text books of Siddha Medicines. 
Name of the drug:KarisalankanniChoornam. 
QUALITATIVE ANALYSIS: 
 
Preparation of the drug for Qualitative Analysis: 5 grams of thedrug accurately 
weighed and placed in 250 ml clean beaker. 50ml of distilled water is added and 
boiled  for 10 minutes. Then it is cooled and filtered in a 100 ml volumetric flask and 
made up to 100 ml with distilled water. 
Methodology and Results: 
Procedure Observation Inference 
Solubility test: 
Test for silicate: A little sample is 
shaken well with distilled water and 
then with con.HCL/con.H2SO4  
Sparingly 
insoluble 
Absence of Silicate 
Action of Heat:Test for Carbonate: A 
Small amout of the sample  is taken in 
a dry test tube and heated gently in the 
non-luminous part of the flame 
No white fumes 
are formed 
Absence of 
Carbonate 
Flame test: Test for Copper: One 
pinch of substance is made into paste 
with Con.Hydrochloric acid in a watch 
glass and introduced into the non-
luminous part of the Bunsen flame. 
No Bluishgreen 
flames appeared 
Absence of Copper 
Ash Test:Test for sodium: A filter is 
soaked into a mixture of sample and 
Cobalt Nitrate solution and introduced 
into the Bunsen flame and ignited 
Yellow colour 
flame is 
developed  
Presence of 
Sodium 
Test for Acid radicles:   
Test for Sulphate: 2 ml of the above 
prepared extract is taken in a test 
tube.To this add 2ml of 4% 
Ammonium Oxalate solution.    
No cloudy 
apperance  is 
formed  
Absence of 
Sulphate 
Test for Chloride: 2ml of the above 
prepared extract is treated with 2ml of 
dilute HCL, until the effervescence 
ceases off. 
 No  Cloudy 
appearance is 
formed 
Absence of 
Chloride 
Test for phosphate : 2 ml extract is No yellow Absence of 
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treated with 2ml of Ammonium 
Molybdate and  add 2 ml of  Con. 
HNO3  
appearance  is 
formed 
Phosphate  
Test for carbonate: 2ml extract is 
treated with 2 ml of Magnesium 
Sulphate. 
No Cloudy 
appearance is 
formed  
Absence of 
Carbonate 
Test for Fluoride and Oxalate: 2ml of 
extract is added with dil. Acetic acid 
and 2ml of Calcium Chloride and 
heated 
No Cloudy 
appearance 
Absence of 
Fluoride and 
Oxalate 
Test for Lead: 2ml of the extract is 
added with 2ml of Potassium Iodide 
solution. 
 
No Yellow 
precipitate is 
formed. 
Absence of Lead 
Test for Aluminium: To the2ml of the 
extract, Sodium Hydroxide is added in 
drops to excess.Characteristic change 
is noted. 
No reddish black 
colour is formed. 
Absence of 
Aluminium 
Test for Iron (Ferrous): 2 ml extract is 
treated with 2ml of Ammonium 
Thiocynate solution  and 2ml of Conc. 
HNO3   is added 
 Blood Red colour 
is formed 
presence of 
Ferrous iron 
Test for Iron (Ferric): 2ml extract is 
treated with Glacial Acetic acid and 
Potassium Ferrocyanide 
No Blue colour is 
formed 
Absence of Ferric 
iron 
Test for Zinc:  To the 2ml of the   
extract Sodium Hydroxide solution is 
added in drops to excess. 
White precipitate 
is not formed 
Absence of  Zinc  
Test for Magnesium:  To the 2ml of 
the extract Sodium Hydroxide solution 
is added in drops to excess. 
White precipitate 
is not formed 
Presence of 
Magnesium  
Test for Calcium: 2 ml of extract is 
taken in a clean test tube. To this add 2 
ml of 4% Ammonium Oxalate 
solution.   
White precipitate 
or  Cloudy 
appearance  is 
formed 
Prsence of Calcium  
Test for Ammonium: To 2ml of   
extract 2ml of Nessler’s reagent and 
excess of NaOH solution are added. 
No formation of   
Brown colour 
Absence of 
Ammonium 
Test for Mercury: 2ml extract is treaed 
with 2ml of  NaOH solution 
 
Formation of 
Yellow 
precipitate 
Absence of 
Mercury 
Test for Arsenic: 2ml of the extract is 
treated with 2ml of Sodium Hydroxide 
solution. 
Brownish Red 
precipitate is 
obtained 
Absence of Arsenic 
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Miscellaneous: 
  
Test for Starch : 2ml extract is treaed 
with weak Iodine solution  
 No Blue colour is 
develoed 
Presence of Starch  
Test for Reducing sugar: 5ml of 
Benedict’s qualitative solution is taken 
in a test tube and allowed to boil for 2 
minutes and add 8-10 drops of the 
extract and again boil it for 2 minutes. 
The colour change is noted. 
Brick Red colour 
is developed 
Absence of 
Reducing sugar 
Test for Alkaloids: 2ml extract is 
treated with 2ml  of Potassium Iodide 
solution and 2ml Picric acid is added 
Presence of 
Reddish colour 
presence of 
Alkaloids 
Test for Tannic acid: 2ml of the extract 
is treated with 2ml of Ferric Chloride 
solution. 
No Black 
precipitate is 
formed 
Presence of Tannic 
acid 
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ANNEXURE – III 
CERTIFICATES 
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ANNEXURE – IV 
PROFORMA 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF  MARUTHUVAM 
AN OPEN CLINICAL TRIAL TO ASSESS THE THERAPEUTIC EFFICACY OF THE SIDDHA DRUG   
“KARISALANKANNI CHOORANAM ”  IN“PITHA PANDU”(IRON DEFECIENCY ANAEMIA) 
FORM I  -  SCREENING AND SELECTION PROFORMA 
       
1. O.P.No   ________ 2. I.P No ________ 3. S.No: ________ Reg No:32101202 
     
4. Name: ________________ 5. Age (years):            6. Gender: Female/male 
 
7. Contact  Nos:    ------------------------------------------ 
 
8.INCLUSION CRITERIA: 
 Age 13-55 of both sexes                                                                              
Yes/No 
 Patient willing to undergo  blood investigations                                         
Yes/No 
 Clinical symtoms of Pallor, Breathlessness, Palpitation, Anorexia,            
Yes/No 
Giddiness, Glossitis, lassitude, Fatigue, koilonychias etc., 
 Hb less than normal range ie.,men:7-13mg/dl,Women:7-10mg/dl              
Yes/No 
  Patient blood smear shows microcytic hypochromic RBC                         
Yes/No          
 Patient willingness for consent to include in the trial                                   
Yes/No 
9.EXCLUSION CRITERIA:  
Pregnancy and lactation Yes No Peptic Ulcer   Yes No 
Severe systemic illness(CA,RA)      Yes No Gasterectomy   Yes No 
Inheriteddefects(sicklecellAnaemi
a,Thalassemia) 
Yes No 
Renal disease 
Yes No 
Steroid exposure for prolonged Yes No Diabetes Yes No 
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period mellitus 
Parasitic infection(Malaria,hook 
worm etc.,) 
Yes No 
Hypertension    
Yes No 
Hypothyroidism/Hyperthyroidism Yes No 
Malabsoption
syndrome 
Yes No 
Cardiac disease Yes No 
Chronic blood 
loss 
Yes No 
10.BLOOD INVESTIGATION:Date: 
Hemoglobin              Gms% 
Red blood cells(RBC)              Millions/cu.mm 
Morphology of RBC  
 
11. ADMITED TO TRAIL YES           NO            If Yes Serial NO: 
 
Date:                                                                                                              
 
 
Station: 
 
Signature of the Investigator:  
 
 
Signature of the Lecturer:                             
                                          
        Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
AN OPEN CLINICAL TRIAL TO ASSESS THE THERAPEUTIC EFFICACY OF THE SIDDHA DRUG  
“KARISALANKANNI CHOORANAM ”  IN “PITHA PANDU” (IRON DEFECIENCY ANAEMIA) 
 
                                                                 FORM I-A  HISTORY PROFORMA  
 REG NO: 
 
1. Serial No of the case:   _______________ 
       
2. Name: ________________    3. Gender:   Female/male 
 
4. Age (years): _________   DOB            
      Date       Month            Year 
5.Address: 
 
6.Occupation: 
 
7. Educational  Status:   A) Illiterate                  B)Literate          
 
8.Height:         cms                9.Weight:         kg 
 
10. Complaints and Duration:   
 
 
 
 
 
11.Habit of 
          A) Smoking               1. Yes; duration ________ years;number-   2.No 
     B)Tobacco chewing   1. Yes; duration ________ years     2.No                                         
               C)Betel Nut chewing   1. Yes; duration ________ years     2.No 
               D)Alcoholism          1. Yes; duration ________ years;Quantity-      ml   2.No 
 
12.DrugHistory:  
Had the patient been treated before with allopathy drug?A)Yes          2)No 
 
13.Dietary style:  A.Pure vegetarian         B.Non-vegetarian     C. mixed diet 
 
14.Mensural History: 
 
 Date:         
 Station: 
 
 Signature of the Investigator: 
 
 Signature of the Lecturer:                                                           
        Signature of the HOD 
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                                       NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
                                                        AYOTHIDASAR PANDITHAR HOSPITAL 
                                                           DEPARTMENT OF MARUTHUVAM 
AN OPEN CLINICAL TRIAL TO ASSESS THE THERAPEUTIC EFFICACY  OF THESIDDHA DRUG 
“KARISALANKANNI CHOORANAM ” IN “PITHA PANDU”(IRON DEFECIENCY ANAEMIA) 
 
               FORM II AND    CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS   
      REG NO: 
1. Serial No: ________    
2. Name: ________________ 
3. Date of assessments: 0
th
 day-______/12
th
 day-______/24
th
 day___________  
 
                                SIDDHA SYSTEM OF EXAMINATION 
 
4.ENVAGAI THERVU:[EIGHT-FOLD EXAMINATION] 
 
 I.NAADI: [PULSE PERCEPTION]  
                            
 0th Day 12th Day 24th Day  0th Day 12th Day 24th Day 
Vali    Iyya vali    
Azhal    Vali Iyyam    
Iyyam    Azhal Iyyam    
Vali Azhal    Iyya Azhal    
Azhal vali        
 
 
II.NAA:[TONGUE] 
 
 0th Day 12th Day 24th Day 
Colour Dark/Yellow/Red/Pale Dark/Yellow/Red/Pale Dark/Yellow/Red/Pale 
Taste Sweet/Bitter/Sour/ 
Pungent/None 
Sweet/Bitter/Sour/ 
Pungent/None 
Sweet/Bitter/Sour/ 
Pungent/None 
Coating Present/Absent Present/Absent Present/Absent 
Fissure Present/Absent Present/Absent Present/Absent 
Saliva Normal/Increased/Decreased Normal/Increased/Decreased Normal/Increased/Decreased 
Dryness Present/Absent Present/Absent Present/Absent 
Glossitis Present/Absent Present/Absent Present/Absent 
Baldness Present/Absent Present/Absent Present/Absent 
 
 
III.NIRAM:[COMPLEXION]    
0th Day 12th Day 24th Day 
Dark/Yellow/ Pale/Other 
 
Dark/Yellow/ Pale/Other 
 
Dark/ Yellow/ Pale/Other 
   
 
IV.MOZHI:[VOICE] 
 
0th Day 12th Day 24th Day 
Normal/High/Low pitched Normal/High/Low pitched Normal/High/Low pitched 
                     
V.VIZHI:[EYES] (Lower palpabrel conjunctiva)     
0th Day 12th Day 24th Day 
Dark/Yellow/Red/ Pale Dark/Yellow/Red/ Pale Dark/Yellow/Red/ Pale 
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 VI. MALAM;[BOWEL HABITS / STOOLS] 
 
 
 
VII.MOOTHIRAM:[URINE EXAMINATION]    
  
Neerkuri 0
th Day 12th Day 24th Day 
Niram[Colour]   White/Yellow/Straw  
coloured/Red/Crystal clear 
White/Yellowish/Straw  
coloured/Red/Crystal clear 
 
White/Yellowish/Straw  
coloured/Red/Crystal clear 
 
Manam[Odour] Present/ Absent  Present/ Absent 
 
Present/ Absent 
 
Nurai[Froth] Nil/Reduced/Increased Nil/Reduced/Increased Nil/Reduced/Increased 
Edai[Sp.gravity]                                Normal/Increased/Reduced  Normal/Increased/Reduced Normal/Increased/Reduced 
Enjal[Deposits] Present/ Absent Present/ Absent 
 
Present/ Absent 
 
Volume   Normal/Increased/Reduced Normal/Increased/Reduced Normal/Increased/Reduced 
NEIKURI    
Serpentine fashion    
Annular/Ringed 
fashion 
   
Pearlbeaded fashion       
Mixed fashion    
Other fashion    
                                 
       
 
VIII. SPARISAM:[PALPATORY  PERCEPTION] 
0th Day 12th Day 24th Day 
Warmth/Hot/ cold/ Sweat Warmth/Hot/ cold/ Sweat Warmth/Hot/ cold/ Sweat 
 
 
 
 
5.THEGI:[ TYPE OF BODY CONSTITUTION]    
 0th day 12th day 24th day 
Vatham predominant    
Pitham predominant    
Kabam predominant    
Thondha udal    
 
 
 
 
 
 0th Day 12th Day 24th Day 
Colour Dark/ Yellow/Red Dark/ Yellow/Red/Pale 
 
 
Dark/ Yellow/Red/Pale 
 
 
Consistency Solid/Semisolid/Watery 
 
Solid/Semisolid/Watery 
 
Solid/Semisolid/Watery 
stool  bulk                          Normal/Reduced 
 
Normal/Reduced Normal/Reduced 
Constipation   Present/Absent 
 
Present/Absent 
 
Present/Absent 
 
Diaarhoea Present/Absent 
 
Present/Absent 
 
Present/Absent 
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6.NILAM:[ LAND WHERE PATIENT LIVED MOST]                    
 0
th day 12th day 24th day 
Kurinji [Hilly terrain]    
Mullai [Forest ranges]    
Marutham [Plains]    
Neithal [Coastal belt]    
Paalai [Arid regions]    
 
 
7.KAALAM:[SEASON] 
0th day 12th day 24th day 
   
 
 
8.GUNAM:[CHARACTER] 
 0
th day 12th day 24th day 
Sathuvam    
Rasatham    
Thamasam    
 
 
9.IYMPORIGAL:[SENSORY ORGANS] 
 0th day 12th day 24th day 
    
Mei [Skin]    
Vai[Buccal cavity]     
Kan [Eyes]    
Mooku [Nose]    
Sevi [ear]    
 
 
10.IYMPULANGAL:[MOTOR ORGANS] 
 
 0th day 12th day 24th day 
    
Kai [upperlimb]    
Kal [lowerlimb]     
Vai [Buccal cavity]    
Eruvai  
[excretory organ] 
   
Karuvai[Reproduc-tive 
organ] 
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11. KOSAM:[SHEATHS] 
 0th day 12th day 24th day 
Annamaya kosam 
 
   
Pranamayakosam    
Manonmayakosam 
 
   
Vingyanamaya kosam 
 
   
Anandhamaya kosam 
 
   
 
 
 
12.MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
 
A)VATHAM:                                                                          
 0th day 12th day 24th day 
Praanan    
Abaanan    
Samaanan  
 
  
Udhaanan    
Viyaanan    
Naahan    
Koorman    
Kirukaran    
Devathathan    
Dhananjeyan    
 
 
  B) PITHAM:               
 0th day 12th day 24th day 
Analapitham    
 Prasakam    
Ranjakam    
Aalosakam    
Saathakam    
   
C) KABAM:                        
 0th day 12th day 24th day 
Avalambagam    
Kilethagam    
Pothagam    
Tharpagam          
Santhigam    
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 13.SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]                                       
  
 0th day 12th day 24th day 
Saaram[chyme]    
Senneer[Blood]     
Oon[Muscle]    
Kozhuppu[Fat]    
Enbu[Bones]    
Moolai[Bonemarrow]    
Sukkilam/Suronitham [Genital 
discharges] 
   
 
 
 
14. SYSTEMIC EXAMINATION: 
 0
th day 12th day 24th day 
CardioVascularSystem    
Respiratory  System          
Gastrointestinal\System        
CentralNervousSystem           
Urogenital System    
Endocrine System    
 
15.GENERAL EXAMINATION: 
 0
th
 day 12
th
 day 24
th
 day 
Height (cms)    
Weight (kg)    
Temperature(°F)       
Pulse rate (permin)    
Heart rate (per min)    
Respiratory rate(per min)    
Blood pressure(mm/Hg)    
Pallor    
Jaundice    
Cyanosis    
Lymphadenopathy    
Pedal edema    
Clubbing    
Jugular vein pulsation    
Peripheral pulse     
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16. CLINICAL SYMPTOMS: 
 0
th day 12th day 24th day 
 Pallor    
 Anorexia    
 Fatigue    
 Tachycardia    
 Palpitation    
 Giddiness     
 Breathlessness    
 Pungent or bitter taste of tounge    
 Angular stomatitis    
 Glossitis    
 Lack of concentration    
 Hair fall    
 Amenorrhoea       
 Oligomennorhoea    
 Anasarca    
 Koilonychia    
 Pica     
    
Date : 
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                        
 
     Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
           AN OPEN CLINICAL TRIAL TO ASSESS THE THERAPEUTIC EFFICACY OF THE SIDDHA 
DRUG  
                     “KARISALANKANNI CHOORANAM ”  IN“PITHA PANDU”(IRON DEFECIENCY 
ANAEMIA) 
                                                         LABORATORY PARAMETERS-CHART 
1. Serial No: ________     2.Reg No:  
3. Name: ________________          4.Age:   _______ years         
5.Gender: Male/Female        .    
BLOOD INVESTIGATION 
0th DAY 
Date: 
25th DAY 
Date: 
NORMAL 
VALUES 
HB( gms%)   M:14-18 ;W:11-15 
T.RBC(milli/cu.mm)   
M:4.5-6.5 ;W:3.5-
5.5 
 
ESR (mm) 
½ hr.  -  
1 hr.   M:0-10 ;W:0-20 
MCV( fl or cu.µ)   76-96 
PCV (%)   M:40-55 ;W:35-45 
MCH (pg)   27-33 
MCHC(gm/dl)(%) 
 
               31-35 
MORPHOLOGY OF RBC 
 
  
            Normocytic 
Normochromic 
T.WBC (cu.mm) 
 
 
DIFFERENTIAL 
COUNT (%) 
                       
4000-11,000 
 
Polymorphs   40-75 
Lymphocutes   20-35 
Monocytes   2-10 
Esonophils   1-6 
 Basophils   0-1 
 
Platelets(lak/ cubic mm)   1,50000-500000 
Blood 
glucose 
(mg/dl) 
Fasting   70-110 
PP   80-140 
Random   80-120 
Lipid 
profile 
(mg/dl) 
Serum cholesterol   150-250 
HDL   30-60 
LDL   Upto 130 
VLDL   40 
TGL   Upto 160 
RFT 
(mg/dl) 
Blood urea   16-50 
Serum creatinine   0.6-1.2 
Serum Uric acid    M:3-9 ;W: 2.5-7.5 
LFT 
(mg/dl) 
Total bilirubin   0.3-1 
Direct bilirubin   0.1-0.3 
Indirect bilirubin   0.2-0.8 
Serum total protein   6-8 
Serum Albumin   3.5-5.5 
Serum globulin   2-3.5 
Fibrinogen(g/dl)   0.2-0.4 
Serum calcium   9-11 
Serum phosphorous   2-5 
SGOT (IU/L)   6-18 
SGPT (IU/L)   3-26 
Alkaline phosphatase (IU)   3-12 
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Urine investigation 
Before TMT 
Date: 
After TMT  
Date: 
Nei kuri   
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
Motion test   
Ova   
Cyst   
Occult blood   
 
Date: 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                          
 
 
          Signature of the HOD                                                                                              
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
À¢ò¾ À¡ñÎ  §¿¡öì¸¡É §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (¸Ã¢ºÄ¡í¸ñ½¢ ÝÃ½õ) ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ  ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
 FORM  IV B  ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ : Dr.M. §¸¡À¢¸¢Õ‰½ý 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷  : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
      ¾¡õÀÃõ º¡É¼§¼¡Ã¢Âõ 
  ¦ºý¨É- 47 
Dr. §¸¡À¢ ¸¢Õ‰½ý ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕ¸¢§Èý. 
À¢ò¾ À¡ñÎ ±ýÛõ §¿¡Â¡ÉÐ þÃò¾¾¡ÐÅ¢ø þÕõÒ ºòÐ Ì¨ÈÅ¢É¡ø ²üÀÎõ ´Õ §¿¡ö,þó§¿¡ö 
¯¼ø ¦ÅÙôÒ, ¯¼ø §º¡÷×, ÁÂì¸õ, ãîÍ Å¡í¸ø, ¨¸ ¸¡ø µö×, ¨¸ôÒ Í¨Å, ¬¸¢Â 
ÌÈ¢Ì½í¸¨Ç §¾¡üÚÅ¢ìÌõ,þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û 
ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ ÀÌ¾¢Â¡¸ Ò¾¢Â 
ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø º÷Å §¿¡ö þÄ¢í¸ ¦ºóàÃõ þó§¿¡öìÌ ÅÆí¸ ÀÃ¢óÐ¨Ã 
¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ 
«í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ 
ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 24¿¡ð¸û ¬Ìõ. ¦ÅÇ¢ 
§¿¡Â¡Ç÷¸û 12 ¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 24¿¡ð¸û ÁÕóÐ ¯ð¦¸¡ûÙõ 
¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý 
«ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ. 
 
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ 
¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ 
«Ç¢ì¸¢§Èý.±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ 
§¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ 
±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û 
¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. À¢ò¾ À¡ñÎ  §¿¡öì¸¡ÉÒ¾¢Â 
ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ, 
Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ 
¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ ¬öÅ¢¨Éò 
¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø 
Å¢Ä¸¢ì¦¸¡ûÇ×õ, ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç 
¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
 
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ 
þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. 
«¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î 
ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ¾¸Åø ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û.    
    
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ 
Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ 
§ÁüÀÊôÒòÐ¨È Á¡½Å÷  
Dr.M. §¸¡À¢ ¸¢Õ‰½ý ¬¸¢Â ±ý¨É 9488085454 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, 
¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â º¢ò¾ 
ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûÇÄ¡õ.   
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É, ¦ºý¨É - 47. 
Àð¼ §ÁüÀÊôÒ ÁÕòÐÅòÐ¨È 
 
  §¿¡öì¸¡É  º¢ò¾  ÁÕó¾¢ý (  )  ÀÃ¢¸Ã¢ôÒò 
¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É  ´ôÒ¾ø  ÀÊÅõ 
 
FORM IV- C ´ôÒ¾ø ÀÊÅõ 
 
                ¿¡ý §ÁüÜÈ¢Â  ¾¸Åø  ÀÊÅò¨¾ ÀÊòÐ «øÄÐ ÀÊì¸ §¸ðÎ 
¦¸¡ñ§¼ý. -Ð ¦¾¡¼÷À¡É Å¢Çì¸í¸¨ÇÔõ §¸ðÎ ¦¾Ã¢óÐ ¦¸¡ñ§¼ý. ±ó¾ Å¢¾ 
ÅüÒÚò¾Ä¢ýÈ¢, ±ý ¦º¡ó¾ Å¢ÕôÀò¾¢ý §ÀÃ¢ø ±ý¨É -ó¾ ¬Ã¡öîº¢ìÌ ¯ðÀÎò¾ 
±ý ÓØÁÉ§¾¡Îõ ÍÂ¿¢¨É§Å¡Îõ ºõÁ¾õ ¦¾Ã¢Å¢ì¸¢§Èý. ±ÉìÌ Å¢ÕôÀÁ¢øÄ¡¾ 
Àðºò¾¢ø ó¾ ¬Ã¡öîº¢Â¢ø ÕóÐ ±ý¨É ±ô§À¡Ð§ÅñÎÁ¡É¡Öõ Å¢ÎÅ¢òÐ 
¦¸¡ûÙõ ¯Ã¢¨Á¨Â ¦ÀüÚû§Çý ±ýÀ¨¾Ôõ «È¢§Åý. 
 
 
  §¾¾¢:                                                       ¨¸¦Â¡ôÀõ: 
 
  ¼õ:                                                      ¦ÀÂ÷     : 
 
 
  §¾¾¢:                                                        º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
  ¼õ:                                                        ¦ÀÂ÷                : 
                                                                  ¯È×Ó¨È         :      
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHU MARUTHUVAM 
AN OPEN CLINICAL TRIAL TO ASSESS THE THERAPEUTIC EFFICACY OF THE SIDDHA DRUG 
“SIDDHA MANDOORAM”  IN“PITHA PANDU”(IRON DEFECIENCY ANAEMIA) 
 
FORM IV -B (WITHDRAWAL FORM) 
 
  
  Name : 
 Age:                         
 Serial No:       
 Reg.No:  32091202 /2011-12 
Date of trial commencement: 
Date of withdrawal from the trial: 
Reason(s) for withdrawal; 
1. Long absence at reporting:                                  Yes/No 
2. Irregular treatment:                                              Yes/No 
3. Shift of locality:                                                    Yes/No 
4. Complication/Adverse reactions if any:               Yes/No 
5. Poor patient compliance:                                       Yes/No 
6.presence of nausea                                                 Yes/No 
7.Presence of abdominal pain:                                   Yes/No 
 
Date :                                                                             
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                     Signature of the HOD  
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                                              AYOTHIDASAR PANDITHAR HOSPITAL 
                                           DEPARTMENT OF   POTHU MARUTHUVAM  
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                                               FORM IV –C (DRUG COMPLIANCE FORM) 
 
Name :____________Reg no:32101202 serial no____ Drug: Karisalankanni chooranam 
 
First Line of treatment:Sesban Leaves soup[84-168ml] with palm jaggery at early morning on empty stomach for 
one day. 
On 1st     day-Date:                ;Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 12th  day-Date:                ;Drugs issued:  (Nos)   /   Drugs returned:    (Nos) 
On 24th  day-Date:                ;Drugs issued:  (Nos)   /   Drugs returned:    (Nos 
  
Day     Date/ §¾¾¢          Morning/ ¸¡¨Ä             Evening/ Á¡¨Ä 
Day 1    
Day2    
Day3    
Day4    
Day5    
Day6    
Day7    
Day8    
Day9    
Day10    
Day11    
Day12    
Day13    
Day14    
Day15    
Day16    
Day17    
Day18    
Day19    
Day20    
Day21    
Day22    
Day23    
Day 24    
Date : 
Station : 
Signature of the Investigator: 
Signature of the Lecturer:                                                         
        Signature of the HOD                  
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                                                      FORM IV D -DIETARY ADVICE FORM 
§º÷ì¸ ÜÊÂ ¯½×¸û: 
¸¡ö¸û:¸ò¾Ã¢À¢ïÍ,ÓÕí¨¸À¢ïÍ,Å¡¨ÆÀ¢ïÍ,«Å¨ÃÀ¢ïÍ,Íñ¨¼¸¡ö, 
¦¿øÄ¢¸¡ö,Å¡¨Æôâ,Á¢ÇÌ,âñÎ,¦Åí¸¡Âõ ¬¸¢Â¨Å Å¡Ãò¾¢üìÌ 
þÃñÎ Ó¨È §º÷ì¸ §ÅñÎõ. 
 
¸£¨Ã¸û:¦À¡ýÉ¡¸ñ½¢,Á½ò¾ì¸¡Ç¢, ÓÕí¨¸¸£¨Ã,  ¬¸¢Â¨Å 
Å¡Ãò¾¢üìÌ þÃñÎ Ó¨È §º÷ì¸ §ÅñÎõ. 
 
ÀÆí¸û:Å¡¨Æ,§ÀÃ£î¨º,¾¢Ã¡ð¨º,¦¸¡öÂ¡,¬ÃïÍ,±ÖÁ¢î¨º,¿¡Åø, 
¾ì¸¡Ç¢, 
¬¸¢Â¨Å Å¡Ãò¾¢üìÌ þÃñÎ Ó¨È  §º÷ì¸ §ÅñÎõ. 
 
¾¡É¢Âí¸û:Àð¼¡É¢,¦¸¡ñ¨¼¸¼¨Ä,±û, ¬¸¢Â¨Å  Å¡Ãò¾¢üìÌ 
þÃñÎ Ó¨È  §º÷ì¸ §ÅñÎõ. 
 
«¨ºÅõ:¦ÅûÇ¡ðÎ¸È¢,®Ãø, Á£ý,¬¸¢Â¨Å Å¡Ãò¾¢üìÌ þÃñÎ Ó¨È  
 §º÷ì¸ §ÅñÎõ. 
 
§º÷ì¸ Ü¼¡¾¨Å¸û: 
      
 ÒÇ¢ ,§¾¿£÷, ¬¸¢Â¨Å §º÷ì¸ Ü¼¡Ð. 
 
 ¦ÅüÈ¢¨Ä,À¡ìÌ §À¡¼ Ü¼¡Ð. 
 
 Ò¨¸Â¢¨Ä §À¡¼ Ü¼¡Ð. 
 
 ÁÐ «ÕóÐ¾ø Ü¼¡Ð. 
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ANAEMIA) 
 
                                                       FORM –IV-E 
                                     
                                      ADVERSE REACTION FORM 
 
Name:  
Age: 
Gender:  Male/Female    
  
Serial No: 
Date of trial commencement: 
 
Date of the adverse reaction occur; 
Time: 
 
Description of Adverse reaction: 
 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                          
 
                                                                                        Signature of the HOD 
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